



HAL
open science

Topical Intestinal Aminoimidazole Agonists of G-Protein-Coupled Bile Acid Receptor 1 Promote Glucagon Like Peptide-1 Secretion and Improve Glucose Tolerance

Manuel Lasalle, Vanessa Hoguet, Nathalie Hennuyer, Florence Leroux, Catherine Piveteau, Loic Belloy, Sophie Lestavel, Emmanuelle Vallez, Emilie Dorchies, Isabelle Duplan, et al.

► To cite this version:

Manuel Lasalle, Vanessa Hoguet, Nathalie Hennuyer, Florence Leroux, Catherine Piveteau, et al.. Topical Intestinal Aminoimidazole Agonists of G-Protein-Coupled Bile Acid Receptor 1 Promote Glucagon Like Peptide-1 Secretion and Improve Glucose Tolerance. *Journal of Medicinal Chemistry*, 2017, 60 (10), pp.4185-4211. 10.1021/acs.jmedchem.6b01873 . inserm-02115415

HAL Id: inserm-02115415

<https://inserm.hal.science/inserm-02115415v1>

Submitted on 30 Apr 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Topical intestinal aminoimidazole agonists of G-Protein-Coupled Bile Acid Receptor 1 promote Glucagon Like Peptide-1 secretion and improve glucose tolerance.

Manuel Lasalle^{†#}, Vanessa Hoguet^{†#}, Nathalie Hennuyer[‡], Florence Leroux[†], Catherine Piveteau[†], Loïc Belloy[‡], Sophie Lestavel[‡], Emmanuelle Vallez[‡], Emilie Dorchies[‡], Isabelle Duplan[‡], Emmanuel Sevin[§], Maxime Culot[§], Fabien Gosselet[§], Rajaa Boulahjar[†], Adrien Herledan[†], Bart Staels[‡], Benoit Deprez^{*†}, Anne Tailleux^{‡◇} Julie Charton^{*†◇}

[†] Univ. Lille, Inserm, Institut Pasteur de Lille, U1177 - Drugs and Molecules for living Systems, F-59000 Lille, France.

[‡] Univ. Lille - EGID, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - Nuclear receptors, cardiovascular diseases and diabetes, F-59000 Lille, France.

[§] Univ. Artois, EA 2465 - Blood-brain barrier laboratory (LBHE), F-62300 Lens, France.

[#] These authors contributed equally to this work.

[◇] These authors contributed equally to this work.

KEYWORDS. TGR5, Aminothioimidazole, GLP-1, glucose tolerance

ABSTRACT. G-Protein-Coupled Bile Acid Receptor 1 (GP-BAR1), also known as Takeda G-protein-coupled receptor 5 (TGR5) is a G Protein Coupled Receptor sensitive to bile acids. Its role in various organs, tissues and cell types, specifically in intestinal endocrine L cells and brown adipose tissue, has made it a promising therapeutical target in several diseases, especially type 2 diabetes and metabolic syndrome. However, recent studies have also shown deleterious on-target effects of systemic TGR5 agonists. To avoid these systemic effects while stimulating the incretin Glucagon Like Peptide-1 (GLP-1) secreting enteroendocrine L-cells, we have designed and obtained a series of potent TGR5 agonists with low intestinal permeability. Some of our weakly permeable compounds display potent GLP-1 secretagogue effect and low effect on gallbladder volume, which translates into improved glucose homeostasis in a preclinical murine model of diet-induced obesity and insulin-resistance. Herein we describe the design, synthesis, characterization, and biological evaluation of such compounds, making the proof of concept of the potential of topical intestinal TGR5 agonists as therapeutic agents in type 2 diabetes using compound **24**.

INTRODUCTION.

Bile acids have been known for over a decade to act not only as lipid solubilizing agents during digestion, but also as signaling molecules, through two main receptors¹ : the nuclear receptor FXR² (identified in 1999), and the G-Protein-Coupled Bile Acid Receptor TGR5^{3,4} (aka GP-BAR1, GPR131, M-BAR identified in 2002). TGR5 acts as a sensor of the prandial state of the organism, by detecting bile acids in various tissues, organs, and cells, such as enteroendocrine L-cells, brown adipose tissue, skeletal striated muscles, but also gallbladder, immune cells and neurons. Based on the existing functional and pharmacological data in preclinical models, TGR5


appears as an attractive target to treat metabolic diseases through different pathways⁵. First, TGR5 expressed in enteroendocrine L-cells promotes the transcription of the proglucagon gene expression and the secretion of the incretin Glucagon-like peptide 1 (GLP-1), which displays numerous beneficial effects on glucose and energy homeostasis (insulin secretion, beta cell preservation, appetite regulation, gastric emptying)⁶. Second, TGR5 activation in brown adipose tissue (BAT) and muscle increases deiodinase 2 gene expression and consequently conversion of the inactive T4 hormone into active thyroxin T3, and uncoupling protein-1 (UCP-1) activation leading to energy expenditure. Interestingly, the link between TGR5 activation in BAT and energy expenditure firstly demonstrated in mouse⁷ has been recently shown also in humans⁸. Nevertheless, recent investigations in preclinical animal models have suggested that systemic TGR5 agonists may trigger unwanted effects such as gallbladder swelling^{9,10}, itching¹¹, or more recently cardiovascular issues¹²⁻¹⁴. In this context, TGR5 localization on enteroendocrine L-cells in the intestine epithelium offers a new opportunity. Indeed, the development of intestinal-targeted agonists may lead to GLP-1 secretagogue compounds with a systemic bioavailability low enough to get rid of on-target as well as off-target systemic side effects.

We aim to obtain compounds with low gastro-intestinal (GI) absorption that can exert their biological activity locally in GI tract while minimizing systemic exposure.¹⁵ This strategy seemed particularly suitable for the development of TGR5 agonists because it would enable TGR5 agonists to stimulate the GLP-1 release by enteroendocrine L-cells without triggering any other TGR5-related effect^{16,17}. To access such compounds, we decided to design our compounds as chimeric molecules associating a “pharmacophore” that would bear the pharmacological activity, and a “kinetophore”, that would control the kinetic properties of the whole molecule, without modifying significantly its effect on the receptor. The kinetophore concept was

introduced in 2006 to describe a highly polar and/or large and hindered chemical moiety that is tethered to a pharmacologically active structure, to drastically modify its pharmacokinetic properties, especially by decreasing its oral absorption¹⁸.

Our efforts firstly focused on optimizing the pharmacophore part and developing structure-activity relationships to determine where to link the kinetophore on the molecules. Analysis of an in-house HTS hit family showed a similarity to a TGR5 agonist (CpdA) we had synthesized to use as a reference, described in a patent by Exelixis¹⁹. To increase the diversity of this triazole family, a classical C-to-N isosteric replacement strategy to the CpdA led to original compound **1** (scheme 1). Surprisingly, although very structurally close to CpdA compound **1** was completely inactive on TGR5 showing SAR in our aminothiotriazole series contrasting with that of Exelixis. Substitution of the extracyclic nitrogen by a methyl gave compound **2** that showed promising activity on both human and murine TGR5 receptors. Switch of the central scaffold from a triazole to an imidazole led to compound **3** with a drastic increase of potency (from 180 nM to 0.8 nM on the murine receptor). Compound **3** was the starting point for the design of agonists bearing several kinetophore moieties. In this paper, we describe SAR around **3**, followed by the design, synthesis and characterization of kinetophore bearing analogs in pharmacokinetic and pharmacodynamics models.


Scheme 1. Isosteric replacement strategy and scaffold switching.



CHEMISTRY

3-amino-5-thio-[1,2,4]triazole series. Synthesis of the 3-amino-5-thio-[1,2,4]triazole derivatives was performed in four to five steps with moderate yield (scheme 2). The first step was the synthesis of the core aminothiotriazole, by a one-pot two-steps reaction²⁰. Selective substitution of the sulfur atom was then carried out in classic nucleophilic substitution conditions to afford the 5-benzylsulfanyl-4-phenyl-4H-[1,2,4]triazol-3-ylamine derivative. Access to compound **1** was enabled via a Chan-Lam coupling, requiring protection and deprotection steps of the exocyclic nitrogen by an acetyl group. Compound **2** was obtained through the same coupling reaction after methylation of the nitrogen by reductive amination.

Scheme 2. Synthetic route to **1-2**.




Reagents and conditions: (a) i) 4-fluorophenylisothiocyanate, DIEA, DMF, 50°C, 15h ii) NaOH 2M, 50°C, 60h, 87% (b) 2-bromomethyl-1,3-difluoro-benzene, DIEA, CH₂Cl₂, room temp., 3h, 98% (c) i) MeONa, paraformaldehyde, MeOH, room temp., 16h ii) NaBH₄, MeOH, reflux, 30 min, 76% (d) Chan-Lam coupling, 3,4-dimethoxyphenylboronic acid, pyridine, Cu(OAc)₂, MS 4Å, CH₂Cl₂, room temp., 24-48h, 11-50% (e) Ac₂O, CH₂Cl₂, room temp., 30 min, 66% (f) AcCl, EtOH, reflux, 30 min, 57%.

5-amino-2-thio-imidazole series. 5-amino-2-thio-imidazoles derivatives were obtained through a 6 steps synthetic route, using simple building blocks such as aniline, amino-acids or benzyl derivatives to speed up the exemplification in this family. The first step was a mono-methylation of the desired aniline by reductive amination. The methylaniline or N-methylbenzylamine was firstly acetylated by chloroacetyl chloride. Then a nucleophilic substitution of the chloride by ammonia afforded the primary amine. This synthetic route was later optimized into a more convenient and efficient route: 1-propylphosphonic acid cyclic anhydride acylation with a Boc N-protected glycine followed by an acidic deprotection of the amino group. Use of either a commercial isothiocyanate or an aniline and TCDI led to the thiourea intermediate. The sulfur atom could then be selectively alkylated by a benzyl derivative to give the corresponding isothiurea. Finally, we took advantage of the 1-propylphosphonic acid cyclic anhydride -


mediated cyclodehydration method that we have developed previously²¹ to obtain the desired 5-amino-2-thioimidazole compounds from the isothiourea intermediates. (Schemes 3-5)

Scheme 3. Synthetic route to **3-6**




Reagents and conditions: (a) i) paraformaldehyde, MeONa, room temp., 16h ii) NaBH₄, MeOH, reflux, 1-3h, 77% (b) Chloroacetyl chloride, DIEA, CH₂Cl₂, 0°C, 30 min (c) aq. NH₃, EtOH, 65°C, 1h, 75% (over two steps) (d) 4-fluorophenylisothiocyanate, NEt₃, EtOH, room temp., 15 min, 76 % (e) R -Cl, NaI, K₂CO₃, CH₃CN, room temperature, 16h, 90-98% (f) 1-propylphosphonic acid cyclic anhydride, DIEA, EtOAc, 150°C (μW), 10-40 min, or reflux (classical heating), 24h, 32-61%.

Scheme 4. Synthetic route to **7-12**



Reagents and conditions: (a) i) paraformaldehyde, MeONa, room temp., 16h ii) NaBH₄, MeOH, reflux, 1-3h, 77% (b) Chloroacetyl chloride, DIEA, CH₂Cl₂, 0°C, 30 min (c) aq. NH₃, EtOH, 65°C, 1h, 75% (over two steps) (b') Boc-Gly-OH, 1-propylphosphonic acid cyclic anhydride, DIEA, EtOAc, room temp., 30 min-48h, 100% (c') TFA (30 %) /DCM, room temp., 30 min, 100% (d) R-N=C=S, NEt₃, EtOH, room temp. or 60°C, 15 min to overnight, 30-53% (d') aniline, TCDI, NEt₃, dioxane, room temp-60°C, overnight, 49% (e) 2-bromomethyl-1,3-difluoro-benzene, NaI, K₂CO₃, CH₃CN, room temperature, 16h, 82-99% (f) 1-propylphosphonic acid cyclic anhydride, DIEA, EtOAc, 150°C (μW), 10-40 min, or reflux (classical heating), 24h, 11-63 %.

Scheme 5. Synthetic route to **13-18**




Reagents and conditions: (a) i) paraformaldehyde, MeONa, room temp., 16h ii) NaBH₄, MeOH, reflux, 1-3h, 51-96% (a') Allyl bromide, K₂CO₃, DMF, 80°C, 16h (b) Chloroacetyl chloride, DIEA, CH₂Cl₂, 0°C, 30 min (c) aq. NH₃, EtOH, 65°C, 1h, 75% (b') Boc-Gly-OH, 1-propylphosphonic acid cyclic anhydride, DIEA, EtOAc, room temp., 30 min-48h, 79-100% (c') TFA (30%)/CH₂Cl₂, room temp., 30 min (d) 4-fluorophenylisothiocyanate, NEt₃, EtOH, room temp., 15-60 min, 90-100% (e) 2-bromomethyl-1,3-difluoro-benzene, NaI, K₂CO₃, CH₃CN,

room temperature, overnight, 58-100% (f) 1-propylphosphonic acid cyclic anhydride, DIEA, EtOAc, 150°C (μ W), 10-40 min, or reflux (classical heating), 24h, 10-59%.

Compound **19** was prepared from 4-fluorophenylisothiocyanate and 2-aminoacetonitrile. After addition on the isothiocyanate, alkylation using 2-bromomethyl-1,3-difluoro-benzene on the sulfur atom was followed by spontaneous cyclization into the 5-amino-2-thioimidazole **19b**. The amino group was then acylated using 3,4-dimethoxybenzoic acyl chloride, prepared from the corresponding carboxylic acid to give compound **19**. (scheme 6)

Scheme 6. Synthetic route to **19**




Reagents and conditions: (a) 2-aminoacetonitrile hydrochloride, NEt_3 , DMF, room temp. to 0°C, 30 min, 80% (b) 2-bromomethyl-1,3-difluoro-benzene, DIEA, CH_3CN , room temp., 5 min (c) 3,4-dimethoxybenzoic acid, thionyl chloride, CH_2Cl_2 , THF, Pyridine, room temp., 4h, 31%.

To prepare compound **22**, 4-bromo-2,6-difluorobenzyl alcohol was reacted with mesyl chloride in presence of trimethylamine. (NMR analysis of the product revealed that the product was not the expected mesylate, but rather the benzyl chloride). This benzyl derivative was then used to afford the corresponding imidazole **20b** in two steps (scheme 7). A Sonogashira coupling using N,N-dimethylpropargylamine was then performed on this imidazole to give **20**. The tertiary

amine was finally methylated to give the corresponding quaternary ammonium, which was first obtained as an iodide (**21**), and then as a formate (**22**) after purification by preparative HPLC in alkaline buffer (ammonium formate buffer pH = 9.2).

Scheme 7. Synthetic route to **20-22**




Reagents and conditions: (a) R-Cl, NaI, K₂CO₃, CH₃CN, 16 h, room temp. 95% (b) 1-propylphosphonic acid cyclic anhydride, DIEA, EtOAc, reflux, 24h, 74% (c) N,N-Dimethylpropargylamine, pyrrolidine, CuI, PdCl₂(dppf)₂, DMF, 80°C, 16h, 47% (d) MeI, THF/Et₂O, room temp., 2-6h, 17-19%.

The compounds bearing a quaternary ammonium **23** or a sulfonate **24** were obtained through a one-step synthesis from the chloropropyl derivative **23b**. Synthesis of the corresponding benzyl derivative **23ii** was carried out starting with the 2,6-difluoro-4-hydroxybenzonitrile (scheme 8). Alkaline hydrolysis of the cyano group was followed by esterification with methanol in acidic conditions. The corresponding methyl ester was reduced into the benzyl alcohol using DIBALH to give compound **23i**. Selective alkylation of the phenolic hydroxyl by 1-bromo-3-

chloropropane was then performed, followed by activation of the benzylic carbon using mesyl chloride to give the compound **23ii**.


Scheme 8. Synthetic route to intermediate **23ii**



Reagents and conditions : (a) i) NaOH, H₂O, reflux, 24h, 94% ii) H₂SO₄, MeOH, reflux, 18h, 90% iii) DIBALH, THF, 0°C, 1.5 h then NaK-tartrate aq (1M), room temp., 0.5 h, 80% (b) i) Cl(CH₂)₃Br, K₂CO₃, CH₃CN, reflux, 3h, 96% ii) MsCl, NEt₃, CH₂Cl₂, 0°C to room temp., 16h, 100%.

Intermediate **23ii** was used to obtain the corresponding imidazole **23b** in two steps (Scheme 9). The sulfonate derivative **24** was readily synthesized from **23b** using sodium sulfite and sodium iodide in a dioxane/water mixture under microwave irradiation²². Quaternary ammonium **23** was obtained by reaction of **23b** with 1,4-diazabicyclo[2.2.2]octane (DABCO) in acetonitrile under microwave irradiation.


Scheme 9. Synthetic route to intermediate **23-24**



Reagents and conditions: (a) **23ii**, K_2CO_3 , CH_3CN , room temp., 16h, 73% (b) 1-propylphosphonic acid cyclic anhydride, DIEA, EtOAc, reflux, 28h, 96% (c) NaI, Na_2SO_3 , dioxane/ H_2O (1/1), μW , $130^\circ C$, 100 min, 36% (d) DABCO, CH_3CN , μW , $100^\circ C$, 30 min, 23%.

Intermediate **25iii** was obtained in 3 steps starting from intermediate **23i**. The phenolic oxygen was first alkylated using 1,3-dibromopropane to give intermediate **25i**. Then a nucleophilic substitution using *tert*-butyl *N-tert*-butoxycarbonylcarbamate was carried out on the bromopropyl derivative to afford intermediate **25ii**. This benzylic alcohol was then converted into the benzyl chloride derivative **25iii** using mesyl chloride as describe above for intermediate **23ii**.


Scheme 10. Synthetic route to intermediate **25iii**



Reagents and conditions: (a) 1,3-dibromopropane, K_2CO_3 , CH_3CN , reflux, 3h, 76% (b) *tert*-butyl *N-tert*-butoxycarbonylcarbamate, Cs_2CO_3 , DMF, $70^\circ C$, 30min, 95% (c) NEt_3 , MsCl, CH_2Cl_2 , $0^\circ C$ to room temp., overnight, 87%.

Intermediate **25iii** was used to obtain the corresponding imidazole **25b** in two steps. After deprotection, amine **25c** was reacted with sodium 2-chloroethanesulfonate in presence of sodium iodide and DIEA in DMF under microwave irradiation (scheme 11).


Scheme 11. Synthetic route to **25**.



Reagents and conditions: (a) **25iii**, DIEA, CH_3CN , room temp., overnight, 35% (b) 1-propylphosphonic acid cyclic anhydride, DIEA, EtOAc, reflux, 48h, 62% (c) TFA (10%), CH_2Cl_2 , room temp., 5h, 98% (d) Sodium 2-chloroethanesulfonate, NaI, DIEA, DMF, μW , $100^\circ C$, 2h, 16%.

Compounds **26-30** were prepared in a similar way replacing glycine by alanine, or correctly protected lysine and glutamic acid (scheme 12).

Scheme 12. Synthetic route to **26-30**.



Reagents and conditions: (a) BocHN-CH(R)-COOH, 1-propylphosphonic acid cyclic anhydride, DIEA, EtOAc, room temp., 30min-1h, 66-97% (b) TFA (30%)/ CH₂Cl₂, 30 min, 100% (c) 4-fluorophenylisothiocyanate, TEA, EtOH, 5 min, 70-79% (d) 2-bromoethyl-1,3-difluoro-benzene, K₂CO₃, Acetonitrile, room temp., overnight, 84-89% (e) 1-propylphosphonic acid cyclic anhydride, DIEA, EtOAc, reflux (classical heating), 48h, 6-32% (f) NaOH 1N, MeOH, room temp., overnight, 93% (g) piperidine, EtOAc, room temp., 60% (h) MeI, DIEA, Et₂O/THF (1/1), room temp., overnight, 20%.


RESULTS AND DISCUSSION

All compounds were evaluated *in vitro* for their TGR5 agonist activity on both human and murine receptors in a CRE-driven luciferase reporter assays in TGR5-transfected HEK293 cells. Full agonist activity (efficacy > 80% measured relative to lithocholic acid 10 μM) was obtained for all active compounds.

Pharmacophore optimization

TGR5 agonist activities on both human and murine receptors of compounds **1** and **2** are reported in Table 1. Surprisingly, compound **1** was shown to be completely inactive on both receptors. In contrast, compound **2** showed promising activity on the murine receptor.

Table 1. *In vitro* activity of compounds **1** and **2**




Example	R	hTGR5		mTGR5	
		EC ₅₀ (nM)		EC ₅₀ (nM)	
1	H	NA ^a		NA ^a	
2	CH ₃	4300	[3800-4900]	180	[150-220]

EC₅₀ values are reported with their 95% confidence intervals in brackets.

^a NA: not active (E_{max} < 10% at all concentrations up to 30 μM).

Replacing the triazole by an imidazole in **3** gave an interesting 2 log improvement of potency on both human and murine receptors (Table 2). We then decided to draw Structure Activity Relationships of this series by exploring the role of the substituents on the aromatics rings. SAR on the benzylic ring on the right-hand side of the molecules are described in the Table 2. The 2,6-difluoro substitution of this phenyl ring appeared to be important for activity, especially on the murine receptor. Indeed, the hEC₅₀/mEC₅₀ ratio dropped from 44 for compound **3** to 2 for compound **5**.

Table 2. *In vitro* activity of compounds **2-6**




Example	X	R	hTGR5	mTGR5
			EC ₅₀ (nM)	EC ₅₀ (nM)
2	N		4300 [3800-4900]	180 [150-220]
3	CH		35 [22-54]	0.8 [0.5-1.4]
4	CH		128 [81-200]	12 [5-32]
5	CH		156 [105-231]	68 [54-85]
6	CH		299 [267-335]	41 [27-63]

EC₅₀ values are reported with their 95% confidence intervals in brackets.

Table 3 describes the SAR on the phenyl ring on the lower part of the molecule. As shown by the drastic decrease in potency for compound **8** and **9**, more hindered group than fluorine are not tolerated at the para position, whether they are electrodonor or electroattractor. On the opposite, adding ortho and meta substitution on the para-fluorophenyl moiety showed interesting potency, with even a slight improvement with the compound **12** compared to compound **3**.

Table 3. *In vitro* activity of compounds **3**, **7-12**



Example		hTGR5 EC ₅₀ (nM)	mTGR5 EC ₅₀ (nM)
3		35 [22-54]	0.8 [0.5-1.4]
7		254 [207-312]	5.1 [4.2-6.1]
8		7745 [7135-8407]	939 [731-1207]
9		900 [804-1008]	366 [321-417]
10		35 [27-45]	2.0 [1.6-2.5]
11		47 [34-65]	4.8 [3.7-6.3]
12		20 [13-30]	0.8 [0.2-3.4]

EC₅₀ values are reported with their 95% confidence intervals in brackets.

Exploration of the SAR on the phenyl ring of the left-hand side of the molecule is described in Table 4. The 4,5-dimethoxy substitution appeared crucial for the compounds activity on TGR5, as removal of one or both methoxy groups (compounds **14** and **15**) lead to a drastic drop of the potency (more than 100 fold on the murine receptor). 4-chloro-3-methoxy and 3,4-dichloro substitution lead to a decrease in potency, especially for the dichloro substitution on compound **16**. Homologation of the 3,4-dimethoxyphenyl to 3,4-dimethoxybenzyl group lead to a less

active compound (**17**). Whereas modification of the phenyl substitution was generally poorly tolerated, modification of the alkyl substitution of the extracyclic nitrogen showed only a moderate decrease of potency (compound **18**). It is worth noting that we have tried several strategies to obtain the N-desmethyl analog of compound **3** but were unable to isolate it, because of its high instability.

Table 4. *In vitro* activity of compounds **3**, **13-19**

Example	R	hTGR5		mTGR5	
		EC ₅₀ (nM)		EC ₅₀ (nM)	
3		CH ₃	35 [22-54]	0.8 [0.5-1.4]	
13		CH ₃	885 [840-932]	44 [37-52]	
14		CH ₃	1106 [986-1240]	141 [120-165]	
15		CH ₃	994 [915-1079]	91 [73-113]	
16		CH ₃	750 [706-799]	507 [456-564]	
17		CH ₃	326 [290-365]	40 [24-66]	
18		-CH ₂ - CH=CH ₂	86 [44-169]	7.7 [6.6-9]	
19		H	NA ^a	≥ 6000	

EC₅₀ values are reported with their 95% confidence intervals in brackets

^a NA: not active (Emax < 10% at all concentrations up to 10μM).


Kinetophore positioning and optimization.

Our strategy to obtain intestine-targeted TGR5 agonists was to introduce on our potent agonists a kinetophore group that would limit the intestinal absorption without effect on the TGR5 agonist activity of such compounds. The keystone of this strategy is the identification of a “mute” position where linking such groups would not impact the target interaction. Analysis of the SAR around compound **3** has demonstrated that the dimethoxy substitution on the left-hand side of the molecule was crucial and that the bottom of the molecule does not tolerate para-substitution by bigger groups than fluorine. We then decided to explore para substitution of the benzyl on the right-hand side of the molecule to add our kinetophore groups. The kinetophores were selected among structural groups making the compound large and/or polar.

In this paper, we will focus on ionic kinetophores, especially permanently ionized quaternary ammonium and sulfonate groups, which cannot be protonated in vivo ($pK_a < -1$).

Table 5 describes the TGR5 agonist activity of compound **3** and its analogs modified by substitution on the para position of the benzyl ring. First, we show here that this position can efficiently tolerate polar and hindered group, as all the compounds maintain a potency and full efficacy comparable to compound **3**. Both positive and negative charges are well tolerated with better activities for the anionic compounds (**24**, **25**).

Table 5. *In vitro* activity of compounds **3**, **20-25**




Example	R	hTGR5	mTGR5
		EC ₅₀ (nM)	EC ₅₀ (nM)
3		35 [22-54]	0.8 [0.5-1.4]
20		71 [62-81]	4.1 [1.7-9.8]
21		177 [146-214]	7.5 [6.2-9.1]
22		260 [234-288]	17 [11-27]
23		238 [210-268]	9.8 [8.6-11.2]
24		24 [16-37]	0.4 [0.3-0.6]
25		77 [41-144]	0.3 [0.3-0.4]

EC₅₀ values are reported with their 95% confidence intervals in brackets.

Finally, we explored the impact of a charged kinetophore moiety on the position 4 of the imidazole ring on potency. As can be seen in Table 6, a drastic loss of potency was observed for all compounds substituted on the position 4 of the imidazole (**26-30**).

Table 6: *In vitro* activity of compounds **3**, **26-30**



Example	R	hTGR5	mTGR5
		EC ₅₀ (nM)	EC ₅₀ (nM)
3	-H	35 [22-54]	0.8 [0.5-1.4]
26	-CH ₃	337 [304-373]	7 [6-8]
27	-(CH ₂) ₄ -NH ₂	> 4500	119 [98-145]
28	-(CH ₂) ₂ -COOMe	1113 [992-1249]	82 [64-104]
29	-(CH ₂) ₂ -COOH	NC ^a	1935 [1483-2526]
30	-(CH ₂) ₄ -N ⁺ (CH ₃) ₃	≥ 10000	254 [195-331]

EC₅₀ values are reported with their 95% confidence intervals in brackets.

^a NC: not calculated (E_{max} < 20% at all concentrations up to 10μM).

The pharmacophore compound **3** and kinetophore-linked compounds **22**, **23** and **24** showing interesting *in vitro* TGR5 activity, were then evaluated for physico-chemical and *in vitro* ADME properties.

As can be seen in Table 7, the kinetophore part of compounds **22-24** profoundly impacts physico-chemical properties: aqueous solubility of compounds **22-24** compared to **3** is largely improved and their lipophilicity decreased.

As polar surface area (PSA) has been described as a predictive parameter of the passive molecular transport through membranes and compound absorption in the GI tract, PSA as well as clogD and AlogP were calculated for compounds **22-24** using Pipeline Pilot™ (Accelrys)²³⁻²⁵.

In our case, the calculated (clogD_{7.4}) was quite different from measured logD_{7.4} for all the evaluated compounds (neutral, cationic and anionic). As can be seen in table 7, PSA is not

impacted by the introduction of our cationic kinetophores (**3** versus **22-23**), because the charge is buried in the tetra-substituted ammonium, and neither a lone pair nor a hydrogen atom remains for hydrogen bonding. In contrast, introduction of the sulfonate group, a fully exposed charge leads to a much higher PSA (140 \AA^2 described as a threshold value to be usually poorly absorbed).

Cellular permeability was performed in Caco-2 monolayer permeability assay. In this assay, both cationic (**22**, **23**) and anionic (**24**) compounds exhibited a very low permeability, much lower than that of our pharmacophore compound **3** ($P_{\text{app A-B}} \leq 0.08 \cdot 10^{-6} \text{ cm}\cdot\text{s}^{-1}$ and $P_{\text{app A-B}} = 5.32 \cdot 10^{-6} \text{ cm}\cdot\text{s}^{-1}$ respectively). In this series, cellular permeability is not correlated with PSA. Indeed, compound **3** and cationic compounds **22** and **23** display the same PSA, but are highly different in term of permeability.

Incubation with mouse liver microsomes *in vitro* revealed that our compounds are metabolically instable ($t_{1/2} = 1.2 \text{ min}$ for compound **24**). This result suggests a high first pass effect for these compounds that will further lower systemic exposure in addition to a low intestinal permeability.

Table 7. *In vitro* ADME evaluation of kinetophore-coupled compounds

Compound	3	22	23	24
kinetophore	∅			
Calculated parameters ¹				
cLogD	6.63	5.93	5.36	4.15
PSA (Å ²)	65	65	73	140
Measured parameters				
Aqueous Solubility (μM)	6.3	>200	>200	>200
LogD (7.4)	3.5	1.0	0.9	0.8
P _{app} A-B ^a recovery (%)	5.32 ^b ± 0.94 84.4 ± 6.9 %	0.08 ± 0.02 ^c 69.8 ± 8.7%	0.016±0.005 69.3 ± 1.2 %	0.031±0.011 80.1 ± 4.2 %
P _{app} B-A ^a recovery (%)	5.47 ^b ± 1.29 106.4 ± 19.7 %	0.24 ± 0.03 ^c 93.4 ± 0.7 %	0.22±0.06 99.6 ± 0.4 %	19±1.91 101.8 ± 3.5 %
Efflux ratio	1	3.1 ^c	14	636
Microsomal stability t _{1/2} (min)	0.7	10.6	N.D.	1.2
Microsomal stability Cl _{int} (μL/min/mg proteins)	1287	264	N.D.	1211

¹ calculated parameters using Pipeline PilotTM (Accelrys)

^a Cell membrane permeability assessed on a Caco-2 cell monolayer. “A-B” indicates the transport from apical side to basolateral side “B-A” indicates the transport from basolateral side to apical side. Compounds were tested at 10 μM. Permeability is expressed in 10⁻⁶ cm.s⁻¹ Permeability classification: low : P_{app} < 2 × 10⁻⁶ cm.s⁻¹; high : P_{app} > 20 × 10⁻⁶ cm.s⁻¹.

^b Compound tested at 5 μM

^c Compound tested as an iodide (ie compound **21**)

Compounds **22** and **24**, bearing interesting *in vitro* activity and very low permeability were chosen for further *in vivo* pharmacokinetic and pharmacodynamic studies in C57Bl6 mice.

The time required by the drug to reach ileum and colon containing the highest density of target L-cells⁶ after oral dosing was unknown. Therefore, compounds **22** and **24** were administered orally at three consecutive time-points (T-6h, T-4h, T-2h; 3 x 20 mg/kg) to ensure the complete

exposure of the GI tract. In order to test the ability of compound **22** to promote GLP-1 secretion, mice were treated with vehicle or compound **22** as described, prior to an oral glucose (2 g/kg) or water load. Blood samples were collected 15 minutes later to measure active GLP-1 plasma concentrations. In addition, sitagliptin (25 mg/kg) was given orally 1 hour prior to blood sample collection to prevent GLP-1 degradation. As expected, glucose increased GLP-1 concentrations in vehicle treated mice (Figure 1, Veh+Water vs Veh+Glc). As expected, compound **22** further enhanced the glucose-induced GLP-1 secretion compared to vehicle (Figure 1, Veh+Glc vs **22**+Glc). Interestingly, compound **22** induced a 4 fold increase in active GLP-1 concentrations even in absence of glucose challenge compared to vehicle treated mice (Figure 1, Veh+Water vs **22**+Water). Thus, compound **22** by itself appears to be a potent GLP-1 secretagogue *in vivo* even in absence of glucose challenge.

In the same experimental setting, **24** lead to a 2.6 fold increase in GLP-1 concentrations compared to the vehicle treated group in absence of glucose challenge (Figure 2). To evaluate the impact of the kinetophore in this approach, the effect of naked pharmacophore **3** was measured *in vivo* at 15.5 mg/kg, *i.e.* the same molar quantity as 20 mg/kg of compound **24**. No difference with vehicle could be detected (data not shown). This contrasts interestingly with what has been observed on kinetophore bearing compounds, and illustrates the necessity of controlling absorption of our TGR5 agonists, to reach the distal section of the gut, where most of L-cells are located.




Figure 1. *In vivo* GLP-1 secretion in C57Bl6 mice. Vehicle (white bars) or compound **22** (grey bars) were administered to mice at 3 consecutive time-points (T-6h, T-4h, T-2h, 3 x 20 mg/kg) before challenge with a bolus of water or glucose (T0). All groups received sitagliptin (25 mg/kg) 45 min prior to blood sample collection (T+15 min). Mean \pm SEM (n = 6/group). * p<0.05, ** p<0.01 (ANOVA and Holm-Sidak test). Veh = vehicle (Tween 0.1%). Glc = glucose (2g/kg). **22** = Compound **22** in Tween 0.1% (3 x 20 mg/kg).




Figure 2. *In vivo* GLP-1 secretion in C57Bl6 mice. Vehicle (white bars) or compound **24** (grey bars) were administered to mice at 3 time-points (T-6h, T-4h, T-2h, 3 x 20 mg/kg) before blood collection (T0) to measure active GLP-1 plasma concentrations. All groups received sitagliptin (25 mg/kg) 45min prior to blood sampling. Mean \pm SEM (n = 8/group). *** p<0.001 (Student's t test)

Then, plasma AUC, as well as liver and gallbladder exposure were measured in mice dosed orally with compounds **22** and **24** at 20 mg/kg. As expected from the low *in vitro* permeability of compounds **22** and **24**, fecal recovery was quantitative (Table 8). Micromolar concentrations were reached after 4 hours in the gallbladder, while 100-fold lower C_{\max} was measured in plasma. Of note, the relatively high concentration in gallbladder results from the biliary excretion of only a small fraction (<0.1% for **24**) of administered compound.

Table 8. Pharmacokinetic parameters of kinetophore-coupled compounds **22** and **24** in C57B16 mice

Compound	22	24
[C] _{plasma} max (nM)	100	102
[C] _{plasma} max (ng/mL)	58	63
T _{max plasma} (min)	15	45
AUC (ng.min/mL)	2909	5774
t _{1/2} (min)	97	317
Liver C _{max} (nM)	nd	385
Gallbladder (tissue and content) C _{max} (nM)	9028	10980
Fecal recovery (%) ^a	88	100

n=3 mice/time; male C57B16/J mice. Compounds were administered orally (20 mg/kg, formulated in Tween 0.1%).

^a Feces collected 24 hours after compound dosing (20 mg/kg). Parent compound was extracted with organic solvent and analyzed quantitatively using mass spectrometry.

Intestinal exposure was then measured for compound **24**. Very interestingly, the results of the exposure of the different sections of GI tract showed that the targeted distal sections (ileum and colon) were maximally exposed by compound **24** 8 hours after oral dosing (Figure 3).




Figure 3. Time-course of compound **24** concentrations in duodenum, jejunum, ileum and colon of C57Bl6 mice, after a single oral administration (20 mg/kg). Mean \pm SEM (n= 3 mice/time).

In light of the results obtained concerning the intestinal exposure by compound **24**, we next explored the effect of the time elapsed between oral dosing and the GLP-1 secretion assay. As maximal GLP-1 secretion is expected when TGR5 is activated in distal sections of the GI tract, we compared GLP-1 secretion at two time-points after oral load by compound **24**. Consistent with the pharmacokinetics observed in the intestine, a 3.6 fold and a 10 fold increase in active GLP-1 concentrations were observed respectively 4 hours and 7 hours after administration of **24** (Figure 4).




Figure 4. *In vivo* GLP-1 secretion in C57Bl6 mice. Vehicle (white bars) or compound **24** (grey bars) were administered to mice 4 hours (t +4h) or 7 hours (t +7h) before blood collection for active GLP-1 plasma concentration measurement. All groups received sitagliptin (25 mg/kg) 45 min prior to blood sampling. Mean \pm SEM (n = 6/group). ** p<0.01 (Student's t test). Vehicle = Tween 0.1%. **24** = Compound **24** in Tween 0.1% (20 mg/kg).

Then, C57Bl6 mice were orally treated with increasing doses of **24** and plasma active GLP-1 concentrations were measured 8 hours post-dosing. Compound **24** induced a dose-dependent GLP-1 secretion (Figure 5A). Gallbladder relaxation, described in rodent treated with both bile acid derivatives and non-steroid small TGR5 agonist molecules^{26,27}, was assessed by gallbladder volume measurement in fasted mice 8 hours after a single oral administration of vehicle or **24** at increasing dose. Interestingly, a high GLP-1 secretion (6-fold increase in active GLP-1 plasma concentrations) was obtained at a dose (5 mg/kg) that did not modify gallbladder volume, suggesting that in these conditions gallbladder exposure is not sufficient to trigger the pharmacological response of the gallbladder (Figure 5B). Gallbladder motility was then studied by gallbladder volume measurement in fasted and re-fed conditions at the highest tested dose (20 mg/kg). In this experiment, we showed that gallbladder volume is not significantly increased by

24 both in fasted and re-fed conditions. We showed moreover that compound **24** does not disrupt food stimulated gallbladder emptying and motility (ejection fraction of 30 and 25 % respectively for vehicle and compound **24**). (Figure 5C) Thus the ratio between the lowest active dose (5 mg/kg) and the highest dose that does not modify gallbladder motility (20 mg/kg) defines a therapeutic window of 4.




A**B****C**

Figure 5. *In vivo* dose response effect of compound **24** in C57Bl6 mice. **A)** GLP-1 secretion after oral administration of Vehicle (white bar) or **24** (grey bars) 8 hours prior to blood sample collection for active GLP-1 plasma concentration measurement. All groups received sitagliptin (25 mg/kg) 45 min prior to blood sampling. Mean \pm SEM (n =6/group). **** p<0.0001 (ANOVA - Dunnet test). **B)** Gallbladder volume in fasted mice 8 hours after oral administration of compound **24**. Mean \pm SEM (n =6/group). ** p<0.01 (ANOVA - Dunnet test). **C)** Gallbladder volume in fasted (6 hours) and re-fed (fasted 4 hours then re-fed for 2 hours) after oral administration of compound **24** (20 mg/kg) or vehicle. Mean \pm SEM (n=6/group). ANOVA – Tukey test. Veh = Vehicle (Tween 0.1%). **24** = Compound **24** in Tween 0.1%.

We have shown that compound **24** is mainly retained in the intestine and triggers GLP-1 secretion in a physiological context, in a dose dependent manner. Next, the GLP-1 secretagogue effect of compound **24** was tested in a pathological context, namely in C57BL6 mice rendered obese and insulin-resistant by feeding a high fat diet (HFD) for 10 weeks. Interestingly, a 20 mg/kg dose of **24** increased active GLP-1 4-fold in HFD-fed mice (Figure 6). This increase in GLP-1 secretion (4-fold) in HFD-fed mice was lower than the one observed in lean mice at the same dose (10-fold, figure 5A).




Figure 6. *In vivo* GLP-1 secretion in C57Bl6 mice fed a HFD. Vehicle (white bars) or compound **24** (grey bars) were administered to mice 8 hours prior to blood sample collection for active GLP-1 plasma concentration measurement. All groups received sitagliptin (25 mg/kg) 45 min prior to blood sampling. Mean \pm SEM (n = 10/group). **** p<0.0001 (Student's t test). Veh = vehicle (Tween 0.1%). **24** = Compound **24** in Tween 0.1% (20 mg/kg).

In order to evaluate the effect of compound **24** on glucose homeostasis, HFD fed mice treated with a single dose of compound **24** were submitted to an oral glucose tolerance test 7 hours later. Compound **24** did not modify basal glycemia (T0 in the OGTT test, Figure 7). Interestingly, after a glucose challenge, glucose concentrations returned faster to the basal state in **24**-treated mice compared to controls as assessed by the time-course and AUC calculation (Figure 7). Thus, the GLP-1 secretion induced by compound **24** translates into improved glucose tolerance in a pathological model.




Figure 7: Effect of compound **24** administration on oral glucose tolerance test in HFD fed C57BL6 mice. Obese, insulin-resistant mice were treated with Vehicle or **24**. (Veh = vehicle (Tween 0.1%). **24** = Compound **24** (20 mg/kg) in Tween 0.1%). 7 hours later, mice were challenged with an oral bolus of glucose (4g/kg) and glucose measured at the indicated time-

points. **A)** Glucose excursion curve. **B)** Incremental area under curve (AUC), expressed as arbitrary unit (A.U.). Mean \pm SEM (n = 8/group). * p<0.05, ** p<0.01 (Student's t test)

It was recently reported that functional TGR5 appears to be mostly located on the basolateral side of enteroendocrine L-cells, suggesting that crossing the intestinal epithelium is required before bile acids or other TGR5 agonists can elicit a GLP-1 secretory response. Under these conditions, lumenally-restricted TGR5 agonists would not induce a strong GLP-1 secretion *in vivo*.²⁸ Interestingly, despite very low permeability in Caco-2 enterocytes in culture and a concordant poor systemic exposure, compound **24** was able to trigger a strong *in vivo* GLP-1 secretion. As can be seen in Table 7, **24** undergoes a very high active efflux (efflux ratio > 600) in the permeability assay on Caco-2 cells, explaining the very low absorption through enterocytes. This also suggests that, in the much less abundant enteroendocrine L-cells which are devoid of efflux mechanisms, a significant fraction of the compound could cross cell membranes and activate TGR5 on basolateral side without contributing to systemic absorption. A useful consequence of its low intestinal absorption is that **24** reaches the distal intestine where TGR5 expression is maximal, and triggers GLP-1 secretion.

CONCLUSIONS. Modification of a potent agonist of TGR5 to decrease intestinal absorption without impacting membrane permeation in target cells, was proven to be a valid strategy to activate enteroendocrine L-cells located in the lower intestinal tract, while creating a potency window between the efficacious dose measured on glucose tolerance and the dose triggering gallbladder response. Compound **24** exhibits high *in vitro* potency and *in vivo* GLP-1

secretagogue effect that translates into an improved glucose tolerance in a pathological murine model of obesity/insulin-resistance. Thanks to a fine-tuned pharmacokinetic behavior, this TGR5 agonist displays attracting *in vivo* efficacy and safety.

Further biological evaluations are on-going to explore in details the mechanisms underlying the effects of compound **24** (BDM72881)²⁹ and support the therapeutic potential of topical intestinal TGR5 agonists for treatment of type 2 diabetes.

EXPERIMENTAL SECTION

***In vitro* TGR5 Assay.** TGR5 activation by compounds and subsequent increase in intracellular cAMP were evaluated using a luciferase reporter gene assay. Human embryonic kidney (HEK) 293 cells were transiently co-transfected with pCMV tag4b-TGR5h (to determine hTGR5 activation) or pCMV AC6-TGR5m (to determine mTGR5 activation) expression plasmids and the pCRE TA-Luciferase reporter plasmid using the JET PEI reagent (Polyplus transfection). Transfected cells were seeded in 96-well plates and incubated overnight with the compounds at increasing concentrations in duplicate. Lithocholic acid (LCA) at 10 μ M was used as a positive reference compound. The cAMP-dependent luciferase expression was followed using the BrightGlo reagent according to the manufacturer (Promega) instructions. Luminescence was measured with a Mithras plate reader (Berthold). Data were expressed as percentage of the 10 μ M LCA value and EC₅₀ values were calculated using XL fit 5 software or GraphPad Prism 5. Concentration-response curves were fitted by a nonlinear regression analysis to a 4 parameters logistic equation.

LC-MS/MS ADME methods. Chromatography was performed using a UPLC system, an Acquity I-Class (Waters). Separation was achieved on a Waters Acquity BEH C18 column (2.1 mm ×50 mm, 1.7µm). The autosampler and column oven temperatures were 10°C and 40°C respectively and the sample injection volume was 1 µL. The mobile phase consisted in 0.1% Formic Acid (FA) in water as solvent A and 0.1% FA in acetonitrile as solvent B at a flowrate of 600 µL/min. The gradient was as follows: 0 - 0.2 min (98%A and 2%B), 2 - 2.5min (2%A and 98%B), 2.6 min (98%A and 2%B), 4 min (98%A and 2%B). Gradient step was linear.

Mass spectrometry was performed using a Xevo TQD (Waters Corporation) mass spectrometer. The detection of analytes was achieved by electrospray ionization (ESI) in the positive mode with the appropriate MRM transition. Other mass spectrometer settings were: capillary voltage and cone voltage were optimized for each compound, desolvation temperature 600°C at a gas flow of 1200 L/h and cone gas flow 50 L/h. The LC-MS/MS instrument was controlled by MassLynx software (Waters).

Solubility/LogD measurements. 10 µL of a 10 mM solution in DMSO of the compound are diluted either in 490 µL of PBS pH 7.4 or in organic solvent MeOH in a 700 µL-microtube (in triplicate). The tubes are gently shaken 24 h at room temperature, then centrifuged for 5 minutes at 4000 rpm. The mixtures are filtered over 0.45 µm filters (Millex-LH Millipore). 10 µL of sample are diluted in 490 µL of MeOH. The solubility is determined by the ratio of mass signal area PBS/ organic solvent.

40 µL of a 10 mM solution in DMSO of the compound were diluted in 1.960 mL of a 1/1 octanol /PBS at pH 7.4 mixture. The mixture was gently shaken 2 h at room temperature. 10 µL of each phase was diluted in 490 µL of MeOH and analyzed by LC-MS/MS. Each compound is tested in

triplicate. Log D was determined as the logarithm of the ratio of concentration of product in octanol and PBS respectively, determined by mass signals.

Microsomal stability. Male mouse (CD-1) liver microsomes (BD Gentest) were used. All incubations were performed in duplicate in a shaking water bath at 37 °C. The incubation mixtures contained 1 µM compound with 1% methanol used as a vehicle, mouse liver microsomes (0.3 mg of microsomal protein per mL), 5 mM MgCl₂, 1 mM NADP, 5 mM glucose 6-phosphate, 0.4 U.mL⁻¹ glucose 6-phosphate dehydrogenase, and 50 mM potassium phosphate buffer (pH 7.4) in a final volume of 0.5 mL. Aliquots were removed at 5, 10, 20, 30, and 40 min after microsomes addition, and the reaction was stopped by adding four volumes of ice-cold acetonitrile containing 200 nM of internal standard. The samples were centrifuged for 10min at 10000 rpm and the supernatants were transferred in matrix tubes for LC-MS: MS analysis. Each compound was quantified by converting the corresponding analyte/internal standard peak area ratios to percentage drug remaining, using the initial ratio values in control incubations as 100%. Propranolol, known as a high hepatic clearance drug in rodents, was used as a quality-control compound for the microsomal incubations. *In vitro* intrinsic clearance (Cl_{int} expressed as µL/min/mg) was calculated according to: the following formula : Cl_{int} = dose/AUC_∞, where dose is the initial amount of drug in the incubation mixture (1 µM) and AUC_∞ is the area under the concentration versus time curve extrapolated to infinity. The slope of the linear regression from log percentage remaining versus incubation time relationships (-k) was used in the conversion to *in vitro* t_{1/2} values by: t_{1/2} = -ln(2)/k.

Caco-2 permeation assay³⁰. 0.4 x 10⁵ Caco-2 Cells (ATCC No. HTB-37), at passage 28, were seeded on 25 cm² plastic flask and changed every second days with complete medium containing high glucose Dulbecco's Modified Eagle's Medium (DMEM) with L-glutamine supplemented

by 10% of Foetal Calf/Bovine Serum, 1% of non-essential amino acids without L-glutamine. The paracellular barrier characteristics of Caco-2 cells monolayer was monitored using measurement of the permeability to the non-permeant fluorescent molecule, Lucifer Yellow (LY). The permeability to Lucifer yellow values ($<1 \times 10^{-6}$ cm/s) attested of the restriction of the paracellular permeability in Caco-2 cultures in the absence of compound. Caco-2 cells were trypsinized after 3 days of incubation while they cover 80-90% of the flask and seeded at a density of 5×10^5 in 75 cm² flasks in complete medium supplemented with 73 nM (around 0.04 µg/mL) of the antibacterial puromycin (3'-[α-Amino-p-methoxyhydrocinnamamido]-3'-deoxy-N,N-dimethyladenosine dihydrochloride). After 5 to 6 days, Caco2 cells reach high cells density ($>0.5 \times 10^5$ cells/cm²) and are then passage into cell HTS 24-well plates with 0.4 µm Polycarbonate membrane inserts. Cells were seeded at 600 000 cells/cm² (200 000 cells/insert) and cultivated for 6 days in complete medium with puromycin. Media was replaced every second days. Compound solutions were prepared in HEPES-buffered Ringer's (RH) solution (NaCl 150 mM, KCl 5.2 mM, CaCl₂ 2.2 mM, MgCl₂ 0.2 mM, NaHCO₃ 6 mM, Glucose 2.8 mM, HEPES 5 mM, water for injection), pH = 7.4 at a final concentration of 1 to 10 µM for tested drugs. For A→B transport experiment, 0.2 mL of the compound solution was placed on the apical side of the cells and samples were taken from the basolateral compartment. For B→A transport experiment 0.8 mL of the solution was placed on the basolateral side of the cells and samples were taken from apical side. Transport Studies were done in Transwell polycarbonate: HTS 24 well plate inserts (surface area: 0.33 cm² - 0.4 µm pore size). Cells were equilibrated for 10 minutes in transport buffer prior to the transport experiment, and then incubations with compounds were performed at 37 °C under agitation. After 1 hour aliquots were taken from each

compartment and sampled in 96-well plates with glass insert. Permeations are calculated using the formulas below:

$$P_{appA \rightarrow B} = \frac{V_B \times AUC_{B(T)}}{T \times S \times AUC_{B(T_0)}}$$

$$P_{appB \rightarrow A} = \frac{V_A \times AUC_{A(T)}}{T \times S \times AUC_{B(T_0)}}$$

V is the volume of solution in apical side (A) or basolateral side (B), AUC is the area of the LC-MS/MS signal for the compound measured in A or B side at initial time (T₀) or at the end of the incubation (T), T is the incubation time and S is the surface area of the insert membrane.

***In vivo* experiments**

Animals and diets. 10-12 old week male C57Bl6 mice were purchased from Charles River (France) and fed *ad libitum* with a standard diet (UAR A04, Villemoisson/Orge, France). For high fat diet (HFD) experiments, 10-12 old week male C57Bl6 mice were fed a HFD (D12492; Research Diets; 60% kcal fat) for 8-10 weeks to induce obesity and insulin-resistance. Experiments were performed in mice with a 30% increase in body weight. All animals were maintained in standard animal cages under conventional laboratory conditions (12h/12h light/dark cycle, 22°C) with *ad libitum* access to food and water. The animals were maintained in compliance with European standards for the care and use of laboratory animals and experimental protocols approved by the local Animal Ethical Committee (agreements N°CEEA 07430, 01134.01 and 01134.03).

***In vivo* GLP-1 secretion.** Mice were fasted from the time of gavage with vehicle or compound as indicated in figure legend, and gavaged with sitagliptin (25 mpk) (MSD) 45 min before blood (250 µL) was sampled by retro-orbital venipuncture under isoflurane anaesthesia in EDTA-

coated tubes containing DPP-4 inhibitors diprotin A (Sigma-Aldrich). Active GLP-1 plasma concentration was measured by ELISA (Millipore).

Gallbladder Volume Measurement. Mice either fasted or fed as indicated in figure legends, were killed by cervical dislocation. Gallbladder volume (length x width x width) was evaluated using a vernier caliper and removed to measure compound content.

Oral Glucose Tolerance Test. After an overnight fasting, mice were gavaged with Vehicle or compound and fasted for 7 hours. A bolus of glucose (4 g/kg) was administered by gavage and glycemia were measured at 0, 15, 30, 60, 90 and 120 min by glucometer (Roche).

Pharmacokinetics. Compounds **22** and **24** were dissolved in distilled water 0.1% tween and administered *per os* at 32 $\mu\text{mol/kg}$ to 10-week old, male, C57Bl6 mice (approx. 25-30 g) (Charles River). Compound **22** was administered to overnight fasted animals. Three mice per time point were anesthetized with isoflurane and aliquots taken from the retro-orbital sinus using sampling heparinated tubes (4 °C) at 10 min, 20 min, 30 min, 1 h, 2 h, 4 h and 8h after administration of a single dose of ligands. The blood samples were centrifuged (5000 g, 15 min) for plasma separation and stored at -80°C before compound measurement. Plasma samples were thawed on ice. Aliquots were precipitated with ice cold acetonitrile (1 to 10 ratio) containing compound **3** (0.2 μM) as internal standard. The samples were vigorously mixed with a vortex and centrifuged for 10 min at 10 000 rpm, 4 °C, and the supernatants were transferred into Matrix tubes for LC-MS/MS analysis. Spiked standard solutions (1, 3, 10, 30, 100, 300, 1000, 3000, 10 000 and 30 000 nM) were prepared the same way. After rodent sacrifice, gallbladders, livers and intestines were removed. Gallbladders were immediately measured using a vernier caliper. Intestine was cut to isolate duodenum, jejunum, ileum and colon. All tissues were frozen in liquid nitrogen and stored at -80°C. Compound in tissues and in rehydrated feces (feces

collected 24 hours after compound dosing of a dedicated group of animals) was extracted with a MeOH/CH₃CN, 50:50 mixture (using a vortex for feces or a Tissue Lyzer II from Qiagen for tissues). After centrifugation (10000 rpm, 10 min, 4°C) of the homogenate samples, supernatants were diluted (1 to 10) with ice acetonitrile containing compound **3** (0.2 μM) as internal standard. After a last centrifugation, the supernatants were transferred into Matrix tubes for LC-MS/MS analysis.

Synthetic Materials and Methods. All commercial reagents and solvents were used without further purification. Microwave-assisted chemical reactions were conducted on a CEM DiscoverTM synthesis system or a Biotage® Initiator+ microwave synthesizer. Flash column chromatography was performed on prepacked columns (Grace ResolvTM flash cartridges, Grace®). Preparative HPLC were performed using a Varian ProStar system using an Omnisphere 10 C18 column (250 mm x 41.4 mm) Dynamax from Varian, Inc. or a Waters-2 system using a XBridgeTM Prep C18 5μm OBDTM (250 mm x 50 mm or 150 x 30 mm). A gradient starting from CH₃CN-H₂O and formic acid (20-80-0.1%) and reaching 100%CH₃CN/0.1% formic acid at a flow rate of 80 mL/minutes was used on the Varian ProStar system. Products were detected by UV absorption at 215 nm and/or 254 nm. A gradient mixture of CH₃CN and water in ammonium formate buffer at pH 9.2 or pH 3.8 and a flow rate at 40 or 80 mL/min was used on Waters-2 system. Products were detected by UV absorption and/or by MS. NMR spectra were recorded on a Bruker DRX-300 spectrometer. Chemical shifts are in parts per million (ppm). The assignments were made using one-dimensional (1D) ¹H and ¹³C spectra and two-dimensional (2D) HSQC, HMBC and COSY spectra. LCMS analysis was performed on a Waters Alliance Micromass ZQ 2000, using an XBridge C18 column (3.5 μm particle size, dimensions 50 mm x 4.6 mm). A mixture of water and acetonitrile was used as mobile phase in gradient-elution. pH of

mobile phase was adjusted with HCOOH and NH₄OH to form a buffer solution at pH 3.8. The analysis time is 5 minutes (at a flow rate at 2 mL/min). Purity (%) was determined by reversed phase HPLC, using UV detection (215 nm), and all compound showed purity greater than 95% unless otherwise stated (17c and 26c). HRMS analysis was performed on a LCT Premier XE Micromass, using a C18 X-Bridge 3.5 μm particle size column, dimensions 50 mm * 4.6 mm. A gradient starting from 100% H₂O 5 mM Ammonium Formate pH=3.8 and reaching 100% CH₃CN 5 mM Ammonium Formate pH=3.8 within 2 min at a flow rate of 2 mL/min was used. Purification yields were not optimized. Final compounds were isolated as amorphous solids without collection of melting point data.

General procedure A. The 3-amino-5-thio-[1,2,4]triazolyl-amine derivative (1 eq) and the phenylboronic acid derivative (1eq) are dissolved in dichloromethane (QS 20 mM). Molecular sieve 4Å, pyridine (2 eq) and copper(II) acetate (Cu(OAc)₂) (1.5 eq) are added to the solution. Reaction mixture is stirred at room temperature for several hours. Pyridine, phenylboronic acid derivative, and Cu(OAc)₂ are added several time until satisfying conversion. Reaction mixture is then filtered on Celite. Filtrate is washed by water, and a saturated aqueous solution of NaHCO₃. Organic phase is dried over MgSO₄, and evaporated to dryness. Residue is purified by flash chromatography (DCM/MeOH).

Procedure B. In a round bottom flask is added the isothioureido-derivative (1 eq), K₂CO₃ (1 eq), sodium Iodide (0.5 eq), and acetonitrile (QS 0.2M). The suspension is stirred at room temperature for 10 min, benzyl halide (1 eq) is then added. The suspension is stirred at room temperature overnight. Reaction mixture is then evaporated; residue is dissolved in EtOAc, washed with water and brine. Organic phase is dried over Na₂SO₄ and evaporated. Residue is purified by flash chromatography (cyclohexane/EtOAc).

Procedure C. In a microwave tube are introduced the isothioureido-acetamide derivative (1 eq), EtOAc (QS 0.1M), DIEA (6 eq), and T3P® (3 eq). Reaction mixture is heated under microwave irradiation at 150°C for 10 min. Reaction mixture is then diluted with EtOAc, washed by saturated aqueous solution of NaHCO₃ and brine. Organic phase is then dried over Na₂SO₄ and evaporated. Residue is purified by flash chromatography (cyclohexane to cyclohexane/EtOAc).

Procedure D. In a round bottom flask are introduced the isothioureido-acetamide derivative (1 eq), EtOAc (QS 0.1M), DIEA (6 eq), and T3P® (3 eq). Reaction mixture is heated at reflux for 24h. After several hours, DIEA, and T3P® are added several times, until completion. Reaction mixture is then diluted in EtOAc, washed by saturated aqueous solution of NaHCO₃ and brine. Organic phase is dried over Na₂SO₄ and evaporated to dryness. Residue is purified by flash chromatography (cyclohexane/EtOAc).

5-Amino-4-(4-fluoro-phenyl)-4H-[1,2,4]triazole-3-thiol (1a). 4-fluorophenylisothiocyanate (1.04 g, 6.54 mmol), aminoguanidinium chloride (1.45 g, 13.1 mmol), DIEA (3.12 mL, 19.6 mmol) were dissolved in DMF (9.40 mL). Reaction mixture was stirred at 50°C for 15 h, then evaporated to dryness. 13 mL of an aqueous solution of NaOH 2M were then added, and reaction mixture was stirred at 50 °C for 18 hours. Suspension was then filtered, and filtrate was neutralized by addition of aqueous HCl 2M and filtrated. Both precipitates were pulled together, to give an orange powder corresponding to the titled product (1.2 g, 87%). MS [M+H]⁺ *m/z* = 210.9, ¹H NMR (300 MHz, DMSO-*d*₆): δ (ppm) 5.96 (s, 2H), 7.38 (m, 4H), 12.80 (s, 1H).

5-(2,6-Difluoro-benzylsulfanyl)-4-(4-fluoro-phenyl)-4H-[1,2,4]triazol-3-ylamine (1b). 5-Amino-4-(4-fluoro-phenyl)-4H-[1,2,4]triazole-3-thiol (**1a**) (501 mg, 2.38 mmol), 2-bromomethyl-1,3-difluoro-benzene (492 mg, 2.37 mmol), DIEA (416 μL, 2.62 mmol) were dissolved in 12 mL of dichloromethane. Reaction mixture was stirred at room temperature for 3

hours, then washed with water and brine, and organic phase was dried over MgSO₄, and evaporated to dryness to give 787 mg of the expected product as a white powder (98%). MS [M+H]⁺ *m/z* = 336.9, ¹H NMR (300 MHz, DMSO-*d*₆): δ (ppm) 3.88 (s, 2H), 5.89 (s, 2H), 7.03 (t, *J* = 8.0 Hz, 2H), 7.26-7.40 (m, 5H).

***N*-[5-(2,6-Difluoro-benzylsulfanyl)-4-(4-fluoro-phenyl)-4*H*-[1,2,4]triazol-3-yl]-acetamide**

(1c). 5-(2,6-Difluoro-benzylsulfanyl)-4-(4-fluoro-phenyl)-4*H*-[1,2,4]triazol-3-ylamine (**1b**) (318 mg, 94.5 μmol) was dissolved in 0.5 mL of dichloromethane and acetic anhydride (450 μL, 4.73 mmol) was then added. Reaction mixture was stirred at room temperature for 30 min. 5 mL of an aqueous solution of NaHCO₃ 2N were then added. Phases were separated, and organic phase was dried over MgSO₄, and evaporated to dryness. Residue was recrystallized in isopropanol to give the titled product as white crystals (238 mg, 66%). MS [M+H]⁺ *m/z* = 378.9, ¹H NMR (300 MHz, DMSO-*d*₆): δ (ppm) 1.84 (s, 3H), 4.19 (s, 2H), 7.05 (t, *J* = 8.0 Hz, 2H), 7.23-7.42 (m, 5H), 10.37 (brs, 1H).

***N*-[5-(2,6-Difluoro-benzylsulfanyl)-4-(4-fluoro-phenyl)-4*H*-[1,2,4]triazol-3-yl]-*N*-(3,4-**

dimethoxy-phenyl)-acetamide (1d). The titled compound was obtained as a yellowish oil (420 mg, 50 %) following procedure A, using *N*-[5-(2,6-Difluoro-benzylsulfanyl)-4-(4-fluoro-phenyl)-4*H*-[1,2,4]triazol-3-yl]-acetamide (**1c**) (570 mg, 1.5 mmol), and 3,4-dimethoxyphenylboronic acid. MS [M+H]⁺ *m/z* = 514.9, ¹H NMR (300 MHz, DMSO-*d*₆): δ (ppm) 1.65 (s, 3H), 3.79 (s, 3H), 3.81 (s, 3H), 4.31 (s, 2H), 7.05-7.18 (m, 3H), 7.24-7.54 (m, 7H).

[5-(2,6-Difluoro-benzylsulfanyl)-4-(4-fluoro-phenyl)-4*H*-[1,2,4]triazol-3-yl]-(3,4-dimethoxy-phenyl)-amine (1). Acetyl chloride (2.4 mL) and ethanol (5 mL) were gently mixed at 0-5°C, and the mixture was added to a solution of *N*-[5-(2,6-Difluoro-benzylsulfanyl)-4-(4-fluoro-

phenyl)-4H-[1,2,4]triazol-3-yl]-N-(3,4-dimethoxy-phenyl)-acetamide (**1d**) (310 mg, 602 μmol) in 4.6 mL of ethanol. Reaction mixture was then heated at 100°C for 30 min. Reaction mixture was then evaporated. The residue was dissolved in EtOAc, washed with water, and with a saturated aqueous solution of NaHCO_3 . Organic phase was dried over MgSO_4 , and evaporated to dryness. Residue was recrystallized in a mixture of isopropanol/methanol to give 163.5 mg of the expected product as a white solid (57%). LC-MS: $t_R = 2.60$ min, MS $[\text{M}+\text{H}]^+ m/z = 472.9$, ^1H NMR (300 MHz, $\text{DMSO}-d_6$): δ (ppm) 3.77 (s, 3H, O-CH₃), 3.78 (s, 3H, O-CH₃), 4.22 (s, 2H, S-CH₂), 5.13 (brs, 1H, NH), 7.00 (d, $J = 8.8$ Hz, 2H, Ar), 7.35-7.55 (m, 8H, Ar). ^{13}C NMR (75 MHz, $\text{DMSO}-d_6$): δ (ppm) 24.0, 56.0, 56.2, 110.9, 112.0, 112.3, 113.1 (t, $J = 18.9$ Hz), 117.5 (d, $J = 23.2$ Hz), 126.6-129.3 (m), 130.9 (t, $J = 10.4$ Hz), 131.3 (d, $J = 8.9$ Hz), 132.4-133.0 (m), 142.2, 146.1, 149.2, 151.9, 160.9, 161.1 (dd, $J = 248.4, 7.2$ Hz), 162.7 (d, $J = 247.9$ Hz).

[5-(2,6-Difluoro-benzylsulfanyl)-4-(4-fluoro-phenyl)-4H-[1,2,4]triazol-3-yl]-methyl-amine (2c). A suspension of 5-(2,6-Difluoro-benzylsulfanyl)-4-(4-fluoro-phenyl)-4H-[1,2,4]triazol-3-ylamine (**1b**) (200 mg, 595 μmol) and sodium methanolate (161 mg, 2.98 mmol) in methanol (QS 0.5M) was added to paraformaldehyde (25 mg, 833 μmol). Reaction mixture was stirred at room temperature for 16 hours. NaBH_4 (22.5 mg, 595 μmol) was then added, and reaction mixture was stirred at reflux for 30 min. After cooling down to room temperature, reaction mixture was partially evaporated. Aqueous KOH 1M was then added. This solution was then extracted by EtOAc. Organic phase was dried over MgSO_4 , and evaporated to dryness. Residue was purified by flash chromatography using as eluent a mixture of DCM/MeOH to give the titled compound as a yellowish solid (157 mg, 76%). MS $[\text{M}+\text{H}]^+ m/z = 350.9$, ^1H NMR (300 MHz, $\text{DMSO}-d_6$): δ (ppm) 2.73 (d, $J = 4.8$ Hz, 3H), 3.91 (s, 2H), 5.82 (q, $J = 4.7$ Hz, 1H), 7.04 (t, $J = 8.0$ Hz, 2H), 7.25-7.43 (m, 5H).

[5-(2,6-Difluoro-benzylsulfanyl)-4-(4-fluoro-phenyl)-4H-[1,2,4]triazol-3-yl]-(3,4-dimethoxy-phenyl)-methyl-amine (2). The titled compound was obtained as a yellowish solid (42.4 mg, 11%) after purification by preparative HPLC, following procedure A using [[5-(2,6-Difluoro-benzylsulfanyl)-4-(4-fluoro-phenyl)-4H-[1,2,4]triazol-3-yl]-methyl-amine (**2c**) (281 mg, 800 μmol) and 3,4-dimethoxyphenylboronic acid. LC-MS: $t_{\text{R}} = 2.60$ min, MS $[\text{M}+\text{H}]^+ m/z = 486.9$. HRMS found 487.1394; $\text{C}_{24}\text{H}_{21}\text{F}_3\text{N}_4\text{O}_2\text{S}$ requires 487.1416. ^1H NMR (300 MHz, CDCl_3): δ (ppm) 2.69 (s, 3H), 3.92 (s, 3H), 3.95 (s, 3H), 4.26 (s, 2H), 6.84-6.94 (m, 3H), 7.10-7.42 (m, 7H).

(3,4-dimethoxy-phenyl)-methyl-amine (3a). In a 250 mL flask were added 3 g of 3,4-dimethoxyaniline and 5.29 g of sodium methoxide in 35 mL of methanol (dried over Na_2SO_4). Then, 1.18 g of paraformaldehyde and 15 mL of methanol (dried over Na_2SO_4) were added. Molecular sieve (4 \AA) was then added and the mixture was stirred overnight at room temperature. 0.74 g of sodium borohydride were then added, and the mixture was heated under reflux for 1 hour. The mixture was then evaporated, dissolved in EtOAc and water, the two phases were separated. The aqueous phase was then basified by addition of a saturated aqueous solution of NaHCO_3 , and extracted by EtOAc. The organic phases were washed with a saturated aqueous solution of NaHCO_3 , brine, dried over Na_2SO_4 and evaporated to dryness to give the titled product as an oily residue (2.67 g, 77 %), which was used without further purification in the next step of the synthesis. MS $[\text{M}+\text{H}]^+ m/z = 168.0$. ^1H NMR (300 MHz, $\text{DMSO}-d_6$): δ (ppm) 2.62 (d, $J = 5.0$ Hz, 3H), 3.61 (s, 3H), 3.69 (s, 3H), 5.20 (q, $J = 4.9$ Hz, 1H), 5.99 (dd, $J = 8.5, 2.5$ Hz, 1H), 6.22, (d, $J = 2.5$ Hz, 1H), 6.71 (d, $J = 8.5$ Hz, 1H).

2-Chloro-N-(3,4-dimethoxy-phenyl)-N-methyl-acetamide (3b). In a 250 mL flask were introduced a solution of 2.67 g of (3,4-dimethoxy-phenyl)-methyl-amine (**3a**) and 7.9 mL of

DIEA in 45 mL of DCM (dried over Na₂SO₄). The solution was stirred at 0°C. Then, a solution of 2.4 mL of chloroacetyl chloride in 30 mL of DCM (dried over Na₂SO₄) was added dropwise in the flask. The mixture was then evaporated to dryness to give a brown residue which was used without further purification in the next step of the synthesis. MS [M+H]⁺ *m/z* = 244.1.

[2-(3,4-Dimethoxy-N-methyl-anilino)-2-oxo-ethyl]ammonium formate (3c). Residue corresponding to 2-Chloro-N-(3,4-dimethoxy-phenyl)-N-methyl-acetamide (**3b**) obtained was dissolved in 25 mL of Ethanol 95°, and added dropwise in a 500 mL flask containing 320 mL of aqueous ammonia at 65°C. Reaction mixture was then evaporated to dryness. Residue was dissolved in DCM, and extracted several times with an aqueous solution of HCOOH 1M. Aqueous phase was then evaporated to dryness, and the residue was triturated in acetonitrile. The supernatant was evaporated to dryness, to give the titled product as a brown powder (3.82 g, 75 % yield over the 2 steps). MS [M+H]⁺ *m/z* = 225.1. ¹H NMR (300 MHz, DMSO-*d*₆): δ (ppm) 3.17 (s, 3H), 3.76-3.77 (m, 6H), 3.99 (s, 2H), 6.90 (dd, *J* = 8.4, 2.2 Hz, 1H), 6.99-7.03 (m, 2H), 8.00 (brs, 3H), 8.20 (s, 1H).

N-(3,4-Dimethoxy-phenyl)-2-[3-(4-fluoro-phenyl)-isothioureido]-N-methyl-acetamide (3d). 1.5 g of 4-fluorophenylisothiocyanate and 1.59 mL of TEA were added in a 250 mL flask in 15 mL of ethanol. 3.2 g of [2-(3,4-dimethoxy-N-methyl-anilino)-2-oxo-ethyl]ammonium formate (**3c**) were dissolved in 115 mL of ethanol, 1.33 mL of TEA were added, and the mixture was added dropwise at room temperature. After the addition, the reaction was over. Reaction mixture was evaporated to dryness and purified by flash chromatography using as eluent a mixture of cyclohexane/EtOAc to give the titled product as a yellowish powder (2.8 g, 76 %). MS [M-H]⁻ *m/z* = 244.1. ¹H NMR (300 MHz, DMSO-*d*₆): δ (ppm) 2.49 (s, 3H), 3.78 (m, 6H), 4.00 (d, *J* =

4.1 Hz, 2H), 6.92 (dd, $J = 8.4, 1.8$ Hz, 1H), 7.01-7.03 (m, 2H), 7.15 (m, 2H), 7.45 (m, 2H), 7.73 (m, 1H), 9.90 (s, 1H).

2-[2-(2,6-Difluoro-benzyl)-3-(4-fluoro-phenyl)-isothioureido]-N-(3,4-dimethoxy-phenyl)-N-methyl-acetamide (3e) The titled product was obtained without purification as an oily residue (1.15 g, 91%), following Procedure B, using N-(3,4-Dimethoxy-phenyl)-2-[3-(4-fluoro-phenyl)-isothioureido]-N-methyl-acetamide (**3d**) (940 mg) and 2-Bromomethyl-1,3-difluoro-benzene (518 mg). MS $[M+H]^+$ $m/z = 504.0$. ^1H NMR (300 MHz, DMSO- d_6): δ (ppm) 3.16 (s, 3H), 3.69-3.76 (m, 8H), 4.19 (s, 2H), 6.61 (m, 2H), 6.79-6.89 (m, 2H), 6.95-7.00 (m, 4H), 7.05-7.13 (m, 3H), 7.38 (m, 1H).

[2-(2,6-Difluoro-benzylsulfanyl)-3-(4-fluoro-phenyl)-3H-imidazol-4-yl]-(3,4-dimethoxy-phenyl)-methyl-amine (3). In a 50 mL flask were added 2-[2-(2,6-difluoro-benzyl)-3-(4-fluoro-phenyl)-isothioureido]-N-(3,4-dimethoxy-phenyl)-N-methyl-acetamide (**3e**) (500 mg), 10 mL EtOAc, NEt_3 (843 μL), and T3P® (1.77 mL). Reaction mixture was then stirred at reflux for 28 hours. After 8 hours, NEt_3 (843 μL) and T3P® (1.77 mL) were added. After 25 hours, NEt_3 (422 μL) and T3P® (885 μL) were added. After dilution with 20 mL EtOAc, the solution was washed with a saturated aqueous solution of NaHCO_3 , and brine. Organic phase was dried over Na_2SO_4 and evaporated. Residue was purified by flash chromatography using as eluent a mixture of DCM/MeOH. The titled product was obtained as an oily residue (160 mg, 33%). LC-MS: $t_R = 3.13$ min, MS $[M+H]^+$ $m/z = 486.3$. HRMS found 486.1437; $\text{C}_{25}\text{H}_{22}\text{F}_3\text{N}_3\text{O}_2\text{S}$ requires 486.1463. ^1H NMR (300 MHz, CDCl_3): δ (ppm) 2.92 (s, 3H), 3.80 (s, 3H), 3.82 (s, 3H), 4.16 (s, 2H), 6.16 (dd, $J = 8.7, 2.7$ Hz, 1H), 6.30 (d, $J = 2.7$ Hz, 1H), 6.72 (d, $J = 8.7$ Hz, 1H), 6.78 (m, 2H), 6.83-6.85 (m, 4H), 6.92 (s, 1H), 7.19 (m, 1H). ^{13}C NMR (75 MHz, CDCl_3): δ (ppm) 25.9, 40.1, 55.9, 56.4, 99.9, 105.5, 111.2, 112.4, 113.6 (t, $J = 19.3$ Hz), 115.9 (d, $J = 22.9$ Hz), 124.4, 129.1,

129.2, 130.8, 138.1, 139.6, 142.7, 143.2, 149.6, 161.1 (dd, $J = 250.0, 7.7$ Hz), 162.2 (d, $J = 249.0$ Hz).

N-(3,4-Dimethoxy-phenyl)-2-[2-(2-fluoro-benzyl)-3-(4-fluoro-phenyl)-isothioureido]-N-methyl-acetamide (4e). The titled product was obtained without purification as an oily residue (254 mg, 96%), following Procedure B, using N-(3,4-Dimethoxy-phenyl)-2-[3-(4-fluoro-phenyl)-isothioureido]-N-methyl-acetamide (**3d**) (195 mg) and 1-(bromomethyl)-2-fluorobenzene (94 mg). MS $[M+H]^+$ $m/z = 486.0$, 1H NMR (300 MHz, DMSO- d_6): δ (ppm) 3.16 (s, 3H), 3.39-3.76 (m, 8H), 4.17 (s, 2H), 6.59-6.89 (m, 4H), 6.95-7.00 (m, 4H), 7.11-7.19 (m, 2H), 7.31 (m, 1H), 7.41 (m, 1H).

(3,4-Dimethoxy-phenyl)-[2-(2-fluoro-benzylsulfanyl)-3-(4-fluoro-phenyl)-3H-imidazol-4-yl]-methyl-amine (4). The titled product was obtained as an orange powder (130 mg, 61%), following Procedure C, using N-(3,4-Dimethoxy-phenyl)-2-[2-(2-fluoro-benzyl)-3-(4-fluoro-phenyl)-isothioureido]-N-methyl-acetamide (**4e**). LC-MS: $t_R = 3.28$ min, MS $[M+H]^+$ $m/z = 468.0$. HRMS found 468.1544; $C_{25}H_{23}F_2N_3O_2S$ requires 468.1557. 1H NMR (300 MHz, $CDCl_3$): δ (ppm) 3.77 (s, 3H), 3.81 (s, 3H), 4.27 (s, 2H), 6.11 (dd, $J = 8.7, 2.7$ Hz, 1H), 6.22 (d, $J = 2.7$ Hz, 1H), 6.69 (d, $J = 8.7$ Hz, 1H), 6.79-6.84 (m, 2H), 6.90-7.06 (m, 5H), 7.20-7.25 (m, 2H). ^{13}C NMR (75 MHz, $CDCl_3$): δ (ppm) 31.8, 40.3, 55.9, 56.5, 100.0, 105.8, 112.4, 115.5 (d, $J = 21.5$ Hz), 116.0 (d, $J = 22.8$ Hz), 123.8, 124.1, 124.7 (d, $J = 14.8$ Hz), 129.1, 129.2, 129.4, 130.7, 131.0, 139.1, 139.3, 142.7, 143.1, 149.6, 160.9 (d, $J = 248.3$ Hz), 162.4 (d, $J = 249.8$ Hz).

2-[2-Benzyl-3-(4-fluoro-phenyl)-isothioureido]-N-(3,4-dimethoxy-phenyl)-N-methyl-acetamide (5e). The titled product was obtained without purification as an oily residue (259 mg, 98%), following Procedure B, using N-(3,4-Dimethoxy-phenyl)-2-[3-(4-fluoro-phenyl)-isothioureido]-N-methyl-acetamide (**3d**) (195 mg) and benzylbromide (85 mg). MS $[M+H]^+$ m/z

= 468.0, ¹H NMR (300 MHz, DMSO-*d*₆): δ (ppm) 3.17 (s, 3H), 3.69-3.76 (m, 8H), 4.14 (s, 2H), 6.61 (m, 3H), 6.88 (m, 1H), 6.95-7.01 (m, 4H), 7.22-7.31 (m, 5H).

[2-Benzylsulfanyl-3-(4-fluoro-phenyl)-3H-imidazol-4-yl]-(3,4-dimethoxy-phenyl)-methyl-amine (5). The titled product was obtained as an orange powder (68 mg, 32%), following Procedure C, using 2-[2-Benzyl-3-(4-fluoro-phenyl)-isothioureido]-N-(3,4-dimethoxy-phenyl)-N-methyl-acetamide (**5e**) (249 mg). LC-MS: *t*_R = 3.32 min, MS [M+H]⁺ *m/z* = 450.0. HRMS found 450.1659; C₂₅H₂₄FN₃O₂S requires 450.1652. ¹H NMR (CDCl₃): δ (ppm) 2.92 (s, 3H), 3.75 (s, 3H), 3.81 (s, 3H), 4.26 (s, 2H), 6.09 (dd, *J* = 8.8, 2.8 Hz, 1H), 6.20 (d, *J* = 2.7 Hz, 1H), 6.68 (d, *J* = 8.8 Hz, 1H), 6.74-6.78 (m, 2H), 6.89-6.95 (m, 2H), 7.04 (s, 1H), 7.19-7.29 (m, 5H). ¹³C NMR (75 MHz, CDCl₃): δ (ppm) 38.7, 40.3, 55.9, 56.5, 99.9, 105.8, 112.4, 115.7, 115.9 (d, *J* = 22.8 Hz), 123.6, 127.4, 128.5, 129.0, 129.3 (d, *J* = 8.6 Hz), 130.7, 137.4, 139.2, 139.4, 142.7, 143.1, 149.5, 162.4 (d, *J* = 248.9 Hz).

N-(3,4-Dimethoxy-phenyl)-2-[2-(2,6-dimethyl-benzyl)-3-(4-fluoro-phenyl)-isothioureido]-N-methyl-acetamide (6e). The titled product was obtained without purification as an oily residue (230 mg, 90%), following Procedure B, using N-(3,4-Dimethoxy-phenyl)-2-[3-(4-fluoro-phenyl)-isothioureido]-N-methyl-acetamide (**3d**) (195 mg) and 2-(chloromethyl)-1,3-dimethylbenzene (77 mg). MS [M+H]⁺ *m/z* = 496.0, ¹H NMR (300 MHz, DMSO-*d*₆): δ (ppm) 2.25 (s, 6H), 3.18 (s, 3H), 3.68-3.77 (m, 8H), 4.14 (s, 2H), 6.69-7.05 (m, 11H).

(3,4-Dimethoxy-phenyl)-[2-(2,6-dimethyl-benzylsulfanyl)-3-(4-fluoro-phenyl)-3H-imidazol-4-yl]-methyl-amine (6). The titled product was obtained as an orange powder (63 mg, 34 %) following procedure C using N-(3,4-Dimethoxy-phenyl)-2-[2-(2,6-dimethyl-benzyl)-3-(4-fluoro-phenyl)-isothioureido]-N-methyl-acetamide (**6e**) (200 mg). LC-MS: *t*_R = 3.45 min, MS [M+H]⁺ *m/z* = 478.0. HRMS found 478.1974; C₂₇H₂₈FN₃O₂S requires 478.1965. ¹H NMR (300 MHz,

CDCl₃): δ (ppm) 2.28 (s, 6H), 2.95 (s, 3H), 3.78 (s, 3H), 3.82 (s, 3H), 4.34 (s, 2H), 6.15 (dd, $J = 8.7, 2.7$ Hz, 1H), 6.25 (d, $J = 2.8$ Hz, 1H), 6.70 (d, $J = 8.7$ Hz, 1H), 6.86-7.05 (m, 8H). ¹³C NMR (75 MHz, CDCl₃): δ (ppm) 19.6, 33.3, 40.4, 56.0, 56.4, 100.1, 106.1, 112.4, 115.9 (d, $J = 23.0$ Hz), 123.4, 127.5, 128.3, 129.3 (d, $J = 8.7$ Hz), 130.8, 132.4, 137.6, 139.4, 140.0, 142.8, 143.1, 149.6, 162.3 (d, $J = 250.2$ Hz).

N-(3,4-Dimethoxy-phenyl)-N-methyl-2-(3-phenyl-isothioureido)-acetamide (7d).

Phenylisothiocyanate (159.5 μ L, 1.33 mmol) and NEt₃ (216 μ L, 1.60 mmol) were added in a 100 mL flask in 2 mL of ethanol. Residue from [2-(3,4-dimethoxy-N-methyl-anilino)-2-oxo-ethyl]ammonium formate (**3c**) (400 mg, 1.33 mmol) was dissolved in 16 mL of ethanol, NEt₃ (180 μ L, 1.33 mmol) was added, and the mixture was added dropwise at room temperature. After the addition, the reaction was over. Reaction mixture was evaporated to dryness, and purified by flash chromatography using as eluent a mixture of DCM/MeOH (99.5/0.5) to give the titled product as a yellowish residue (162 mg, 34 %). MS [M+H]⁺ $m/z = 359.9$.

2-[2-(2,6-Difluoro-benzyl)-3-phenyl-isothioureido]-N-(3,4-dimethoxy-phenyl)-N-methyl-acetamide (7e). The titled product was obtained as yellowish solid (183 mg, 84%), without purification, following Procedure B, using *N*-(3,4-Dimethoxy-phenyl)-*N*-methyl-2-(3-phenyl-isothioureido)-acetamide (**7d**) (162 mg, 450 μ mol) and 2-Bromomethyl-1,3-difluoro-benzene (93 mg, 450 μ mol). MS [M+H]⁺ $m/z = 486.0$, ¹H NMR (300 MHz, CDCl₃): δ (ppm) 3.27 (s, 3H), 3.81-3.87 (m, 8H), 4.12 (s, 2H), 6.68-7.21 (m, 11H).

[2-(2,6-Difluoro-benzylsulfanyl)-3-phenyl-3H-imidazol-4-yl]-(3,4-dimethoxy-phenyl)-methyl-amine (7). 2-[2-(2,6-Difluoro-benzyl)-3-phenyl-isothioureido]-*N*-(3,4-dimethoxy-phenyl)-*N*-methyl-acetamide (**7e**) (183 mg, 0.38 mmol) was dissolved in 3.8 mL of EtOAc. DIEA (395 μ L, 2.26 mmol), and T3P® in EtOAc (666 μ L, 1.13 mmol) were then added. The

reaction mixture was heated under microwave irradiation at 150°C for 10 min. Reaction mixture was then diluted with EtOAc, washed with a saturated aqueous solution of NaHCO₃, and brine. Organic phase was then dried over Na₂SO₄ and evaporated to dryness. Residue was then purified by flash chromatography using as eluent a mixture of cyclohexane/EtOAc (85/15), and then again by flash chromatography using as eluent a mixture of cyclohexane/DCM (1/1) to DCM/MeOH (99/1) to give the titled product as a reddish solid (21 mg, 11%). LC-MS: t_R = 3.10 min, MS [M+H]⁺ m/z = 467.9. HRMS found 468.1547; C₂₅H₂₃F₂N₃O₂S requires 468.1557. ¹H NMR (300 MHz, CDCl₃): δ (ppm) 2.90 (s, 3H), 3.80 (s, 3H), 3.82 (s, 3H), 4.18 (s, 2H), 6.17 (dd, J = 8.7, 2.8 Hz, 1H), 6.31 (d, J = 2.8 Hz, 1H), 6.70-6.83 (m, 3H), 6.99-7.04 (m, 3H), 7.18 (m, 1H), 7.25-7.32 (m, 3H). ¹³C NMR (75 MHz, CDCl₃): δ (ppm) 25.7, 40.0, 55.9, 56.5, 99.8, 105.3, 111.3 (m), 112.4, 113.6 (t, J = 19.4 Hz), 124.2, 127.3, 128.7, 128.9, 129.1 (t, J = 9.9 Hz), 134.9, 138.3, 139.5, 142.6, 143.3, 149.6, 161.3 (dd, J = 249.8, 7.4 Hz).

N-(3,4-Dimethoxy-phenyl)-2-[3-(4-methoxy-phenyl)-isothioureido]-N-methyl-acetamide

(8d). 4-methoxyphenylisothiocyanate (184.0 μL, 1.33 mmol) and NEt₃ (216 μL, 1.60 mmol) were added in a 100 mL flask in 2 mL of ethanol. [2-(3,4-dimethoxy-N-methyl-anilino)-2-oxo-ethyl]ammonium formate (**3c**) (400 mg, 1.33 mmol) was dissolved in 16 mL of ethanol, NEt₃ (180 μL, 1.33 mmol) was added, and the mixture was added dropwise at room temperature. After the addition, the reaction was over. Reaction mixture was evaporated to dryness, and purified by flash chromatography using as eluent a mixture of DCM/MeOH (99/1), to give the titled product as a yellowish powder (157 mg, 30%). MS [M+H]⁺ m/z = 389.9.

2-[2-(2,6-Difluoro-benzyl)-3-(4-methoxy-phenyl)-isothioureido]-N-(3,4-dimethoxy-phenyl)-N-methyl-acetamide (8e). The titled product was obtained as an orange solid (170 mg, 82%) without purification, following Procedure B, using N-(3,4-Dimethoxy-phenyl)-2-[3-(4-methoxy-

phenyl)-isothioureido]-N-methyl-acetamide (**8d**) (157 mg, 400 μmol) and 2-Bromomethyl-1,3-difluoro-benzene (83 mg, 400 μmol). MS $[\text{M}+\text{H}]^+$ $m/z = 516.0$. ^1H NMR (300 MHz, CDCl_3): δ (ppm) 3.28 (s, 3H), 3.71 (s, 3H), 3.82-3.88 (m, 8H), 4.12 (s, 2H), 6.70-6.85 (m, 9H), 7.17 (m, 1H).

[2-(2,6-Difluoro-benzylsulfanyl)-3-(4-methoxy-phenyl)-3H-imidazol-4-yl]-(3,4-dimethoxy-phenyl)-methyl-amine (8). 2-[2-(2,6-Difluoro-benzyl)-3-(4-methoxy-phenyl)-isothioureido]-N-(3,4-dimethoxy-phenyl)-N-methyl-acetamide (**8e**) (170 mg, 0.33 mmol) was dissolved in 3.3 mL of EtOAc. DIEA (346 μL , 1.98 mmol), and T3P® in EtOAc (583 μL , 0.98 mmol) were then added. The mixture was heated under microwave irradiation at 150°C for 10 min. Reaction mixture was then diluted with EtOAc, washed with a saturated aqueous solution of NaHCO_3 , and brine. Organic phase was then dried over Na_2SO_4 and evaporated to dryness. Residue was then purified by flash chromatography using as eluent a mixture of cyclohexane/EtOAc (85/15), to give the titled product a reddish solid (77 mg, 46%). LC-MS: $t_{\text{R}} = 3.08$ min, MS $[\text{M}+\text{H}]^+$ $m/z = 498.0$. HRMS found 498.1672; $\text{C}_{26}\text{H}_{25}\text{F}_2\text{N}_3\text{O}_3\text{S}$ requires 498.1663. ^1H NMR (300 MHz, CDCl_3) : δ (ppm) 2.91 (s, 3H), 3.77 (s, 3H), 3.80-3.81 (m, 6H), 4.17 (s, 2H), 6.16 (dd, $J = 8.7, 2.8$ Hz, 1H), 6.30 (d, $J = 2.7$ Hz, 1H), 6.70-6.83 (m, 5H), 6.93 (m, 2H), 7.01 (s, 1H), 7.18 (m, 1H). ^{13}C NMR (75 MHz, CDCl_3): δ (ppm) 25.6, 39.9, 55.4, 55.9, 56.5, 99.6, 105.1, 111.2 (m), 112.4, 113.6 (t, $J = 19.6$ Hz), 114.1, 124.2, 127.5, 128.5, 129.1 (t, $J = 10.4$ Hz), 138.6, 139.6, 142.4, 143.4, 149.5, 159.5, 161.2 (dd, $J = 250.1, 7.9$ Hz).

N-(3,4-Dimethoxy-phenyl)-N-methyl-2-[3-(4-trifluoromethyl-phenyl)-isothioureido]-acetamide (9d). 4-(trifluoromethyl)phenylisothiocyanate (332 mg, 1.63 mmol) and TEA (264 μL , 1.96 mmol) were added in a 100 mL flask in 2 mL of ethanol. [2-(3,4-dimethoxy-N-methyl-anilino)-2-oxo-ethyl]ammonium formate (**3c**) (490 mg, 1.63 mmol) was dissolved in 18 mL of

ethanol, NEt₃ (220 μL, 1.63 mmol) was added and the mixture was added dropwise at room temperature. After the addition, the reaction was over. Reaction mixture was evaporated to dryness, and purified by flash chromatography using as eluent a mixture of cyclohexane/EtOAc (6/4), to give the titled product as a yellowish powder (352 mg, 50%). MS [M+H]⁺ *m/z* = 427.9. ¹H NMR (300 MHz, DMSO-*d*₆): δ (ppm) 3.18 (s, 3H), 3.78 (s, 3H), 3.79 (s, 3H), 4.02 (d, *J* = 3.8 Hz, 2H), 6.93 (dd, *J* = 8.5, 2.2 Hz, 1H), 7.01-7.06 (m, 2H), 7.65 (d, *J* = 8.6 Hz, 2H), 7.80 (d, *J* = 8.6 Hz, 2H), 8.08 (s, 1H), 10.3 (s, 1H).

2-[2-(2,6-Difluoro-benzyl)-3-(4-trifluoromethyl-phenyl)-isothioureido]-N-(3,4-dimethoxy-phenyl)-N-methyl-acetamide (9e). The titled product was obtained as an orange solid (438 mg, 96 %) without purification, following Procedure B, using N-(3,4-Dimethoxy-phenyl)-N-methyl-2-[3-(4-trifluoromethyl-phenyl)-isothioureido]-acetamide (**9d**) (352 mg) and 2-Bromomethyl-1,3-difluoro-benzene (170 mg). MS [M+H]⁺ *m/z* = 554.0. ¹H NMR (300 MHz, DMSO-*d*₆): δ (ppm) 3.16 (s, 3H), 3.68 (s, 3H), 3.76 (m, 5H), 4.21 (s, 2H), 6.77-6.88 (m, 3H), 6.95-6.99 (m, 2H), 7.05-7.11 (m, 3H), 7.39 (m, 1H), 7.49 (d, *J* = 8.4 Hz, 2H).

[2-(2,6-Difluoro-benzylsulfanyl)-3-(4-trifluoromethyl-phenyl)-3H-imidazol-4-yl]-(3,4-dimethoxy-phenyl)-methyl-amine (9). 2-[2-(2,6-Difluoro-benzyl)-3-(4-trifluoromethyl-phenyl)-isothioureido]-N-(3,4-dimethoxy-phenyl)-N-methyl-acetamide (**9e**) (438 mg, 0.79 mmol) was dissolved in 8 mL of EtOAc. DIEA (829 μL, 4.75 mmol), and T3P® in EtOAc (1.40 mL, 2.37 mmol) were then added. The mixture was heated under microwave irradiation at 150°C for 10 min. Reaction mixture was then diluted with EtOAc, washed with a saturated aqueous solution of NaHCO₃, and brine. Organic phase was then dried over Na₂SO₄ and evaporated to dryness. Residue was then purified by flash chromatography using as eluent a mixture of cyclohexane/EtOAc (85/15), to give the titled compound as an orange solid (166 mg, 39 %). LC-

MS: $t_R = 3.42$ min, MS $[M+H]^+ m/z = 535.9$. HRMS found 536.1433; $C_{26}H_{22}F_5N_3O_2S$ requires 536.1431. 1H NMR (300 MHz, $CDCl_3$): δ (ppm) 2.92 (s, 3H), 3.80 (s, 3H), 3.83 (s, 3H), 4.16 (s, 2H), 6.19 (dd, $J = 8.7, 2.7$ Hz, 1H), 6.31 (d, $J = 2.7$ Hz, 1H), 6.72 (d, $J = 8.8$ Hz, 1H), 6.79 (m, 2H), 7.06 (s, 1H), 7.13 (d, $J = 8.3$ Hz, 2H), 7.18 (m, 1H), 7.53 (d, $J = 8.3$ Hz, 2H). ^{13}C NMR (75 MHz, $CDCl_3$): δ (ppm) 26.3, 40.3, 56.0, 56.5, 100.2, 106.0, 111.4 (m), 112.5, 113.5 (t, $J = 19.3$ Hz), 123.7 (q, $J = 271.3$ Hz), 126.1 (q, $J = 10.1$ Hz), 130.6 (q, $J = 32.6$ Hz), 137.9, 138.0, 139.8, 143.0, 149.7, 161.2 (dd, $J = 250.0, 7.4$ Hz).

***tert*-Butyl N-[2-(3,4-dimethoxy-N-methyl-anilino)-2-oxo-ethyl]carbamate (10b).** In a 250 mL flask was added (3,4-dimethoxy-phenyl)-methyl-amine (**3a**) (903 mg, 5.405 mmol) in 4 mL of EtOAc. Then 2-(*tert*-butoxycarbonylamino)acetic acid (1136 mg, 6.486 mmol), T3P® (4.777 mL, 5159 mmol) and DIEA (2.832 mL, 16.21 mmol) were added. The mixture was stirred at room temperature for 30 min. Then reaction mixture was diluted with EtOAc, washed with water, with a saturated aqueous solution of $NaHCO_3$ and brine. The organic phase was dried over $MgSO_4$, and evaporated to dryness, to give 1.77 g of reddish powder corresponding to the expected product, leading to a 100% yield. MS $[M+H]^+ m/z = 325.0$. 1H NMR (300 MHz, $CDCl_3$): δ (ppm) 1.42 (s, 9H), 3.27 (s, 3H), 3.68 (s, 2H), 3.89 (m, 6H), 6.68 (d, $J = 2.4$ Hz, 1H), 6.76 (dd, $J = 8.4, 2.4$ Hz, 1H), 6.86 (d, $J = 8.5$ Hz, 1H).

[2-(3,4-Dimethoxy-N-methyl-anilino)-2-oxo-ethyl] ammonium; 2,2,2-trifluoroacetate (10c). In a 50 mL flask *tert*-butyl N-[2-(3,4-dimethoxy-N-methyl-anilino)-2-oxo-ethyl]carbamate (**10b**) (1770 mg, 5.458 mmol) was dissolved in 13.6 mL of DCM. TFA (5.526 mL, 72.21 mmol) was added and the reaction mixture was stirred at room temperature for 15 minutes. Reaction mixture was evaporated to dryness to give purple oil, corresponding to the expected product. Residue was used without further purification in the next step of the synthesis. MS $[M+H]^+ m/z = 225.1$.

***N*-(3,4-Dimethoxy-phenyl)-2-[3-(3-chloro-4-fluoro-phenyl)-isothioureido]-*N*-methyl-acetamide (10d).** In a 100 mL flask were added 2-Chloro-1-fluoro-4-isothiocyanato-benzene (318 mg, 1.697 mmol) and NEt₃ (0.275 mL, 2.036 mmol) in 5 mL of ethanol. A solution of [2-(3,4-dimethoxy-*N*-methyl-anilino)-2-oxo-ethyl] ammonium; 2,2,2-trifluoroacetate (**10c**) (574 mg, 1.697 mmol) and NEt₃ (0.229 mL, 1.697 mmol) in 20 mL of ethanol was added dropwise at room temperature. Reaction mixture was then evaporated to dryness and purified by flash chromatography using as eluent a mixture of DCM/MeOH (98/2) to give the titled product as a pale green powder (367 mg, 53 %). MS [M+H]⁺ *m/z* = 412.0. ¹H NMR (300 MHz, DMSO-*d*₆): δ (ppm) 3.17 (s, 3H), 3.77 (s, 3H), 3.79 (s, 3H), 4.00 (d, *J* = 4.2 Hz, 2H), 6.93 (dd, *J* = 8.4, 2.3 Hz, 1H), 7.34-7.36 (m, 2H), 7.84-7.95 (m, 2H), 10.05 (s, 1H).

2-[2-(2,6-Difluoro-benzyl)-3-(3-chloro-4-fluoro-phenyl)-isothioureido]-*N*-(3,4-dimethoxy-phenyl)-*N*-methyl-acetamide (10e). The titled product was obtained as an orange oil (238 mg, 99 %) without purification, following Procedure B, using *N*-(3,4-dimethoxy-phenyl)-2-[3-(3-chloro-4-fluoro-phenyl)-isothioureido]-*N*-methyl-acetamide (**10d**) (184 mg) and 2-Bromomethyl-1,3-difluoro-benzene (92 mg). MS [M+H]⁺ *m/z* = 538.1. ¹H NMR (300 MHz, CDCl₃): δ (ppm) 3.29 (s, 3H), 3.79-3.93 (m, 8H), 4.13 (s, 2H), 6.57-7.00 (m, 9H), 7.15-7.27 (m, 1H).

[2-(2,6-Difluoro-benzylsulfanyl)-3-(3-chloro-4-fluoro-phenyl)-3H-imidazol-4-yl]-(3,4-dimethoxy-phenyl)-methyl-amine (10). The titled product is obtained as an orange powder (126 mg, 55%), following Procedure C, using 2-[2-(2,6-Difluoro-benzyl)-3-(3-chloro-4-fluoro-phenyl)-isothioureido]-*N*-(3,4-dimethoxy-phenyl)-*N*-methyl-acetamide (**10e**) (238 mg). LC-MS: *t*_R = 3.55 min, MS [M+H]⁺ *m/z* = 520.1. HRMS found 520.1063; C₂₅H₂₁³⁵ClF₃N₃O₂S requires 520.1073. ¹H NMR (300 MHz, CDCl₃): δ (ppm) 2.96 (s, 3H), 3.80 (s, 3H), 3.82 (s, 3H), 4.14 (s,

2H), 6.15 (dd, $J = 8.7, 2.7$ Hz, 1H), 6.71 (d, $J = 8.7$ Hz, 1H), 6.77-6.89 (m, 3H), 6.91 (dd, $J = 6.4, 2.5$ Hz, 1H), 7.01 (t, $J = 8.5$ Hz, 1H), 7.03 (s, 1H), 7.20 (m, 1H). ^{13}C NMR (75 MHz, CDCl_3): δ (ppm) 26.3, 40.6, 56.0, 56.5, 100.6, 106.5, 111.3 (m), 112.3, 113.6 (t, $J = 19.4$ Hz), 116.6 (d, $J = 22.4$ Hz), 121.2 (d, $J = 19.1$ Hz), 124.0, 127.5 (d, $J = 7.7$ Hz), 129.3 (t, $J = 10.2$ Hz), 129.7, 131.4 (d, $J = 3.9$ Hz), 137.9, 139.9, 142.9, 143.2, 149.7, 157.8 (d, $J = 251.7$ Hz), 161.1 (dd, $J = 249.7, 7.6$ Hz).

***N*-(3,4-Dimethoxy-phenyl)-2-[3-(2,4-difluoro-phenyl)-isothioureido]-*N*-methyl-acetamide**

(11d). In a 100mL flask were added 2,4-difluoro-1-isothiocyanato-benzene (290 mg, 1.698 mmol) and NEt_3 (0.275 mL, 2.037 mmol) in 5 mL of ethanol. A solution of [2-(3,4-dimethoxy-*N*-methyl-anilino)-2-oxo-ethyl] ammonium; 2,2,2-trifluoroacetate (**10c**) (574 mg, 1.698 mmol) and NEt_3 (0.229 mL, 1.698 mmol) in 20 mL of ethanol was added dropwise at room temperature. Reaction mixture was then evaporated to dryness. Residue was then purified by flash chromatography using as eluent a mixture of DCM/ methanol (98/2) to give 335 mg of a yellowish powder corresponding to the expected product, leading to a 50% yield. MS $[\text{M}+\text{H}]^+$ $m/z = 396.1$. ^1H NMR (300 MHz, $\text{DMSO}-d_6$): δ (ppm) 3.16 (s, 3H), 3.76 (s, 3H), 3.78 (s, 3H), 4.00 (s, 2H), 6.90-7.08 (m, 4H), 7.29 (m, 1H), 7.62 (m, 1H), 7.98 (brs, 1H), 9.59 (brs, 1H).

2-[2-(2,6-Difluoro-benzyl)-3-(2,4-difluoro-phenyl)-isothioureido]-*N*-(3,4-dimethoxy-

phenyl)-*N*-methyl-acetamide (11e). The titled product was obtained as a yellowish oil (413 mg, 93 %) without purification, following Procedure B, using *N*-(3,4-dimethoxy-phenyl)-2-[3-(2,4-difluoro-phenyl)-isothioureido]-*N*-methyl-acetamide (**11d**) (335 mg) and 2-Bromomethyl-1,3-difluoro-benzene (175 mg). MS $[\text{M}+\text{H}]^+$ $m/z = 522.2$. ^1H NMR (300 MHz, CDCl_3): δ (ppm) 3.31 (s, 3H), 3.83-3.99 (m, 8H), 4.18 (s, 2H), 6.65 -6.93 (m, 9H), 7.17-7.25 (m, 1H).

[2-(2,6-Difluoro-benzylsulfanyl)-3-(2,4-difluoro-phenyl)-3H-imidazol-4-yl]-(3,4-dimethoxy-phenyl)-methyl-amine (11). The titled product is obtained as a reddish solid (226 mg, 56%), following Procedure C, using 2-[2-(2,6-Difluoro-benzyl)-3-(2,4-difluoro-phenyl)-isothioureido]-N-(3,4-dimethoxy-phenyl)-N-methyl-acetamide (**11e**) (413 mg). LC-MS: $t_R = 3.47$ min, MS $[M+H]^+ m/z = 504.1$. HRMS found 504.1382; $C_{25}H_{21}F_4N_3O_2S$ requires 504.1369. 1H NMR (300 MHz, $CDCl_3$): δ (ppm) 3.02 (s, 3H), 3.77 (s, 3H), 3.80 (s, 3H), 4.17 (m, 2H), 6.14 (dd, $J = 8.7, 2.8$ Hz, 1H), 6.25 (d, $J = 2.8$ Hz, 1H), 6.64-6.76 (m, 2H), 6.77-6.87 (m, 4H), 7.05 (s, 1H), 7.20 (m, 1H). ^{13}C NMR (75 MHz, $CDCl_3$): δ (ppm) 26.2, 40.7, 55.8, 56.4, 100.6, 104.9 (dd, $J = 26.4, 23.7$ Hz), 106.2, 111.1-112.1 (m), 113.7 (t, $J = 19.4$ Hz), 119.1 (dd, $J = 13.0, 4.1$ Hz), 123.8, 129.2 (t, $J = 10.3$ Hz), 130.5 (d, $J = 10.2$ Hz), 138.7, 140.4, 142.7, 143.0, 149.4, 157.8 (dd, $J = 255.1, 12.9$ Hz), 161.2 (dd, $J = 250.2, 7.5$ Hz), 162.9 (dd, $J = 252.4, 11.3$ Hz).

N-(3,4-Dimethoxy-phenyl)-2-[3-(4-fluoro-3-methoxy-phenyl)-isothioureido]-N-methyl-acetamide (12d). In a 25 mL flask, TCDI (133 mg, 0.749 mmol) was dissolved in 3 mL of dioxane. [2-(3,4-dimethoxy-N-methyl-anilino)-2-oxo-ethyl] ammonium; 2,2,2-trifluoroacetate (**10b**) (230 mg, 0.681 mmol) in 3.50 mL of dioxane was then added dropwise. The solution was then stirred at room temperature for 1.5 hours. 4-fluoro-3-methoxy-aniline (106 mg, 0.750 mmol) and NEt_3 (285 μ L, 2.04 mmol) were added to the solution. Reaction mixture was stirred at 60°C overnight. Solvent was then removed. Residue was dissolved in EtOAc, and washed with water, with an aqueous HCl 0.1N solution, and dried over $MgSO_4$. After evaporation, residue was purified by flash chromatography using as eluent a mixture of cyclohexane/EtOAc (8/2) to give the titled product as an orange solid (136 mg, 49 %). MS $[M+H]^+ m/z = 408.1$. 1H NMR (300 MHz, $DMSO-d_6$): δ (ppm) 3.16 (s, 3H), 3.74-3.82 (m, 9H), 4.00 (d, $J = 4.2$ Hz, 2H); 6.84-

6.96 (m, 2H), 6.98-7.06 (m, 2H), 7.15 (dd, $J = 11.3, 8.7$ Hz, 1H), 7.37 (dd, $J = 7.9, 2.2$ Hz, 1H), 7.77 (brs, 1H), 9.91 (s, 1H).

2-[2-(2,6-Difluoro-benzyl)-3-(4-fluoro-3-methoxy-phenyl)-isothioureido]-N-(3,4-dimethoxy-phenyl)-N-methyl-acetamide (12e). The titled product was obtained as a yellowish oil (156 mg, 91%) without purification, following Procedure B, using *N*-(3,4-dimethoxy-phenyl)-2-[3-(4-fluoro-3-methoxy-phenyl)-isothioureido]-*N*-methyl-acetamide (**12d**) (124 mg) and 2-Bromomethyl-1,3-difluoro-benzene (63 mg). MS $[M+H]^+$ $m/z = 534.2$. ^1H NMR (300 MHz, CDCl_3): δ (ppm) 3.28 (s, 3H), 3.78-3.84 (m, 11H), 4.11 (brs, 2H), 5.82 (s, 1H), 6.29 (brs, 1H), 6.44 (d, $J = 6.3$ Hz, 1H), 6.61-6.89 (m 6H), 7.13-7.26 (m, 1H).

[2-(2,6-Difluoro-benzylsulfanyl)-3-(4-fluoro-3-methoxy-phenyl)-3H-imidazol-4-yl]-(3,4-dimethoxy-phenyl)-methyl-amine (12). The titled product is obtained as an orange powder (143 mg, 63%), following Procedure C, using 2-[2-(2,6-Difluoro-benzyl)-3-(4-fluoro-3-methoxy-phenyl)-isothioureido]-*N*-(3,4-dimethoxy-phenyl)-*N*-methyl-acetamide (**12e**) (156 mg). LC-MS: $t_R = 3.42$ min, MS $[M+H]^+$ $m/z = 516.2$. HRMS found 516.1558; $\text{C}_{26}\text{H}_{24}\text{F}_3\text{N}_3\text{O}_3\text{S}$ requires 516.1569. ^1H NMR (300 MHz, CDCl_3): δ (ppm) 2.90 (s, 3H), 3.54 (s, 3H), 3.82 (s, 6H), 4.20 (s, 2H), 6.18 (dd, $J = 8.7, 2.8$ Hz, 1H), 6.33 (d, $J = 2.8$ Hz, 1H), 6.54 (dd, $J = 7.5, 2.4$ Hz, 1H), 6.59-6.64 (m, 1H), 6.75 (d, $J = 8.7$ Hz, 1H), 6.78-6.86 (m, 2H), 6.98 (dd, $J = 10.8, 8.6$ Hz, 1H), 7.06 (s, 1H), 7.14-7.24 (m, 1H). ^{13}C NMR (75 MHz, CDCl_3): δ (ppm) 25.7, 39.9, 55.9, 56.0, 56.6, 99.7, 105.2, 111.1-111.4 (m), 112.6, 112.7 (d, $J = 2.4$ Hz), 113.6 (t, $J = 19.4$ Hz), 115.9 (d, $J = 19.6$ Hz), 119.7 (d, $J = 7.3$ Hz), 124.9, 129.2 (t, $J = 10.2$ Hz), 130.9 (d, $J = 3.6$ Hz), 138.6, 139.0, 142.6, 143.5, 147.5 (d, $J = 11.6$ Hz), 149.8, 152.0 (d, $J = 248.9$ Hz), 161.2 (dd, $J = 249.9, 7.7$ Hz).

(4-Chloro-3-methoxy-phenyl)-methyl-amine (13a). In a 50 mL flask were added 4-Chloro-3-methoxy-phenylamine (907 mg), sodium methoxide (1.56 g), 10 mL anhydrous methanol, and paraformaldehyde (690 mg). Reaction mixture was then stirred overnight at room temperature. Then, paraformaldehyde (173 mg) and sodium methoxyde (311 mg) were added, and reaction mixture was heated at reflux for 1 hour. Sodium borohydride (436 mg) was then added, and reaction mixture was stirred at reflux for 4 hours. Once back at room temperature, mixture was partially evaporated, and aqueous KOH 1M (50 mL) was then added. The obtained suspension was extracted by Et₂O, organic phase was dried over Na₂SO₄ and evaporated. The obtained residue was purified by flash chromatography using as eluent a mixture of cyclohexane/EtOAc (8/2) to give the titled product as a brown powder (650 mg, 66 %). MS [M+H]⁺ *m/z* = 171.9. ¹H NMR (300 MHz, DMSO-*d*₆): δ (ppm) 2.66 (d, *J* = 4.9 Hz, 3H), 3.77 (s, 3H), 5.80 (q, *J* = 4.9 Hz, 1H), 6.09 (dd, *J* = 8.7, 2.5 Hz, 1H), 6.25 (d, *J* = 2.4 Hz, 1H), 7.04 (d, *J* = 8.7 Hz, 1H).

2-Chloro-N-(4-chloro-3-methoxy-phenyl)-N-methyl-acetamide (13b). In a 100 mL flask were introduced a solution of 620 mg of (4-Chloro-3-methoxy-phenyl)-methyl-amine (**13a**) and 1.7 mL of DIEA in 18 mL of DCM (dried over Na₂SO₄). The solution was stirred at 0°C. Then, a solution of 568 μL of chloroacetyl chloride in 14 mL of DCM (dried over Na₂SO₄) was added dropwise in the flask. The mixture was then evaporated to dryness to give a brown residue which was used without further purification in the next step of the synthesis. MS [M+H]⁺ *m/z* = 248.0.

2-Amino-N-(4-chloro-3-methoxy-phenyl)-N-methyl-acetamide (13c). Residue corresponding to 2-Chloro-N-(4-chloro-3-methoxy-phenyl)-N-methyl-acetamide (**13b**) (3.6 mmol) was dissolved in 6mL EtOH 95°. The obtained solution was added dropwise in aqueous ammonia (30% w/w, 75 mL) at 65 °C. After 1 hour stirring at 65 °C, reaction mixture was evaporated. The residue was dissolved in water, pH was adjusted to 10, and the solution was extracted several

times by DCM. Organic phases were dried over Na_2SO_4 and evaporated, to give a brown oily residue. It was used without further purification in the next step of the synthesis. MS $[\text{M}+\text{H}]^+$ $m/z = 229.0$.

N-(4-Chloro-3-methoxy-phenyl)-2-[3-(4-fluoro-phenyl)-isothioureido]-N-methyl-acetamide (13d). In a 250 mL flask, 4-fluorophenylisothiocyanate (551.4 mg) and NEt_3 (583 μL) were dissolved in 3 mL of ethanol. A solution 2-amino-N-(4-chloro-3-methoxy-phenyl)-N-methyl-acetamide (**13c**) in 48 mL of ethanol was added dropwise at room temperature. After 1 hour stirring at room temperature, mixture was evaporated to dryness, and residue was purified by flash chromatography using as eluent a mixture of cyclohexane/DCM (1/1) to pure DCM. The titled product was obtained as a yellowish powder (546 mg, 39 % yield over the 3 steps). MS $[\text{M}+\text{H}]^+$ $m/z = 382.1$. ^1H NMR (300 MHz, $\text{DMSO}-d_6$): δ (ppm) 3.21 (s, 3H), 3.88 (s, 3H), 4.06 (brs, 2H), 7.01 (m, 1H), 7.16 (m, 2H), 7.26 (brs, 1H), 7.45 (m, 2H), 7.52 (d, $J = 8.3$ Hz, 1H), 7.76 (brs, 1H), 9.90 (brs, 1H).

N-(4-Chloro-3-methoxy-phenyl)-2-[2-(2,6-difluoro-benzyl)-3-(4-fluoro-phenyl)-isothioureido]-N-methyl-acetamide (13e). The titled product was obtained as an oily residue (603 mg, 87 %), without purification, following Procedure B, using N-(4-Chloro-3-methoxy-phenyl)-2-[3-(4-fluoro-phenyl)-isothioureido]-N-methyl-acetamide (**13d**) (468 mg) and 2-Bromomethyl-1,3-difluoro-benzene (254 mg). MS $[\text{M}+\text{H}]^+$ $m/z = 508.2$. ^1H NMR (300 MHz, $\text{DMSO}-d_6$): δ (ppm) 3.20 (s, 3H), 3.79-3.89 (m, 5H), 4.19 (s, 2H), 6.23 (brs, 2H), 6.95-7.10 (m, 6H), 7.18 (s, 1H), 7.38 (m, 1H), 7.48 (m, 1H).

(4-Chloro-3-methoxy-phenyl)-[2-(2,6-difluoro-benzylsulfanyl)-3-(4-fluoro-phenyl)-3H-imidazol-4-yl]-methyl-amine (13). In a microwave tube were introduced N-(4-Chloro-3-methoxy-phenyl)-2-[2-(2,6-difluoro-benzyl)-3-(4-fluoro-phenyl)-isothioureido]-N-methyl-

acetamide (**13e**) (145 mg), 3 mL of EtOAc, DIEA (74,8 μ L), and T3P® (168 μ L). Reaction mixture was then heated twice under microwave irradiation, at 100°C for 10 min. T3P® (348 μ L) and DIEA (206 μ L) were then added, and the mixture was heated at 150°C for 20 min under microwave irradiation. Reaction mixture was washed with a saturated aqueous solution of NaHCO₃, and brine. Organic phase was dried over Na₂SO₄ and evaporated. The obtained residue was purified by flash chromatography using as eluent a mixture of DCM/cyclohexane and then DCM/MeOH to give a yellowish residue corresponding to the titled product (83 mg, 59%). LC-MS: $t_R = 3.77$ min, MS [M+H]⁺ $m/z = 508.2$. HRMS found 490.0953; C₂₄H₁₉³⁵ClF₃N₃OS requires 490.0968. ¹H NMR (300 MHz, DMSO-*d*₆): δ (ppm) 2.96 (s, 3H), 3.75 (s, 3H), 4.08 (s, 2H), 6.09 (dd, $J = 8.8, 2.7$ Hz, 1H), 6.27 (d, $J = 2.6$ Hz, 1H), 7.02-7.07 (m, 3H), 7.11-7.15 (m, 3H), 7.21 (m, 2H), 7.37 (m, 1H). ¹³C NMR (75 MHz, DMSO-*d*₆): δ (ppm) 26.0, 26.8, 56.2, 98.2, 106.4, 110.7, 112.1 (d, $J = 23.9$ Hz), 113.8 (t, $J = 19.9$ Hz), 116.5 (d, $J = 23.2$ Hz), 125.2, 130.0, 130.1 (d, $J = 9.1$ Hz), 130.5 (t, $J = 10.9$ Hz), 131.2, 137.9, 138.6, 149.0, 155.3, 161.0 (dd, $J = 248.8, 7.4$ Hz), 162.3 (d, $J = 245.9$ Hz).

***tert*-Butyl *N*-[2-(4-methoxy-*N*-methyl-anilino)-2-oxo-ethyl]carbamate (**14b**)**. In a 25 mL flask was added 4-methoxy-*N*-methyl-aniline (274 mg, 2 mmol) in 4 mL of EtOAc. Then 2-(*tert*-butoxycarbonylamino)acetic acid (420 mg, 2.4 mmol), T3P® (1.768 mL, 3 mmol) and DIEA (1.048 mL, 6 mmol) were added. The mixture was stirred for 30 min at room temperature. Then the reaction mixture was diluted with EtOAc, washed with water, with a saturated aqueous solution of NaHCO₃ and brine. The organic phase was dried over MgSO₄, filtered and then evaporated, to give the titled product as a bronze solid (463 mg, 79 %). MS [M+H]⁺ $m/z = 295.1$.

[2-(4-Methoxy-*N*-methyl-anilino)-2-oxo-ethyl] ammonium; 2,2,2-trifluoroacetate (14c**)**.
Tert-butyl *N*-[2-(4-methoxy-*N*-methyl-anilino)-2-oxo-ethyl]carbamate (**14b**) (463.70 mg, 1.575

mmol) was dissolved in 4 mL of DCM. TFA (20.84 mmol, 1.595 mL) was added and the reaction mixture was stirred at room temperature for 30 minutes. Solvent was removed to give viscous reddish oil. 510 mg of residue was obtained corresponding to the expected product and to a rest of 4-methoxy-*N*-methyl-aniline. Residue was used in the next step without further purification. MS $[M+H]^+$ $m/z = 195.0$. 1H NMR (300 MHz, $CDCl_3$): δ (ppm) 3.20 (s, 3H), 3.57 (s, 2H), 3.83 (s, 3H), 6.95 (d, $J = 8.9$ Hz, 2H), 7.12 (d, $J = 9.0$ Hz, 2H), 7.80 (s, 3H).

***N*-(4-Methoxy-phenyl)-2-[3-(4-fluoro-phenyl)-isothioureido]-*N*-methyl-acetamide (14d).** In a 100 mL flask were added 4-fluorophenylisothiocyanate (1.575 mmol, 241 mg) and NEt_3 (1.890 mmol, 0.255 mL) in 5 mL of ethanol. A solution of [2-(4-methoxy-*N*-methyl-anilino)-2-oxo-ethyl] ammonium; 2,2,2-trifluoroacetate (**14c**) (1.575 mmol, 485 mg) and NEt_3 (1.575 mmol, 0.213 mL) in 20 mL of ethanol was added dropwise at room temperature. Reaction mixture was evaporated to dryness to give 865 mg of pale green powder, corresponding to the titled product. Residue was used without further purification in the next step of the synthesis. MS $[M+H]^+$ $m/z = 348.0$.

2-[2-(2,6-Difluoro-benzyl)-3-(4-fluoro-phenyl)-isothioureido]-*N*-(4-methoxy-phenyl)-*N*-methyl-acetamide (14e). The titled product was obtained without purification as yellow oil (727 mg, 97 %) following procedure B, using *N*-(4-methoxy-phenyl)-2-[3-(4-fluoro-phenyl)-isothioureido]-*N*-methyl-acetamide (**14d**) (547 mg) and 2-(bromomethyl)-1,3-difluoro-benzene (513 mg). MS $[M+H]^+$ $m/z = 475.1$.

[2-(2,6-Difluoro-benzylsulfanyl)-3-(4-fluoro-phenyl)-3H-imidazol-4-yl]--(4-methoxy-phenyl)-methyl-amine (14). The titled product was obtained as an orange powder (120 mg, 17%), following Procedure C, using 2-[2-(2,6-Difluoro-benzyl)-3-(4-fluoro-phenyl)-isothioureido]-*N*-(4-methoxy-phenyl)-*N*-methyl-acetamide (**14e**) (726 mg). LC-MS : $t_R = 3.59$ min; MS $[M+H]^+$

$m/z = 456.1$. HRMS found 456.1369; $C_{24}H_{20}F_3N_3OS$ requires 456.1357. 1H NMR (300 MHz, $CDCl_3$): δ (ppm) 2.92 (s, 3H), 3.76 (s, 3H), 4.18 (brs, 2H), 6.57-6.60 (m, 2H), 6.70-6.77 (m, 2H), 6.80-6.86 (m, 2H), 6.92-6.95 (m, 4H), 7.00 (s, 1H), 7.15-7.23 (m, 1H). ^{13}C NMR (75 MHz, $CDCl_3$): δ (ppm) 25.9, 40.2, 55.7, 111.3 (m), 113.6, 114.4, 115.4, 115.9 (d, $J = 23.0$ Hz), 124.1, 129.0-129.3 (m), 130.9 (d, $J = 3.4$ Hz), 138.1, 140.0, 142.7, 153.1, 161.3 (dd, $J = 250.0, 7.4$ Hz), 162.3 (d, $J = 249.2$ Hz).

3-Methoxy-*N*-methyl-aniline (15a). In a 25mL flask were added 3-methoxyaniline (2.0 mmol, 0.224 mL) and sodium methoxide (10 mmol, 545 mg) in 3.5 mL of anhydrous methanol. Then, paraformaldehyde (4 mmol, 119 mg) was diluted in 1.5 mL of anhydrous methanol and the solution was added to the mixture. Molecular sieves (4 Å) was then added and the mixture was stirred overnight at room temperature. The mixture was heated under reflux for 1 hour with sodium borohydride (2 mmol, 75.6 mg), then sodium borohydride (3.172 mmol, 120 mg) was added again and reaction mixture was stirred under reflux for 3 hours. The reaction mixture was filtered on Celite, evaporated, dissolved in EtOAc and water, and the two phases were separated. The aqueous phase was then basified by addition of a saturated aqueous solution of $NaHCO_3$, and extracted by EtOAc. The organic phase were washed with a saturated aqueous solution of $NaHCO_3$ and brine, dried over $MgSO_4$, evaporated and dried under reduced pressure to give the titled product as brown oil (266 mg, 96%). MS $[M+H]^+$ $m/z = 138.0$. 1H NMR (300 MHz, $CDCl_3$): δ (ppm) 2.84 (s, 3H), 3.78 (s, 3H), 6.19 (t, $J = 2.3$ Hz, 1H), 6.26-6.31 (m, 2H), 7.10 (t, $J = 8.1$ Hz, 1H).

***tert*-Butyl *N*-[2-(3-methoxy-*N*-methyl-anilino)-2-oxo-ethyl]carbamate (15b).** In a 25 mL flask was added 3-methoxy-*N*-methyl-aniline (**15a**) (1.554 mmol, 213 mg) in 1 mL of EtOAc. Then 2-(*tert*-butoxycarbonylamino)acetic acid (1.865 mmol, 326 mg), T3P® (2.331 mmol, 1.374 mL)

and DIEA (4.662 mmol, 814 μ L) were added, and the mixture was stirred for 30 min at room temperature. Then the reaction mixture was diluted with EtOAc. The solution was washed with water, then with a saturated aqueous solution of NaHCO₃ and brine. The organic phase was dried over MgSO₄, and filtered and then evaporated and dried under reduced pressure to give a light brown solid. This residue was purified by flash chromatography using as eluent a mixture of DCM/cyclohexane (9/1) to pure DCM and then DCM/ MeOH (1000/1) to give the expected product as a yellowish powder (444 mg, 97%). MS [M+H]⁺ m/z = 295.2.

[2-(3-Methoxy-*N*-methyl-anilino)-2-oxo-ethyl] ammonium; 2,2,2-trifluoroacetate (15c). *tert*-butyl *N*-[2-(3-methoxy-*N*-methyl-anilino)-2-oxo-ethyl]carbamate (**15b**) (444.4 mg, 1.510 mmol) was dissolved in 4 mL of DCM. TFA (19.97 mmol, 1.529 mL) was added and the reaction mixture was stirred at room temperature for 30 minutes. Solvent was removed to give a viscous reddish oil. 699 mg of residue were obtained corresponding to the expected product and to a rest of 3-methoxy-*N*-methyl-aniline. Residue was used without further purification in the next step of the synthesis. MS [M+H]⁺ m/z = 195.1.

***N*-(3-Methoxy-phenyl)-2-[3-(4-fluoro-phenyl)-isothioureido]-*N*-methyl-acetamide (15d).** In a 100 mL flask were added 1-fluoro-4-isothiocyanato-benzene (1.287 mmol, 446 mg) and NEt₃ (1.544 mmol, 0.208 mL) in 2 mL of ethanol. A solution of [2-(3-methoxy-*N*-methyl-anilino)-2-oxo-ethyl] ammonium; 2,2,2-trifluoroacetate (**15c**) (1.287 mmol, 446 mg) and NEt₃ (4.254 mmol, 0.574 mL) in 20 mL of ethanol was added dropwise at room temperature. Reaction mixture was evaporated to dryness to give oil. This oil was purified by flash chromatography using as eluent a mixture of DCM/MeOH (98/2), to give the titled product as a white solid (361 mg, 69 %). MS [M+H]⁺ m/z = 386.0. ¹H NMR (300 MHz, DMSO-*d*₆): δ (ppm) 3.19 (s, 3H), 3.78

(s, 3H), 4.03 (brs, 2H), 6.92-7.04 (m, 3H), 7.09-7.21 (m, 2H), 7.30-7.50 (m, 3H), 7.68-7.79 (m, 1H).

2-[2-(2,6-Difluoro-benzyl)-3-(4-fluoro-phenyl)-isothioureido]-N-(3-methoxy-phenyl)-N-methyl-acetamide (15e). The titled product was obtained as an orange solid (136 mg, 94 %) following procedure B without purification, using *N*-(3-methoxy-phenyl)-2-[3-(4-fluoro-phenyl)-isothioureido]-*N*-methyl-acetamide (**15d**) (100 mg) and 2-(bromomethyl)-1,3-difluoro-benzene (60 mg). MS $[M+H]^+$ m/z =474.1. ^1H NMR (300 MHz, CDCl_3): δ (ppm) 3.32 (s, 3H), 3.81 (s, 3H), 3.90 (brs, 2H), 4.13 (brs, 2H), 6.68-6.96 (m, 9H), 7.16-7.26 (m, 1H), 7.34 (t, J = 8.1 Hz, 1H).

[2-(2,6-Difluoro-benzylsulfanyl)-3-(4-fluoro-phenyl)-3H-imidazol-4-yl]-(3-methoxy-phenyl)-methyl-amine (15). 2-[2-(2,6-Difluoro-benzyl)-3-(4-fluoro-phenyl)-isothioureido]-*N*-(3-methoxy-phenyl)-*N*-methyl-acetamide (**15e**) (136 mg, 0.27 mmol) was dissolved in 2.7 mL of EtOAc. DIEA (283 μL , 1.62 mmol), and T3P® in EtOAc (477 μL , 0.83 mmol) were then added. The mixture was heated under microwave irradiation at 150°C for 10 min. DIEA (283 μL , 1.62 mmol), and T3P® in EtOAc (477 μL , 0.83 mmol) were added again, and reaction mixture was heated again under microwave irradiation at 150°C for 10 min. DIEA (142 μL , 0.81 mmol), and T3P® in EtOAc (240 μL , 0.41 mmol) were added again, and reaction mixture was heated again under microwave irradiation at 150°C for 10 min. DIEA (142 μL , 0.81 mmol), and T3P® in EtOAc (240 μL , 0.41 mmol) were added again, and reaction mixture was heated again under microwave irradiation at 150°C for 10 min. Reaction mixture was then diluted with EtOAc, washed with water, with a saturated aqueous solution of NaHCO_3 , and brine. Organic phase was then dried over Na_2SO_4 and evaporated. Residue was then purified by flash chromatography using as eluent a mixture of cyclohexane/EtOAc (85/15), to give the titled compound as an

orange residue (12.1 mg, 10 %). LC-MS: $t_R = 3.62$ min, MS $[M+H]^+ m/z = 456.1$. HRMS found 456.1341; $C_{24}H_{20}F_3N_3OS$ requires 456.1357. 1H NMR (300 MHz, $CDCl_3$): δ (ppm) 2.91 (s, 3H), 3.77 (s, 3H), 4.19 (s, 2H), 6.22 (t, $J = 2.3$ Hz, 1H), 6.25 (dd, $J = 8.2, 2.3$ Hz, 1H), 6.37 (dd, $J = 8.2, 2.3$ Hz, 1H), 6.81-6.86 (m, 2H), 6.94-6.99 (m, 4H), 7.05 (s, 1H), 7.10 (t, $J = 8.1$ Hz, 1H), 7.15-7.25 (m, 1H). ^{13}C NMR (75 MHz, $CDCl_3$): δ (ppm) 25.8, 39.4, 55.2, 99.9, 103.5, 106.3, 111.3 (m), 113.5 (t, $J = 19.3$ Hz), 116.0 (d, $J = 22.9$ Hz), 125.3, 129.1 (d, $J = 8.8$ Hz), 129.2 (t, $J = 10.3$ Hz), 129.8, 130.7 (d, $J = 3.1$ Hz), 138.5, 138.7, 149.9, 160.6, 161.2 (dd, $J = 250.2, 7.6$ Hz), 162.3 (d, $J = 249.3$ Hz).

3,4-Dichloro-N-methyl-aniline (16a). In a 25mL flask were added 3,4-dichloroaniline (324 mg, 2.0 mmol) and sodium methoxide (540 mg, 10 mmol) in 3.5 mL of anhydrous methanol. Then, paraformaldehyde (120 mg, 4 mmol) was diluted in 1.5 mL of anhydrous methanol and the solution was added to the mixture. Molecular sieves (4 Å) was then added and the mixture was stirred overnight at room temperature. The mixture was then heated under reflux for 1 hour with sodium borohydride (151 mg, 4 mmol). Reaction mixture was then filtered on Celite, evaporated, residue was dissolved in EtOAc and water, and the two phases were separated. Aqueous phase was then basified by addition of a saturated aqueous solution of $NaHCO_3$, and extracted by EtOAc. Organic phases were washed with a saturated aqueous solution of $NaHCO_3$ and brine, dried over $MgSO_4$, evaporated and dried under vacuum to give yellow oil corresponding to the titled product (227 mg, 64 %). MS $[M+H]^+ m/z = 179.9$. 1H NMR (300 MHz, $CDCl_3$): δ (ppm) 2.83 (s, 3H), 6.48 (dd, $J = 8.7, 2.8$ Hz, 1H), 6.70 (d, $J = 2.8$ Hz, 1H), 7.21 (d, $J = 8.8$ Hz, 1H).

tert-Butyl N-[2-(3,4-dichloro-N-methyl-anilino)-2-oxo-ethyl]carbamate (16b). In a 10 mL flask were 3,4-dichloro-N-methyl-aniline (**16a**) (226 mg, 1.287 mmol) in 2.6 mL of EtOAc. Then 2-(tert-butoxycarbonylamino)acetic acid (608 mg, 3.474 mmol), T3P® (2.27 mL, 3.859

mmol) and DIEA (1.012 mL, 5.791 mmol) were added. The mixture was stirred at 40°C for 2 days. Then the reaction mixture was diluted with EtOAc, washed with water, with a saturated aqueous solution of NaHCO₃ and brine. The organic phase was dried over MgSO₄, and evaporated to dryness to give yellowish oil. For the next step of the synthesis, yield was considered to be 100%. MS [M+H-H₂C=C(CH₃)₂]⁺ *m/z* = 277.0. ¹H NMR (300 MHz, CDCl₃): δ (ppm) 1.40 (m, 9H), 3.25 (s, 3H), 3.65 (s, 2H), 3.35 (s, 1H), 7.10 (dd, *J* = 8.4, 2.4 Hz, 1H), 3.37 (d, *J* = 2.3 Hz, 2H), 7.72 (d, *J* = 8.5 Hz, 1H).

[2-(3,4-Dichloro-N-methyl-anilino)-2-oxo-ethyl] ammonium; 2,2,2-trifluoroacetate (16c).

Tert-butyl N-[2-(3,4-dichloro-N-methyl-anilino)-2-oxo-ethyl]carbamate (**16b**) (428 mg, 1.287 mmol) was dissolved in 4 mL of DCM. TFA (1.30 mL, 17.03 mmol) was added and the reaction mixture was stirred at room temperature for 30 minutes. Solvent was removed to give oil. Residue was used without further purification in the next step of the synthesis. MS [M+H]⁺ *m/z* = 235.1.

***N*-(3,4-Dichloro-phenyl)-2-[3-(4-fluoro-phenyl)-isothioureido]-*N*-methyl-acetamide (16d).** In a 100 mL flask were added 4-fluorophenylisothiocyanate (237 mg, 1.54 mmol) and NEt₃ (0.208 mL, 1.544 mmol) in 2 mL of ethanol. A solution of [2-(3,4-dichloro-N-methyl-anilino)-2-oxo-ethyl] ammonium; 2,2,2-trifluoroacetate (**16c**) (446 mg 1.287 mmol) and NEt₃ (0.574 mL, 4.25 mmol) in 20 mL of ethanol was added dropwise at room temperature. Reaction mixture was then evaporated to dryness. The residue was purified by flash chromatography using as eluent a mixture of DCM/MeOH (98/2), to give a white solid corresponding to the titled product (550 mg, quantitative yield). MS [M+H]⁺ *m/z* = 386.0, ¹H NMR (300 MHz, DMSO-*d*₆): δ (ppm) 3.21 (s, 3H), 4.09 (s, 2H), 7.16 (m, 2H), 7.41-7.47 (m, 3H), 7.74-7.80 (m, 3H), 9.90 (s, 1H).

2-[2-(2,6-Difluoro-benzyl)-3-(4-fluoro-phenyl)-isothioureido]-N-(3,4-dichloro-phenyl)-N-methyl-acetamide (16e). The titled product was obtained as a yellowish oil (334 mg, 90 %), without purification, following Procedure B, using *N*-(3,4-dichloro-phenyl)-2-[3-(4-fluoro-phenyl)-isothioureido]-*N*-methyl-acetamide (**16d**) (280 mg) and 2-Bromomethyl-1,3-difluorobenzene (150 mg). MS $[M+H]^+$ $m/z = 512.1$. 1H NMR (300 MHz, $CDCl_3$): δ (ppm) 3.31 (s, 3H), 3.92 (s, 2H), 4.12 (s, 2H), 6.75-6.98 (m, 6H), 7.13 (m, 1H), 7.23 (m, 1H), 7.38 (m, 1H), 7.53 (d, $J = 8.5$ Hz, 1H).

[2-(2,6-Difluoro-benzylsulfanyl)-3-(4-fluoro-phenyl)-3H-imidazol-4-yl]-(3,4-dichloro-phenyl)-methyl-amine (16). The titled product was obtained as an orange powder (143 mg, 44%), following Procedure C, using 2-[2-(2,6-Difluoro-benzyl)-3-(4-fluoro-phenyl)-isothioureido]-*N*-(3,4-dichloro-phenyl)-*N*-methyl-acetamide (**16e**) (334 mg). LC-MS: $t_R=3.97$ min; MS $[M+H]^+$ $m/z = 496.0$. HRMS found 494.0457; $C_{23}H_{16}^{35}Cl_2F_3N_3S$ requires 494.0472. 1H NMR ($CDCl_3$): δ (ppm) 2,92 (s, 3H), 4,19 (s, 2H), 6,45 (dd, $J = 8.9, 3.1$ Hz, 1H), 6,72 (d, $J = 3.0$ Hz, 1H), 6,87 (t, $J = 7.7$ Hz, 1H), 6,82-6,95 (m, 6H), 7,05 (s, 1H), 7,2 (d, $J = 2.6$ Hz, 1H), 7,22 (d, $J = 2.6$ Hz, 1H). ^{13}C NMR (75 MHz, $CDCl_3$): δ (ppm) 25.8, 39.6, 111.4 (m), 112.5, 113.5 (t, $J = 19.4$ Hz), 114.5, 116.3 (d, $J = 23.1$ Hz), 121.7, 125.6, 129.0 (d, $J = 8.8$ Hz), 129.3 (t, $J = 10.3$ Hz), 130.4, 132.9, 137.4, 139.5, 148.0, 161.2 (dd, $J = 250.0, 7.3$ Hz), 162.5 (d, $J = 249.9$ Hz).

2-Chloro-N-[(3,4-dimethoxyphenyl)methyl]-N-methylacetamide (17b). In a 100mL flask was introduced commercial [(3,4-dimethoxyphenyl)methyl](methyl)amine (**17a**) (1.05 mL, 5.3 mmol) and DIEA (2.74 mL, 15.89 mmol) in 13 mL of DCM (dried over Na_2SO_4). The solution was stirred at 0°C. Then, chloroacetyl chloride (0.84 mL, 10.59 mmol) in 13 mL of DCM (dried over Na_2SO_4) was added dropwise in the flask. The mixture was then evaporated to dryness to

give a brown residue. Conversion was considered to be 100% for the next reaction. MS $[M+H]^+$ $m/z = 257.9$.

[(3,4-Dimethoxy-benzyl)-methyl-carbamoyl]-methyl-ammonium formate (17c). 2-chloro-N-[(3,4-dimethoxyphenyl)methyl]-N-methylacetamide (**17b**) was dissolved in 9 mL of Ethanol at 95°C and added dropwise in a 250 mL flask containing 100 mL of aqueous ammonia at 65°C. After the addition, heating was stopped. The mixture was evaporated to dryness. The residue was then dissolved in DCM, and extracted several times by an aqueous solution of HCOOH 1M. During this extraction, a precipitate appeared and was filtered. The filtrate was then evaporated to dryness, and the residue was triturated in acetonitrile. The supernatant was evaporated to dryness, to give the titled product as a pale brown oily residue (90% UV_{215nm} purity) (1.51 g, 90%). MS $[M+H]^+$ $m/z = 239.0$.

N-(3,4-Dimethoxy-benzyl)-2-[3-(4-fluoro-phenyl)-thioureido]-N-methyl-acetamide (17d). 732 mg of 4-fluorophenylisothiocyanate and 774 μ L of NEt_3 were added in a 250 mL flask in 4 mL Ethanol. [(3,4-dimethoxy-benzyl)-methyl-carbamoyl]-methyl-ammonium formate (**17c**) (1.51 g, 4.78 mmol) was dissolved in 60 mL of ethanol and 645 μ L of NEt_3 were then added. This solution was added dropwise at room temperature. After the addition, the reaction was over. Reaction mixture was evaporated to dryness, and purified by flash chromatography using as eluent a mixture of cyclohexane/EtOAc (6/4) to give the titled product as a yellowish solid (880 mg, 47% yield). MS $[M+H]^+$ $m/z = 391.9$. 1H NMR (300 MHz, $MeOD-d_4$): δ (ppm) 2.91-2.99 (m, 3H), 3.81-3.84 (m, 6H), 4.47-4.58 (m, 4H), 6.81-6.98 (m, 3H), 7.08-7.15 (m, 2H), 7.39-7.45 (m, 2H).

2-[2-(2,6-Difluoro-benzyl)-3-(4-fluoro-phenyl)-isothioureido]-N-(3,4-dimethoxy-benzyl)-N-methyl-acetamide (17e). The titled product was obtained as an oily residue (207 mg, 58%),

following Procedure B, using N-(3,4-Dimethoxy-benzyl)-2-[3-(4-fluoro-phenyl)-thioureido]-N-methyl-acetamide (**17d**) (0,300 g) and 2-Bromomethyl-1,3-difluoro-benzene (77 mg). MS $[M+H]^+$ $m/z = 518.0$. 1H NMR (300 MHz, DMSO- d_6): δ (ppm) 2.85 (m, 3H), 3.65 (m, 3H), 3.70 (s, 3H), 4.15 (m, 2H), 4.23 (m, 2H), 4.47 (m, 2H), 6.64 (m, 2H), 6.77-6.89 (m, 4H), 6.99 (m, 2H), 7.09 (m, 2H), 7.39 (m, 1H).

[2-(2,6-Difluoro-benzylsulfanyl)-3-(4-fluoro-phenyl)-3H-imidazol-4-yl]-(3,4-dimethoxy-benzyl)-methyl-amine (17). The titled product was obtained as a yellowish powder (91 mg, 47 %) following procedure C using 2-[2-(2,6-Difluoro-benzyl)-3-(4-fluoro-phenyl)-isothioureido]-N-(3,4-dimethoxy-benzyl)-N-methyl-acetamide (**17e**) (200 mg). LC-MS: $t_R = 3.33$ min, MS: $[M+H]^+$ $m/z = 499.9$. HRMS found 500.1622; $C_{26}H_{24}F_3N_3O_2S$ requires 500.1620. 1H NMR (300 MHz, $CDCl_3$): δ (ppm) 2.48 (s, 3H), 3.68 (s, 2H), 3.77 (s, 3H), 3.86 (s, 3H), 4.10 (s, 2H), 6.37 (d, $J = 1.9$ Hz, 1H), 6.56 (dd, $J = 8.2, 1.9$ Hz, 1H), 6.74 (d, $J = 8.1$ Hz, 1H), 6.77-6.85 (m, 3H), 7.10-7.22 (m, 5H). ^{13}C NMR (75 MHz, $CDCl_3$): δ (ppm) 26.0, 40.4, 55.8, 55.9, 60.6, 110.6, 111.1, 111.3, 113.5 (t, $J = 19.0$ Hz), 116.0 (d, $J = 22.1$ Hz), 117.6, 121.0, 129.1 (t, $J = 10.1$ Hz), 129.7, 129.9 (d, $J = 8.5$ Hz), 131.6 (d, $J = 2.3$ Hz), 136.4, 145.8, 148.3, 148.8, 161.2 (dd, $J = 250.0, 7.7$ Hz), 162.3 (d, $J = 248.9$ Hz).

N-Allyl-3,4-dimethoxy-aniline (18a). Allyl bromide (0.519 mL, 6.0 mmol) was added dropwise to a solution of 3,4-dimethoxyaniline (919 mg, 6.0 mmol) and K_2CO_3 (1.99 g, 14.4 mmol) in DMF (15 mL). The solution was heated to 80 °C and stirred at this temperature overnight. The reaction mixture was then filtered, washed with H_2O and extracted with EtOAc. The combined organic extracts were washed with brine, dried over Na_2SO_4 and evaporated to dryness. Residue was purified by flash chromatography using as eluent a mixture of cyclohexane/EtOAc (8/2) to give the titled product as a pale yellowish oil (587 mg, 51 %). MS $[M+H]^+$ $m/z = 194.0$. 1H NMR

(300 MHz, CDCl₃): δ (ppm) 3.74 (Dt, $J = 5.5, 1.5$ Hz, 2H), 3.81 (s, 3H), 3.84 (s, 3H), 5.17 (Dq, $J = 10.3, 1.5$ Hz, 1H), 5.29 (Dq, $J = 17.2, 1.6$ Hz, 1H), 5.98 (Ddt, $J = 17.2, 10.6, 5.3$ Hz, 1H), 6.18 (dd, $J = 8.5, 2.6$ Hz, 1H), 6.29 (d, $J = 2.6$ Hz, 1H), 6.75 (d, $J = 8.5$ Hz, 1H).

***tert*-Butyl N-[2-(N-allyl-3,4-dimethoxy-anilino)-2-oxo-ethyl]carbamate (18b)**. In a 100mL flask were added N-allyl-3,4-dimethoxy-aniline (**18a**) (587.0 mg, 3.04 mmol), 6 mL of EtOAc, Boc-Gly-OH (638.6 mg, 3.65 mmol), T3P® (2.69 mL, 4.56 mmol), and DIEA (1.59 mL, 9.11 mmol). Reaction mixture was then stirred at room temperature for 2 hours. The reaction mixture was diluted with EtOAc, washed with a saturated aqueous solution of NaHCO₃ and brine, and the organic phase was dried over Na₂SO₄ and evaporated to give the titled product as yellowish viscous oil (1.07 g, 100 %). MS [M+H]⁺ $m/z = 351.1$. ¹H NMR (300 MHz, CDCl₃): δ (ppm) 1.41 (s, 9H), 3.66 (d, $J = 4.2$ Hz, 2H), 3.85 (s, 3H), 3.88 (s, 3H), 4.26 (d, $J = 6.4$ Hz, 2H), 5.04-5.19 (m, 2H), 5.39 (brs, 1H), 5.85 (Ddt, $J = 16.8, 10.3, 6.5$ Hz, 1H), 6.64 (d, $J = 2.2$ Hz, 1H), 6.72 (dd, $J = 8.4, 2.4$ Hz, 1H), 6.83 (d, $J = 8.4$ Hz, 1H).

[2-(N-Allyl-3,4-dimethoxy-anilino)-2-oxo-ethyl]ammonium;2,2,2-trifluoroacetate (18c).

Tert-butyl N-[2-(N-allyl-3,4-dimethoxy-anilino)-2-oxo-ethyl]carbamate (**18b**) (1.07 g, 3.05 mmol) was dissolved in 7 mL of DCM. 3 mL of TFA were then gently added and reaction mixture was then stirred at room temperature for 30 min. Reaction mixture was then evaporated to dryness, to give pale orange oil, corresponding to the titled product. This oil will enter in the next step without further purification. Yield was considered to be 100%. MS [M+H]⁺ $m/z = 251.1$.

N-Allyl-N-(3,4-dimethoxy-phenyl)-2-[3-(4-fluoro-phenyl)-isothioureido]-acetamide (18d). 4-fluorophenylisothiocyanate (468 mg, 3.05 mmol) and NEt₃ (494 μ L, 3.66 mmol) were added in a 250 mL flask in 9 mL Ethanol. [2-(N-allyl-3,4-dimethoxy-anilino)-2-oxo-

ethyl]ammonium;2,2,2-trifluoroacetate (**18c**) (3.05 mmol) was dissolved in 31 mL of ethanol, NEt₃ was added until pH was over 8 and the mixture was added dropwise at room temperature. After the addition, the reaction was over. After one hour stirring at room temperature, a precipitate has appeared. It was then filtered, to give a white powder of the powder corresponding to the titled product (1.09 g, 88%). MS [M+H]⁺ *m/z* = 404.1. ¹H NMR (300 MHz, DMSO-*d*₆): δ (ppm) 3.75 (s, 3H), 3.78 (s, 3H), 4.01 (d, *J* = 4.4 Hz, 2H), 4.23 (d, *J* = 5.8 Hz, 2H), 5.01-5.20 (m, 2H), 5.80 (Ddt, *J* = 16.0, 11.5, 5.7 Hz, 1H), 6.87 (dd, *J* = 7.3, 1.1 Hz, 1H), 6.93-7.05 (m, 2H), 7.09-7.21 (m, 2H), 7.38-7.51 (m, 2H), 7.74 (brs, 1H), 9.89 (s, 1H).

N-Allyl-2-[2-(2,6-difluoro-benzyl)-3-(4-fluoro-phenyl)-isothioureido]-N-(3,4-dimethoxy-phenyl)-acetamide (18e). In a 25mL flask were added N-Allyl-N-(3,4-dimethoxy-phenyl)-2-[3-(4-fluoro-phenyl)-isothioureido]-acetamide (**18d**) (400 mg, 0.99 mmol), K₂CO₃ (137 mg, 0.99 mmol), sodium iodide (74 mg, 0.50 mmol), and 5 mL of acetonitrile. The suspension was stirred at room temperature for 10 min, and 2-(bromomethyl)-1,3-difluoro-benzene (205 mg, 0.99 mmol) was then added. The suspension was stirred at room temperature overnight. The medium was then evaporated, residue was dissolved in EtOAc, washed with water and brine, organic phase was dried over Na₂SO₄ and evaporated to dryness to give 543 mg of an orange solid corresponding to the titled product (100 %). MS [M+H]⁺ *m/z* = 530.2. ¹H NMR (300 MHz, CDCl₃): δ (ppm) 3.81-3.92 (m, 8H), 4.13 (brs, 2H), 4.29 (d, *J* = 6.3 Hz, 2H), 5.07-5.21 (m, 2H), 5.78-5.96 (m, 1H), 6.63-6.95 (m, 10H), 7.21 (m, 1H).

Allyl-[2-(2,6-difluoro-benzylsulfanyl)-3-(4-fluoro-phenyl)-3H-imidazol-4-yl]-(3,4-dimethoxy-phenyl)-amine (18). In a microwave tube were introduced N-Allyl-2-[2-(2,6-difluoro-benzyl)-3-(4-fluoro-phenyl)-isothioureido]-N-(3,4-dimethoxy-phenyl)-acetamide (**18e**) (373 mg, 0.7 mmol), 7 mL of EtOAc, DIEA (738 μL, 4.2 mol), and T3P® (1245 μL, 2.1 mmol).

The mixture was heated under microwave irradiation at 150°C for 10 min. Reaction mixture was then diluted with EtOAc, washed with water, with a saturated aqueous solution of NaHCO₃, and with brine. Organic phase was then dried over Na₂SO₄ and evaporated. Residue was then purified by flash chromatography using as eluent a mixture of CHCl₃/MeOH (99/1) to give an orange solid corresponding to the titled product (192 mg, 53 %). LC-MS: t_R = 3.27 min, MS [M+H]⁺ m/z = 512.1. HRMS found 512.1617; C₂₇H₂₄F₃N₃O₂S requires 512.1620. ¹H NMR (300 MHz, CDCl₃): δ (ppm) 3.75-3.86 (m, 8H), 4.15 (s, 2H), 5.2-5.14 (m, 2H), 5.67 (Ddt, J = 17.4, 10.0, 5.5 Hz, 1H), 6.17 (dd, J = 8.7, 2.8 Hz, 1H), 6.30 (d, J = 2.8 Hz, 1H), 6.69 (d, J = 8.8 Hz, 1H), 6.74-6.86 (m, 2H), 6.88-6.98 (m, 4H), 7.04 (s, 1H), 7.18 (tt, J = 8.4, 6.5 Hz, 1H). ¹³C NMR (75 MHz, CDCl₃): δ (ppm) 25.9, 55.3, 55.9, 56.4, 100.7, 106.6, 111.0-111.5 (m), 112.2, 113.6 (t, J = 19.3 Hz), 115.8 (d, J = 22.9 Hz), 117.3, 125.5, 129.2 (t, J = 10.8 Hz), 129.4 (d, J = 8.9 Hz), 130.8 (d, J = 3.2 Hz), 133.6, 138.4, 142.4, 142.7, 149.5, 161.2 (dd, J = 250.0, 7.6 Hz), 162.3 (d, J = 249.2 Hz).

1-Cyanomethyl-3-(4-fluoro-phenyl)-isothiourea (19a). 2-aminoacetonitrile hydrochloride (725 mg, 7.83 mmol) and NEt₃ (1090 μL, 7.83 mmol) were added in 12 mL of DMF. Then a solution of 4-fluoro-phenylisothiocyanate (1.00 g, 6.53 mmol) in 2 mL of DMF was added and the reaction mixture was stirred at room temperature for 5 min, then cooled down to 0°C. After addition of roughly 60 mL water, a precipitate was obtained. The mixture was stirred at 0°C for 30 min and filtrated. The purple crystals obtained correspond to the titled product (1.09 g, 80 %). MS [M+H]⁺ m/z = 209.9. ¹H NMR (300 MHz, DMSO-*d*₆): δ (ppm) 4.49 (d, J = 5.5 Hz, 2H), 7.20 (t, J = 8.7 Hz, 2H), 7.38 (Dd, J = 8.6, 5.0 Hz, 2H), 8.03 (brs, 1H), 10.02 (s, 1H).

2-(2,6-Difluoro-benzylsulfanyl)-3-(4-fluoro-phenyl)-3H-imidazol-4-ylamine (19b). In a 50 mL flask were added 1-Cyanomethyl-3-(4-fluoro-phenyl)-isothiourea (**19a**) (1.09 g, 5.21 mmol),

10 mL of dry acetonitrile, sodium iodide (390 mg, 2.60 mmol), 2-Bromomethyl-1,3-difluorobenzene (1.08 g) and DIEA (891 μ L, 5.21 mmol). Reaction mixture was stirred at room temperature for 5 min. Reaction mixture was then diluted with EtOAc, washed with water and brine, dried over Na_2SO_4 and evaporated. All attempts to purify that compound were unsuccessful, due to its instability. Next step of the synthesis was performed on the crude residue. MS $[\text{M}+\text{H}]^+$ $m/z = 335.9$.

N-[2-(2,6-Difluoro-benzylsulfanyl)-3-(4-fluoro-phenyl)-3H-imidazol-4-yl]-3,4-dimethoxybenzamide (19). 3,4-dimethoxybenzoic acid (130 mg, 0.72 mmol) was dissolved in 752 μ L of a mixture of thionyl chloride and DCM (2/8, V/V). After one hour stirring at room temperature, it was evaporated. Then 2-(2,6-Difluoro-benzylsulfanyl)-3-(4-fluoro-phenyl)-3H-imidazol-4-ylamine (**19b**) (200 mg, 0.36 mmol) in 1.8 mL dry THF and Pyridine (57.9 μ L, 0.72 mmol) were added over the residue, and the mixture was stirred at room temperature for 4 h. Reaction mixture was then evaporated, dissolved in EtOAc, washed with water, with a saturated aqueous solution of NaHCO_3 and brine. Organic phase was dried over Na_2SO_4 and evaporated. Residue was purified by flash chromatography using as eluent a mixture of cyclohexane/ EtOAc (7/3) and then DCM/MeOH (98/2) to give a reddish solid corresponding to the pure titled product (56 mg, 31%). LC-MS: $t_R = 2.80$ min, MS $[\text{M}+\text{H}]^+$ $m/z = 499.8$. HRMS found 500.1256; $\text{C}_{25}\text{H}_{20}\text{F}_3\text{N}_3\text{O}_3\text{S}$ requires 500.1256. ^1H NMR (300 MHz, CDCl_3): δ (ppm) 3.87 (s, 3H), 3.89 (s, 3H), 4.13 (s, 2H), 6.75-6.87 (m, 3H), 7.05-7.26 (m, 7H), 7.37 (d, $J = 2.0$ Hz, 1H), 8.15 (s, 1H). ^{13}C NMR (75 MHz, CDCl_3): δ (ppm) 26.0, 56.1, 110.4, 110.9, 111.2-111.6 (m), 113.2 (t, $J = 19.2$ Hz), 116.6 (d, $J = 23.0$ Hz), 120.1, 123.4, 125.5, 129.3, 129.5 (t, $J = 10.2$ Hz), 129.7 (d, $J = 8.8$ Hz), 130.1 (d, $J = 3.3$ Hz), 138.7, 149.2, 152.6, 161.3 (dd, $J = 254.5, 3.7$ Hz), 162.9 (d, $J = 250.5$ Hz), 165.9.

2-[2-(4-Bromo-2,6-difluoro-benzyl)-3-(4-fluoro-phenyl)-isothioureido]-N-(3,4-dimethoxy-phenyl)-N-methyl-acetamide (20a). (4-Bromo-2,6-difluoro-phenyl)-methanol (892 mg) and NEt_3 (594 μL) were dissolved in dry DCM at 0°C . Mesylchloride (310 μL) was then added dropwise, and the mixture was stirred at room temperature overnight. Water was then added to quench the reaction. Organic phase was washed with water and brine, dried over Na_2SO_4 and evaporated to give an orange oil corresponding to 5-bromo-2-(chloromethyl)-1,3-difluoro-benzene. ^1H NMR (300 MHz, CDCl_3): δ (ppm) 4.62 (s, 2H), 7.14 (d, $J = 6.7$ Hz; 2H). The titled product was then obtained as a yellowish powder (1.07 g, 95 %) following procedure B using N-(3,4-Dimethoxy-phenyl)-2-[3-(4-fluoro-phenyl)-isothioureido]-N-methyl-acetamide (**3d**) (750 mg), and 5-bromo-2-(chloromethyl)-1,3-difluoro-benzene (461 mg). MS $[\text{M}+\text{H}]^+$ $m/z = 583.8$. ^1H NMR (300 MHz, $\text{DMSO}-d_6$): δ (ppm) 3.15 (s, 3H), 3.73 (m, 8H), 4.14 (s, 2H), 6.60 (m, 2H), 6.79 (brs, 1H), 6.86 (m, 1H), 6.97 (m, 4H), 7.46 (m, 2H).

[2-(4-Bromo-2,6-difluoro-benzylsulfanyl)-3-(4-fluoro-phenyl)-3H-imidazol-4-yl]-(3,4-dimethoxy-phenyl)-methyl-amine (20b). The titled product was obtained as an orange oil (867 mg, 74 %) following procedure D using 2-[2-(4-Bromo-2,6-difluoro-benzyl)-3-(4-fluoro-phenyl)-isothioureido]-N-(3,4-dimethoxy-phenyl)-N-methyl-acetamide (**20a**) (1.07 g). MS $[\text{M}+\text{H}]^+$ $m/z = 565.9$. ^1H NMR (300 MHz, $\text{DMSO}-d_6$): δ (ppm) 2.91 (s, 3H), 3.64-3.65 (m, 6H), 3.97 (s, 2H), 6.04 (dd, $J = 8.6, 2.6$ Hz, 1H), 6.20 (d, $J = 2.8$ Hz, 1H), 6.76 (d, $J = 8.7$ Hz, 1H), 6.96 (s, 1H), 7.11 (dd, $J = 9.0, 5.1$ Hz, 2H), 7.19 (m, 2H), 7.41 (m, 2H).

(3,4-Dimethoxy-phenyl)-[2-[4-(3-dimethylamino-prop-1-ynyl)-2,6-difluoro-benzylsulfanyl]-3-(4-fluoro-phenyl)-3H-imidazol-4-yl]-methyl-amine (20). In a 25 mL flask, [2-(4-Bromo-2,6-difluoro-benzylsulfanyl)-3-(4-fluoro-phenyl)-3H-imidazol-4-yl]-(3,4-dimethoxy-phenyl)-methyl-amine (**20b**) (600 mg, 1.06 mmol), dimethylpropargylamine (172 μL , 1.60 mmol), pyrrolidine

(133 μL , 1.60 mmol) were added in 5 mL of dry and degassed DMF. Then, $\text{PdCl}_2(\text{dppf})_2$ (68 mg, 53 μmol) and CuI (20 mg, 106 μmol) are added. Reaction mixture was heated under argon at 80°C for 6h. Reaction mixture was cooled down to room temperature, diluted with EtOAc, washed with brine, dried over Na_2SO_4 and evaporated. Crude product was purified by flash chromatography using as eluent a mixture of DCM/cyclohexane and then DCM/MeOH, to give 281 mg of a white powder (47 %). LC-MS: $t_{\text{R}} = 2.82$ min, MS $[\text{M}+\text{H}]^+ m/z = 566.9$. HRMS found 567.2054; $\text{C}_{30}\text{H}_{29}\text{F}_3\text{N}_4\text{O}_2\text{S}$ requires 567.2042. ^1H NMR (300 MHz, CDCl_3): δ (ppm) 2.35 (s, 6H), 2.91 (s, 3H), 3.45 (s, 2H), 3.79 (s, 3H), 3.82 (s, 3H), 4.08 (s, 2H), 6.15 (dd, $J = 8.7, 2.7$ Hz, 1H), 6.28 (d, $J = 2.7$ Hz, 1H), 6.72 (d, $J = 8.7$ Hz, 1H), 6.87 (d, $J = 8.0$ Hz, 2H), 6.97 (m, 4H), 7.02 (s, 1H).

(3-{4-[5-[(3,4-Dimethoxy-phenyl)-methyl-amino]-1-(4-fluoro-phenyl)-1H-imidazol-2-ylsulfanylmethyl]-3,5-difluoro-phenyl}-prop-2-ynyl)-trimethyl-ammonium iodide (21). In a 25 mL flask were added (3,4-Dimethoxy-phenyl)-[2-[4-(3-dimethylamino-prop-1-ynyl)-2,6-difluoro-benzylsulfanyl]-3-(4-fluoro-phenyl)-3H-imidazol-4-yl]-methyl-amine (**20**) (254 mg, 448 μmol), and 5 mL of a mixture dry Et_2O /dry THF (1:1). Iodomethane (27.7 μL , 1.345 mmol) was then added, and reaction mixture was stirred at room temperature. After 1h30 and 4h, iodomethane (27.7 μL , 1.345 mmol) was added again. Reaction mixture was then evaporated to dryness. Residue was triturated in Et_2O , filtrated, and the residue was purified by preparative HPLC (ammonium formate buffer, pH 3.8) to give the titled product as a brown residue (55 mg, 17%). LC-MS: $t_{\text{R}} = 2.83$ min, MS $[\text{M}]^+ m/z = 581.1$. HRMS found 581.2212; $\text{C}_{31}\text{H}_{32}\text{F}_3\text{N}_4\text{O}_2\text{S}$ requires 581.2198. ^1H NMR (300 MHz, $\text{DMSO}-d_6$): δ (ppm) 2.92 (s, 3H), 3.21 (s, 9H), 3.64 (s, 3H), 3.65 (s, 3H), 4.01 (s, 2H), 4.68 (s, 2H), 6.06 (dd, $J = 8.8, 2.8$ Hz, 1H), 6.21 (d, $J = 2.7$ Hz, 1H), 6.75 (d, $J = 8.8$ Hz, 1H), 6.95 (s, 1H), 7.13-7.25 (m, 4H), 7.40 (m, 2H). ^{13}C NMR (75 MHz,

DMSO-*d*₆): δ (ppm) 26.2, 52.7, 52.9, 55.9, 56.7, 80.7, 88.1, 100.1, 105.6; 113.8, 115.6, 116.3, 116.5, 122.0, 124.4, 130.2, 131.5, 136.5, 140.4, 142.6, 143.4, 149.8, 160.6, 162.2.

(3-{4-[5-[(3,4-Dimethoxy-phenyl)-methyl-amino]-1-(4-fluoro-phenyl)-1H-imidazol-2-ylsulfanylmethyl]-3,5-difluoro-phenyl}-prop-2-ynyl)-trimethyl-ammonium formate (22).

(3,4-Dimethoxy-phenyl)-[2-[4-(3-dimethylamino-prop-1-ynyl)-2,6-difluoro-benzylsulfanyl]-3-(4-fluoro-phenyl)-3H-imidazol-4-yl]-methyl-amine (**20**) (365 mg, 644 μ mol) was dissolved in 6.4 mL of a mixture of dry Et₂O/THF (1/1), under argon, and iodomethane (80 μ L, 1.29 mmol) was then added. Reaction mixture was stirred at room temperature. After 1h30 iodomethane (80 μ L, 1.29 mmol) was added again. After 30 min, reaction mixture was evaporated to dryness. Residue was then purified twice by preparative HPLC (HCOOH 0.1% first, then ammonium formate buffer, pH 9.2) to give the titled product as a yellowish powder (75 mg, 19%). LC-MS: $t_R = 2.83$ min, MS [M]⁺ $m/z = 581.1$. HRMS found 581.2213; C₃₁H₃₂F₃N₄O₂S requires 581.2198. ¹H NMR (300 MHz, CDCl₃): δ (ppm) 2.94 (s, 3H), 3.45 (s, 9H), 3.78-3.80 (m, 6H), 4.01 (s, 2H), 4.87 (s, 2H), 6.16 (dd, $J = 8.7, 2.7$ Hz, 1H), 6.27 (d, $J = 2.7$ Hz, 1H), 6.71 (d, $J = 8.7$ Hz, 1H), 6.96-7.07 (m, 7H), 8.58 (s, 1H). ¹³C NMR (75 MHz, CDCl₃): δ (ppm) 25.9, 40.5, 53.4, 56.0, 56.6, 57.1, 89.6, 100.4, 106.0, 112.6, 115.5 (d, $J = 26.8$ Hz), 116.2 (d, $J = 23.0$ Hz), 116.8 (t, $J = 19.2$ Hz), 121.4 (t, $J = 12.5$ Hz), 124.3, 129.4 (d, $J = 8.7$ Hz), 131.0 (d, $J = 3.2$ Hz), 137.3, 140.4, 143.0, 143.2, 149.7, 160.9 (dd, $J = 251.9, 9.1$ Hz), 162.5 (d, $J = 250.3$ Hz), 167.5.

2,6-Difluoro-4-hydroxy-benzoic acid. 2,6-Difluoro-4-hydroxy-benzonitrile (1.5 g) was dissolved in 7 mL distilled water and a solution of 1,35 g of NaOH in 4 mL water was then added. Reaction mixture was then heated at reflux for 4 days. Heating was then stopped, and reaction mixture was acidified by adding concentrated HCl, and extracted with Et₂O. Organic phase was then extracted by a saturated aqueous solution of NaHCO₃. This aqueous solution was

then acidified by adding concentrated HCl, and then extracted by Et₂O. Organic phase was dried over Na₂SO₄, and evaporated, to give the titled product as a white solid (1.58 g, 94 %). MS [M-H]⁻ *m/z* = 172.9. ¹H NMR (300 MHz, DMSO-*d*₆): δ (ppm) 6.49 (m, 2H), 10.96 (brs, 1H), 13.20 (brs, 1H).

2,6-Difluoro-4-hydroxy-benzoic acid methyl ester. 2,6-difluoro-4-hydroxy-benzoic acid (1.58 g) was dissolved in 18 mL of methanol, concentrated sulphuric acid (257 μL) was then added and reaction mixture was heated at reflux overnight. Reaction mixture was then evaporated, and residue was dissolved in EtOAc, washed twice with water, brine, and dried over Na₂SO₄ and evaporated to give the titled product as a white powder (1.48 g, 90 %). MS [M-H]⁻ *m/z* = 187.1. ¹H NMR (300 MHz, DMSO-*d*₆): δ (ppm) 3.80 (s, 3H), 6.54 (m, 2H), 11.12 (s, 1H).

3,5-Difluoro-4-hydroxymethyl-phenol (23i). In a 100 mL flask were added 2,6-Difluoro-4-hydroxy-benzoic acid methyl ester (1.48 g), 26 mL anhydrous THF, and 34 mL of a 1M solution of diisobutylaluminum hydride (DIBAL-H) in cyclohexane at 0-5°C. Reaction mixture was then stirred at this temperature for 1.5h, and then poured into a 250 mL flask containing 27 mL of cold (0-5°C) 1M aqueous potassium sodium L-tartrate solution. Reaction mixture was stirred at room temperature for 30 min. Aqueous phase was extracted by EtOAc, and combined organic phases were then washed with brine, dried over Na₂SO₄, and evaporated. Aqueous phase was acidified to pH 5, and extracted by EtOAc. Organic phase was dried over Na₂SO₄ and evaporated. The titled product was obtained as a yellowish powders (1g, 80%). MS [M-H]⁻ *m/z* = 159.0. ¹H NMR (300 MHz, DMSO-*d*₆): δ (ppm) 4.36 (d, *J* = 5.2 Hz, 2H), 5.00 (t, *J* = 5.5 Hz, 1H), 6.41 (m, 2H), 10.28 (s, 1H).

[4-(3-Chloropropoxy)-2,6-difluoro-phenyl]methanol. 1-bromo-3-chloro-propane (1.30 mL, 13.2 mmol), 3,5-Difluoro-4-hydroxymethyl-phenol (**23i**) (2.64 mmol, 423 mg) and K₂CO₃ (365

mg, 2.64 mmol) were added in acetonitrile (9 mL) and the reaction mixture was stirred at reflux for 3 hours. The solvent was removed under reduced pressure. The crude was dissolved in EtOAc and washed with water. The aqueous phase was extracted by EtOAc, washed with brine and dried over Na₂SO₄. The solvents were removed under reduced pressure, to give the titled product as colorless oil (602 mg, 96 %). MS [M+H-H₂O]⁺ *m/z* = 218.9. ¹H NMR (300 MHz, CDCl₃): δ (ppm) 2.24 (quin, *J* = 6.1 Hz, 2H), 3.73 (t, *J* = 6.3 Hz, 2H), 4.10 (t, *J* = 5.8 Hz, 2H), 4.71 (s, 2H), 6.41-6.52 (m, 2H).

2-Chloromethyl-5-(3-chloro-propoxy)-1,3-difluoro-benzene (23ii). [4-(3-chloropropoxy)-2,6-difluoro-phenyl]methanol (602 mg, 2.54 mmol) and NEt₃ (428 μL, 3.17 mmol) were dissolved in 5 mL dry DCM at 0°C. Mesylchloride (197 μL, 2.54 mmol) was then added dropwise, and the mixture was stirred at room temperature overnight. Reaction mixture was then evaporated to dryness. Water was added to quench the reaction. The organic phase was then washed with water and brine, and dried over Na₂SO₄, and then evaporated. The obtained residue corresponding to the titled product would enter in the next step of the synthesis without further purification.

2-[2-[2,6-Difluoro-4-(3-chloropropoxy)-benzyl]-3-(4-fluoro-phenyl)-isothioureido]-N-(3,4-dimethoxy-phenyl)-N-methyl-acetamide (23a). The titled product was obtained as a yellowish solid (915 mg, 73 %), following Procedure B, using N-(3,4-Dimethoxy-benzyl)-2-[3-(4-fluoro-phenyl)-thioureido]-N-methyl-acetamide (**3d**) (800 mg) and 2-Chloromethyl-5-(3-chloropropoxy)-1,3-difluoro-benzene (**23ii**). MS [M+H]⁺ *m/z* = 595.9. ¹H NMR (300 MHz, CDCl₃): δ (ppm) 2.15 (quin, *J* = 5.9 Hz, 2H), 3.27 (s, 3H), 3.66 (t, *J* = 6.2 Hz, 2H), 3.76-3.93 (m, 8H), 3.95-4.14 (m, 4H), 6.32-6.46 (m, 2H), 6.60-6.94 (m, 7H).

[2-(2,6-Difluoro-4-(3-chloropropoxy)-benzylsulfanyl)-3-(4-fluoro-phenyl)-3H-imidazol-4-yl]-N-(3,4-dimethoxy-phenyl)-methyl-amine (23b). The titled product was obtained as a brown

solid (895 mg, 96%), following Procedure D (without Flash Chromatography purification), using 2-[2-[2,6-Difluoro-4-(3-chloropropoxy)-benzyl]-3-(4-fluoro-phenyl)-isothioureido]-N-(3,4-dimethoxy-phenyl)-N-methyl-acetamide (**23a**) (915 mg). MS $[M+H]^+$ $m/z = 577.9$. 1H NMR (300 MHz, $CDCl_3$): δ (ppm) 2.21 (quin, $J = 6.0$ Hz, 2H), 2.91 (s, 3H), 3.72 (t, $J = 6.2$ Hz, 2H), 3.77-3.86 (m, 6H), 4.00-4.14 (m, 4H), 6.16 (dd, $J = 8.7, 2.8$ Hz, 1H), 6.30 (d, $J = 2.7$ Hz, 1H), 6.32-6.42 (m, 2H), 6.72 (d, $J = 8.7$ Hz, 1H), 6.91-7.05 (m, 5H). ^{13}C NMR (75 MHz, $CDCl_3$): δ (ppm) 25.8, 31.8, 40.1, 41.1, 55.9, 56.4, 64.8, 98.0-98.6 (m), 100.0, 105.5, 105.6 (t, $J = 20.2$ Hz), 112.4, 115.9 (d, $J = 22.9$ Hz), 124.3, 129.2 (d, $J = 8.7$ Hz), 130.9 (d, $J = 3.1$ Hz), 138.5, 139.5, 142.7, 143.2, 149.6, 159.5 (t, $J = 14.1$ Hz), 161.7 (dd, $J = 248.1, 11.0$ Hz), 162.3 (d, $J = 249.2$ Hz).

2-[[4-[3-(1-Aza-4-azoniabicyclo[2.2.2]octan-4-yl)propoxy]-2,6-difluoro-phenyl]methylsulfanyl]-N-(3,4-dimethoxyphenyl)-3-(4-fluorophenyl)-N-methyl-imidazol-4-amine ; formate (23**).** [2-(2,6-Difluoro-4-(3-chloropropoxy)-benzylsulfanyl)-3-(4-fluorophenyl)-3H-imidazol-4-yl]-(3,4-dimethoxy-phenyl)-methyl-amine (**23b**) (225 mg, 370 μ mol) and 1,4-diazabicyclo[2.2.2]octane (DABCO) (112 mg, 1.0 mmol) were dissolved in dry acetonitrile (3.7 mL). Reaction mixture was then heated under microwave irradiation at 100 °C for 30 min. It was then evaporated to dryness and purified by preparative HPLC (ammonium formate buffer, pH = 9.2) to give the titled compound as a pale orange powder (60 mg, 23%). LC-MS: $t_R = 2.47$ min; MS $[M]^+$ $m/z = 654.2$. HRMS found 654.2733; $C_{34}H_{39}F_3N_5O_3S$ requires 654.2726. 1H NMR (300 MHz, $CDCl_3$): δ (ppm) 2.31 (brs, 2H), 2.94 (s, 3H), 3.32 (brs, 6H), 3.48-3.82 (m, 14H), 3.94 (s, 2H), 4.06 (brs, 2H), 6.16 (dd, $J = 8.7, 2.7$ Hz, 1H), 6.27 (d, $J = 2.7$ Hz, 1H), 6.35-6.47 (m, 2H), 6.71 (d, $J = 8.8$ Hz, 1H), 6.93-7.11 (m, 5H), 8.60 (s, 1H). ^{13}C NMR (75 MHz, $CDCl_3$): δ (ppm) 22.1, 25.7, 40.3, 45.3, 52.6, 55.9, 56.5, 61.8, 65.2, 98.2-98.8 (m), 100.1, 105.9, 106.0 (t,

$J = 20.1$ Hz), 112.5, 116.0 (d, $J = 22.9$ Hz), 123.9, 129.3 (d, $J = 8.8$ Hz), 130.9 (d, $J = 3.2$ Hz), 137.8, 140.1, 142.8, 143.1, 149.6, 159.0 (t, $J = 14.1$ Hz), 161.6 (dd, $J = 248.2, 11.0$ Hz), 162.3 (d, $J = 249.3$ Hz).

3-[4-[[5-(3,4-Dimethoxy-N-methyl-anilino)-1-(4-fluorophenyl)imidazol-2-

yl]sulfanylmethyl]-3,5-difluoro-phenoxy]propane-1-sulfonate; ammonium (24). In a 2-5 mL microwave tube, [2-(2,6-Difluoro-4-(3-chloropropoxy)-benzylsulfanyl)-3-(4-fluoro-phenyl)-3H-imidazol-4-yl]-(3,4-dimethoxy-phenyl)-methyl-amine (**23b**) (540 mg, 0.89 mmol) was dissolved in 6 mL of a mixture of dioxane and water (1/1, V/V). Sodium sulfite (559 mg, 4.44 mmol) and sodium iodide (133 mg, 0.89 mmol) were then added. Reaction mixture was heated under microwave irradiation at 130°C for 30 min and then at 130°C for 40 min. Then Sodium sulfite (223 mg, 1.8 mmol) and sodium iodide (53 mg, 0.36 mmol) were added again, before heating under microwave irradiation at 130 °C for 30 min. Reaction mixture was evaporated to dryness and purified by preparative HPLC (ammonium formate buffer pH = 3.8) to give the titled product a yellowish powder (207 mg, 36 %). LC-MS: $t_R = 2.40$ min, MS $[M]^+ m/z = 622.1$. HRMS found 624.1453; $C_{28}H_{27}F_3N_3O_6S_2$ requires 624.1450. 1H NMR (300 MHz, MeOD- d_4): δ (ppm) 2.18-2.30 (m, 2H), 2.92-3.02 (m, 5H), 3.73 (s, 3H), 3.75 (s, 3H), 3.93 (s, 2H), 4.11 (t, $J = 6.3$ Hz, 2H), 6.16 (dd, $J = 8.7, 2.8$ Hz, 1H), 6.30 (d, $J = 2.7$ Hz, 1H), 6.48-6.58 (m, 2H), 6.78 (d, $J = 8.7$ Hz, 1H), 6.89-6.98 (m, 2H), 6.99-7.11 (m, 3H). ^{13}C NMR (75 MHz, MeOD- d_4): δ (ppm) 24.6, 26.6, 39.8, 47.7, 55.2, 55.8, 67.2, 98.0-98.3 (m), 101.7, 105.3 (t, $J = 20.0$ Hz), 107.6, 113.1, 115.3, (d, $J = 23.4$ Hz), 121.4, 129.7 (d, $J = 9.0$ Hz), 130.6 (d, $J = 3.1$ Hz), 137.3, 141.1, 142.9, 143.5, 149.8, 160.2 (t, $J = 14.3$ Hz), 161.5 (dd, $J = 246.6, 11.2$ Hz), 162.6 (d, $J = 248.3$ Hz).

[4-(3-Bromopropoxy)-2,6-difluoro-phenyl]methanol (25i). 1,3-dibromopropane (950.87 μ L, 9.37 mmol), 3,5-difluoro-4-(hydroxymethyl)phenol (300 mg, 1.87 mmol) and K_2CO_3 (258.95

mg, 1.87 mmol) were added in acetonitrile (6 mL) and the reaction mixture was stirred at reflux for 3 hours. The solvent was removed under reduced pressure. The crude was dissolved in EtOAc and washed with water. The aqueous phase was extracted with EtOAc and washed with brine, dried under Na_2SO_4 . The solvents were removed under reduced pressure, and the crude was purified by flash chromatography using as eluent a mixture of Cy/EA (80/20) to give 400 mg of [4-(3-bromopropoxy)-2,6-difluoro-phenyl]methanol as a colorless oil, leading to a 76% yield. MS $[\text{M}+\text{H}]^+$ $m/z = 264$.

***tert*-Butyl N-*tert*-butoxycarbonyl-N-[3-[3,5-difluoro-4-(hydroxymethyl)-phenoxy]propyl]-carbamate (25ii).** [4-(3-bromopropoxy)-2,6-difluoro-phenyl]methanol **25i** (320 mg, 1.14 mmol) was dissolved in 11 mL of dry dimethylformamide. *tert*-butyl N-*tert*-butoxycarbonylcarbamate (247.33 mg, 1.14 mmol) and cesium carbonate (370.91 mg, 1.14 mmol) were added and the reaction mixture was stirred at 70°C for 30 min. The solvent was removed. The crude was dissolved in EtOAc, washed with water, dried over Na_2SO_4 . The solvent was removed. The crude was purified by flash chromatography using as eluent a mixture of Cy/EA (90/10) to give 500 mg of *tert*-butyl N-*tert*-butoxycarbonyl-N-[3-[3,5-difluoro-4-(hydroxymethyl)phenoxy]propyl]carbamate as a colorless oil, leading to a 95% yield. MS $[\text{M}+\text{H}]^+$ $m/z = 344$. ^1H NMR (300 MHz, $\text{DMSO}-d_6$): δ (ppm) 1.41 (s, 18H), 1.87-1.96 (q, $J = 12.6, 6.1$ Hz, 2H), 3.64 (t, $J = 6.9$ Hz, 2H), 3.99 (t, $J = 5.7$ Hz, 2H), 4.39 (d, $J = 5.7$ Hz, 2H), 5.08 (t, $J = 5.4$ Hz, 2H), 6.59-6.68 (m, 2H).

***tert*-Butyl N-*tert*-butoxycarbonyl-N-[3-[4-(chloromethyl)-3,5-difluorophenoxy]propyl]carbamate (25iii).** *Tert*-butyl N-*tert*-butoxycarbonyl-N-[3-[3,5-difluoro-4-(hydroxymethyl)phenoxy]propyl]-carbamate **25ii** (520 mg, 1.25 mmol) and NEt_3 (420.17 μL , 3.11 mmol) were dissolved in dry dichloromethane at 0°C. Mesylchloride (144.91 μL , 1.87

mmol) was then added dropwise, and the mixture was stirred at room temperature overnight. Water was then added to quench the reaction. The organic phase was then washed with water and brine, and dried over Na₂SO₄, and then evaporated to give 475 mg of the titled compound as colorless oil, leading to a 87% yield. It will be used without further purification in the next step of the synthesis. MS [M+H]⁺ *m/z* = 453.0.

***tert*-Butyl N-*tert*-butoxycarbonyl-N-[3-[4-[[*(Z)*]-N-[2-(3,4-dimethoxy-N-methyl-anilino)-2-oxo-ethyl]-N'-(4-fluorophenyl)carbamimidoyl]sulfanylmethyl]-3,5-difluoro-phenoxy]propyl]carbamate (25a).** In a 50 mL flask were added N-(3,4-dimethoxyphenyl)-2-[[*(Z)*]-N-(4-fluorophenyl)-C-sulfanyl-carbonimidoyl]amino]-N-methyl-acetamide (411.3 mg, 1.09 mmol), DIEA (206.57 μL, 1.2 mmol), and 2.5 mL of acetonitrile. The suspension was stirred at room temperature for 10 min, and residue from *tert*-butyl N-*tert*-butoxycarbonyl-N-[3-[4-(chloromethyl)-3,5-difluoro-phenoxy]propyl]carbamate (**25iii**) (475 mg, 1.09 mmol) in 3 mL of acetonitrile was then added. The suspension was stirred at room temperature overnight. The solvent was then evaporated, residue was dissolved in EtOAc, washed with water and brine, organic phase was dried over Na₂SO₄ and evaporated. Residue was then purified by flash chromatography using as eluent a mixture of cyclohexane/EtOAc (6/4) to give 300 mg (35 %) of **25a** as yellowish oil. MS [M+H]⁺ *m/z* = 777. ¹H NMR (300 MHz, DMSO-*d*₆): δ (ppm) 1.37 (s, 18H), 1.89 (t, *J* = 6.4 Hz, 2H), 3.16 (s, 3H), 3.61 (t, *J* = 7.0 Hz, 2H), 3.68 (s, 3H), 3.71-3.74 (m, 2H), 3.76 (s, 3H), 3.98 (t, *J* = 5.4 Hz, 2H), 4.10 (s, 2H), 6.58-6.63 (m, 2H), 6.66 (d, *J* = 9.6 Hz, 2H), 6.88 (d, *J* = 8.3 Hz, 2H), 6.90-7.01 (m, 4H).

***tert*-Butyl N-*tert*-butoxycarbonyl-N-[3-[4-[[5-(3,4-dimethoxy-N-methyl-anilino)-1-(4-fluorophenyl)imidazol-2-yl]sulfanylmethyl]-3,5-difluoro-phenoxy]propyl]carbamate (25b).** In 100 mL flask were introduced *tert*-butyl N-*tert*-butoxycarbonyl-N-[3-[4-[[*(Z)*]-N-[2-(3,4-

dimethoxy-N-methyl-anilino)-2-oxo-ethyl]-N'-(4-fluorophenyl)carbamimidoyl]sulfanylmethyl]-3,5-difluoro-phenoxy]propyl]carbamate (300 mg, 0,39 mmol), 4 mL of EtOAc, DIEA (0.4 mL, 2.32 mmol), and T3P® (0.68 mL, 1.16 mmol). The mixture was heated at reflux for 7h. After 7 hours, DIEA (0.4 mL, 2.32 mmol) and T3P® (0.68 mL, 1.16 mmol) were added again. After 24 hours, DIEA (0.4 mL, 2.32 mmol), and T3P® (0.68 mL, 1.16 mmol) were added again. After 48 hours, the reaction was over and the reaction mixture was diluted in EtOAc. The solution was then washed with a saturated aqueous solution of NaHCO₃, and with brine. Organic phase was dried over Na₂SO₄ and evaporated to dryness. Residue was purified by flash chromatography using as eluent a mixture of DCM/MeOH (99/1) to give 183 mg of the titled compound as orange oil, leading to a 62% yield. MS [M+H]⁺ *m/z* = 759. ¹H NMR (300 MHz, DMSO-*d*₆): δ (ppm) 1.40 (s, 18H), 1.91 (t, *J* = 6.3 Hz, 2H), 2.92 (s, 3H), 3.63 (s, 3H), 3.64 (s, 3H), 3.63 (t, *J* = 6.3 Hz, 2H), 3.98 (t, *J* = 5.5 Hz, 2H), 3.98 (s, 2H), 6.03-6.07 (dd, *J* = 8.7, 2.8 Hz, 1H), 6.20 (d, *J* = 2.8 Hz, 1H), 6.63 (d, *J* = 9.8 Hz, 2H), 6.73 (d, *J* = 8.7 Hz, 1H), 6.95 (s, 1H), 7.10-7.23 (m, 4H).

2-[[4-(3-Aminopropoxy)-2,6-difluoro-phenyl]methylsulfanyl]-N-(3,4-dimethoxyphenyl)-3-(4-fluorophenyl)-N-methyl-imidazol-4-amine (25c). *Tert*-butyl *N-tert*-butoxycarbonyl-N-[3-[4-[[5-(3,4-dimethoxy-N-methyl-anilino)-1-(4-fluorophenyl)imidazol-2-yl]sulfanylmethyl]-3,5-difluoro-phenoxy]propyl]carbamate (180 mg, 0.24 mmol) was diluted in 4 mL of dry DCM and 400 μL of TFA were added. The reaction mixture was stirred at 0°C during 30 min and at room temperature during 5h. The crude was diluted in DCM, washed with a saturated aqueous solution of NaHCO₃, dried over Na₂SO₄. The solvent was removed to give 130 mg of the titled compound as yellow oil, leading as a 98% yield. It was used without further purification in the next step of the synthesis. MS [M+H]⁺ *m/z* = 559. ¹H NMR (300 MHz, DMSO-*d*₆): δ (ppm) 1.74-1.79 (m,

2H), 2.68 (t, $J = 6.6$ Hz, 2H), 2.92 (s, 3H), 3.32 (s, 2H), 3.63 (s, 3H), 3.64 (s, 3H), 3.98 (s, 2H), 4.03 (t, $J = 6.6$ Hz, 2H), 6.03-6.07 (dd, $J = 8.8, 2.8$ Hz, 1H), 6.20 (d, $J = 2.8$ Hz, 1H), 6.67 (d, $J = 9.8$ Hz, 2H), 6.73 (d, $J = 8.8$ Hz, 1H), 6.96 (s, 1H), 7.09-7.23 (m, 4H).

2-[3-[4-[[5-(3,4-Dimethoxy-N-methyl-anilino)-1-(4-fluorophenyl)imidazol-2-

yl]sulfanylmethyl]-3,5-difluoro-phenoxy]propyl-(2-sulfonatoethyl)amino]ethanesulfonate;

diammonium (25). In a microwave tube were added 2-[[4-(3-aminopropoxy)-2,6-difluorophenyl]methylsulfanyl]-N-(3,4-dimethoxyphenyl)-3-(4-fluorophenyl)-N-methyl-imidazol-4-amine (92 mg, 0.16 mmol), Sodium 2-chloroethanesulfonate (219.44 mg, 1.32 mmol), sodium iodide (24.69 mg, 0.16 mmol) and DIEA (114.75 μ L, 0.66 mmol) in 700 μ L of DMF. The reaction mixture was heated under microwave irradiation at 100°C for 2 h. The reaction mixture was evaporated to dryness and was purified by preparative HPLC (ammonium formate buffer pH = 3.8) to give 22 mg of the titled compound as a colorless oil, leading to a 16% yield. LC-MS: $t_R = 2.65$ min, MS $[M+2H]^{2+}$ $m/z = 775$. HRMS found 775.1745; $C_{32}H_{35}F_3N_4O_9S_3$ requires 775.1753. 1H NMR (300 MHz, MeOD- d_4): δ (ppm) 2.26-2.32 (m, 2H), 2.98 (s, 3H), 3.26 (t, $J = 6.7$ Hz, 4H), 3.48 (t, $J = 7.2$ Hz, 2H), 3.65 (t, $J = 6.7$ Hz, 4H), 3.74 (s, 3H), 3.75 (s, 3H), 3.91 (s, 2H), 4.11 (t, $J = 5.6$ Hz, 1H), 6.14-6.18 (dd, $J = 8.6, 2.8$ Hz, 1H), 6.29 (d, $J = 2.8$ Hz, 1H), 6.58 (d, $J = 9.5$ Hz, 2H), 6.78 (d, $J = 8.6$ Hz, 1H), 6.92-7.07 (m, 5H). ^{13}C NMR (75 MHz, MeOD- d_4): δ (ppm) 23.7, 26.5, 39.6, 44.8, 50.3, 51.4, 55.2, 56.0, 65.7, 98.0-98.6 (m), 101.0, 106.0 (t, $J = 20.1$ Hz), 106.8, 113.3, 115.3 (d, $J = 23.4$ Hz), 122.8, 129.6, 129.7, 130.8, 137.4, 140.7, 143.1, 143.2, 149.8, 159.6 (t, $J = 14.0$ Hz), 161.5 (dd, $J = 246.7, 10.9$ Hz), 162.5 (d, $J = 247.9$ Hz).

tert-Butyl N-[2-(3,4-dimethoxy-N-methyl-anilino)-1-methyl-2-oxo-ethyl]carbamate (26a). In a 10 mL flask were added (3,4-Dimethoxy-phenyl)-methyl-amine (**3a**) (275 mg, 1.55 mmol), EtOAc (3 mL), Boc-Ala-OH (351 mg, 1.86 mmol), T3P® (1366 μ L, 2.319 mmol), and DIEA

(810 μL , 4.64 mmol). Reaction mixture was then stirred at room temperature for 1 hour. The reaction mixture was diluted with EtOAc, washed with water, saturated aqueous solution of NaHCO_3 and brine, and the organic phase was dried over Na_2SO_4 and evaporated to give 523 mg of *tert*-butyl N-[2-(3,4-dimethoxy-N-methyl-anilino)-1-methyl-2-oxo-ethyl]carbamate as a yellow powder, leading to a 66 % yield. MS $[\text{M}+\text{H}]^+$ $m/z = 339.2$.

[2-(3,4-Dimethoxy-N-methyl-anilino)-1-methyl-2-oxo-ethyl]ammonium;2,2,2-

trifluoroacetate (26b). *tert*-butyl N-[2-(3,4-dimethoxy-N-methyl-anilino)-1-methyl-2-oxo-ethyl]carbamate (**26a**) (345 mg, 1.0 mmol) was dissolved in 2.3 mL of dichloromethane. 1 mL of TFA was then gently added and reaction mixture was then stirred at room temperature for 30 min. Reaction mixture was then evaporated to dryness, to give [2-(3,4-dimethoxy-N-methyl-anilino)-1-methyl-2-oxo-ethyl]ammonium;2,2,2-trifluoroacetate as a purple oil. This oil will enter the next step without further purification. Yield was considered to be 100%. MS $[\text{M}+\text{H}]^+$ $m/z = 239.1$.

N-(3,4-Dimethoxy-phenyl)-2-[3-(4-fluoro-phenyl)-isothioureido]-N-methyl-propionamide

(26c). 4-fluorophenylisothiocyanate (150 mg, 0.982 mmol) and NEt_3 (159 μL , 1.18 mmol) were added in a 50 mL flask in 3 mL Ethanol. [2-(3,4-dimethoxy-N-methyl-anilino)-1-methyl-2-oxo-ethyl]ammonium; 2,2,2-trifluoroacetate (**26b**) (346 mg, 0.982 mmol) was dissolved in 10 mL of ethanol, NEt_3 was added until pH was over 8 and the mixture was added dropwise at room temperature. After the addition, the reaction was over. Reaction mixture was evaporated to dryness, and purified by flash chromatography using as eluent a mixture of cyclohexane/EtOAc (7/3), to give 295 mg of the titled compound as a white powder (94% purity), leading to a 72 % yield. MS $[\text{M}+\text{H}]^+$ $m/z = 392.1$. ^1H RMN ($\text{DMSO-}d_6$): δ (ppm) 1.10 (d, $J = 6.9$ Hz, 3H), 3.15 (s,

3H), 3.75-3.80 (m, 6H), 4.99 (m, 1H), 6.96 (dd, $J = 8.5, 2.3$ Hz, 1H), 7.10 (d, $J = 8.5$ Hz, 1H), 7.06-7.19 (m, 3H), 7.41-7.51 (m, 2H), 7.83 (d, $J = 7.7$ Hz, 1H).

2-[2-(2,6-Difluoro-benzyl)-3-(4-fluoro-phenyl)-isothioureido]-N-(3,4-dimethoxy-phenyl)-N-methyl-propionamide (26d). In a 5 mL flask were added N-(3,4-dimethoxy-phenyl)-2-[3-(4-fluoro-phenyl)-isothioureido]-N-methyl-propionamide (**26c**) (75 mg, 180 μ mol), K_2CO_3 (26 mg, 188 μ mol), sodium iodide (14 mg, 93 μ mol), and 1 mL of acetonitrile (QS 0.2 M). The suspension was stirred at room temperature for 10 min, and 2-(bromomethyl)-1,3-difluorobenzene (40 mg, 193 μ mol) was then added. The suspension was stirred at room temperature for 16 hours. The medium was then evaporated, residue was dissolved in EtOAc, washed with water and brine, organic phase was dried over Na_2SO_4 and evaporated to dryness. Residue was purified by flash chromatography using as eluent a mixture of DCM/MeOH (97/3) to give 78 mg of the titled compound as a white solid, leading to a 84% yield. MS $[M+H]^+$ $m/z = 518.2$. 1H NMR (300 MHz, CD_2Cl_2): δ (ppm) 1.22 (d, $J = 6.4$ Hz, 3H), 3.25 (s, 3H), 3.63 (s, 3H), 3.85 (s, 3H), 4.11 (s, 2H), 4.58 (brs, 1H), 6.65-7.02 (m, 10H), 7.28 (m, 1H).

[2-(2,6-Difluoro-benzylsulfanyl)-3-(4-fluoro-phenyl)-5-methyl-3H-imidazol-4-yl]-(3,4-dimethoxy-phenyl)-methyl-amine (26). 2-[2-(2,6-Difluoro-benzyl)-3-(4-fluoro-phenyl)-isothioureido]-N-(3,4-dimethoxy-phenyl)-N-methyl-propionamide (**26d**) (78 mg, 0.15 mmol) was dissolved in 1.5 mL of dry EtOAc. DIEA (157.9 μ L, 0.90 mmol), and T3P® in EtOAc (266 μ L, 0.45 mmol) were then added. Half of the mixture was heated with microwave at 150°C for 10 min. The expected product was observed, starting material has disappeared, but unfortunately, reaction mixture was dirty. The other half of the reaction mixture was heated at reflux for 45 hours. T3P® (3 eq) and DIEA (6 eq) were added after 4, 19, and 24 hours. T3P® (1.5 eq) and DIEA (3 eq) were added after 42 hours. Reaction mixture was then diluted with EtOAc, washed

with water, a saturated aqueous solution of NaHCO₃, and brine. Organic phase was then dried over Na₂SO₄ and evaporated. Residue was then purified by preparative HPLC (ammonium formate buffer pH 3.8) to give 4.5 mg of the titled compound as a yellowish solid, leading to a 6 % yield. MS [M+H]⁺ *m/z* = 500.1. ¹H NMR (300 MHz, CDCl₃): δ (ppm) 2.11 (s, 3H, CH₃), 2.87 (s, 3H, N-CH₃), 3.84 (s, 3H, O-CH₃), 3.86 (s, 3H, O-CH₃), 4.13 (s, 2H, S-CH₂), 6.10 (dd, *J* = 8.7, 2.8 Hz, 1H, Ar), 6.23 (d, *J* = 2.8 Hz, 1H, Ar), 6.76-6.83 (m, 3H, Ar), 6.93-6.97 (m, 4H, Ar), 7.19 (m, 1H, Ar). ¹³C NMR (75 MHz, CDCl₃): δ (ppm) 12.4, 26.3, 38.6, 55.9, 56.5, 98.1, 103.5, 111.1-111.3 (m), 112.7, 113.8 (t, *J* = 19.6 Hz), 115.9 (d, *J* = 22.9 Hz), 128.9 (d, *J* = 8.6 Hz), 129.1 (t, *J* = 10.0 Hz), 131.2, 133.6, 134.4, 136.6, 142.0, 142.9, 149.8, 161.2 (dd, *J* = 249.9, 7.7 Hz), 162.1 (d, *J* = 248.8 Hz).

9H-Fluoren-9-ylmethyl N-[(5S)-5-(*tert*-butoxycarbonylamino)-6-(3,4-dimethoxy-N-methyl-anilino)-6-oxo-hexyl]carbamate (27a). In a 50 mL flask were added 3,4-dimethoxy-N-methylaniline (**3a**) (500 mg, 2.99 mmol), 6 mL of EtOAc, (2R)-2-(*tert*-butoxycarbonylamino)-6-(9H-fluoren-9-ylmethoxycarbonylamino)hexanoic acid (1681.33 mg, 3.59 mmol), DIEA (1.57 mL, 8.97 mmol) and T3P® (2.64 mL, 4.49 mmol). The reaction mixture was then stirred at 50°C for 1 hour. The reaction mixture was diluted in EtOAc, washed with a saturated aqueous solution of NaHCO₃ and with brine, and the organic phase was dried over MgSO₄ and evaporated to dryness to give 1.85 g of the titled compound as dark red oil, leading to a quantitative yield. It was used without further purification in the next step of the synthesis. MS [M+H]⁺ *m/z* = 618.

[(1S)-1-[(3,4-Dimethoxyphenyl)-methyl-carbamoyl]-5-(9H-fluoren-9-ylmethoxycarbonylamino)pentyl]ammonium;2,2,2-trifluoroacetate (27b). 9H-fluoren-9-ylmethyl N-[(5S)-5-(*tert*-butoxycarbonylamino)-6-(3,4-dimethoxy-N-methyl-anilino)-6-oxo-hexyl]carbamate (**27a**) (1.85 g, 2.99 mmol) and TFA (2.56 mL, 33.42 mmol) were dissolved in 5

mL of DCM. The reaction mixture was stirred at room temperature for 1 h. 1 mL of TFA was added again at the reaction mixture and it was stirred at room temperature for 30 minutes. The reaction mixture was evaporated to dryness to give 1.58 g of the titled compound as purple oil, leading to a quantitative yield. It was used without further purification in the next step of the synthesis. MS $[M+H]^+$ $m/z = 518$.

9H-Fluoren-9-ylmethyl N-[(5S)-6-(3,4-dimethoxy-N-methyl-anilino)-5-[[Z]-N-(4-fluorophenyl)-C-sulfanyl-carbonimidoyl]amino]-6-oxo-hexyl]carbamate (27c). 1-fluoro-4-isothiocyanato-benzene (0.46 g, 2.99 mmol) and NEt_3 (0.4 mL, 2.99 mmol) were added in a 500 mL flask in 20 mL of ethanol. [(1S)-1-[(3,4-dimethoxyphenyl)-methyl-carbamoyl]-5-(9H-fluoren-9-ylmethoxycarbonylamino)pentyl]ammonium;2,2,2-trifluoroacetate (**27b**) (1.89 g, 2.99 mmol) was dissolved in 20 mL of ethanol, NEt_3 (0.47 mL, 3.47 mmol) were added, and the mixture was added dropwise at room temperature. Then 1 mL of NEt_3 was added to reach pH 10. The reaction mixture was evaporated to dryness. Purification of the crude by flash chromatography using as eluent a mixture of cyclohexane/EtOAc (50/50) gave 1.58 g of the titled compound as yellowish oil, leading to a 79% yield. MS $[M+H]^+$ $m/z = 671$. 1H NMR (300 MHz, $CDCl_3$): δ (ppm) 1.09-1.36 (m, 4H), 1.46-1.70 (m, 2H), 3.00 (s, 2H), 3.20 (s, 3H), 3.87 (s, 3H), 3.93 (s, 3H), 4.18 (d, $J = 7.3$ Hz, 1H), 4.36 (d, $J = 7.1$ Hz, 2H), 4.91 (t, $J = 5.6$ Hz, 1H), 6.88 (s, 2H), 6.99 (t, $J = 8.5$ Hz, 2H), 7.12 (s, 1H), 7.20-7.42 (m, 6H), 7.57 (d, $J = 7.4$ Hz, 2H), 7.67 (s, 1H), 7.74 (d, $J = 7.4$ Hz, 2H), 8.51 (s, 1H).

9H-Fluoren-9-ylmethyl N-[(5S)-5-[[Z]-C-[(2,6-difluorophenyl)methylsulfanyl]-N-(4-fluorophenyl)carbonimidoyl]amino]-6-(3,4-dimethoxy-N-methyl-anilino)-6-oxo-hexyl]carbamate (27d). In a 25 mL flask were added 2-(bromomethyl)-1,3-difluoro-benzene (486.14 mg, 2.348 mmol), K_2CO_3 (357.02 mg, 2.583 mmol) and 11.7 mL of acetonitrile. The

suspension was stirred at room temperature for 10 minutes and 9H-fluoren-9-ylmethyl N-[(5S)-6-(3,4-dimethoxy-N-methyl-anilino)-5-[[4-fluoroanilino)-sulfanyl-methyl]amino]-6-oxo-hexyl]carbamate (**27c**) (1.58 g, 2.35 mmol) was then added. The suspension was stirred at room temperature overnight. The reaction mixture was then evaporated, residue was dissolved in EtOAc, washed with water and brine, organic phase was dried over MgSO₄ and evaporated to dryness to give 1.87 g of the desired product as dark oil, leading to a 89% yield. It was used without further purification in the next step of the synthesis. MS [M+H]⁺ *m/z* = 799. ¹H NMR (300 MHz, CDCl₃): δ (ppm) 1.30 (brs, 4H), 1.62 (brs, 3H), 3.08 (brs, 2H), 3.27 (brs, 3H), 3.62 (s, 3H), 3.84 (s, 3H), 4.08 (brs, 2H), 4.19 (m, 1H), 4.39 (d, *J* = 6.9 Hz, 2H), 4.70 (brs, 1H), 5.24 (brs, 1H), 6.74 (brs, 1H), 6.75-6.95 (m, 8H), 7.15-7.23 (m, 1H), 7.30 (t, *J* = 7.4 Hz, 2H), 7.39 (t, *J* = 7.4 Hz, 2H), 7.57 (d, *J* = 7.2 Hz, 2H), 7.76 (d, *J* = 7.2 Hz, 2H).

9H-Fluoren-9-ylmethyl N-[4-[2-[(2,6-difluorophenyl)methylsulfanyl]-5-(3,4-dimethoxy-N-methyl-anilino)-1-(4-fluorophenyl)imidazol-4-yl]butyl]carbamate (27e). In a 50 mL flask were added 9H-fluoren-9-ylmethyl N-[(5S)-5-[[Z]-C-[(2,6-difluorophenyl)methylsulfanyl]-N-(4-fluorophenyl)carbonimidoyl]amino]-6-(3,4-dimethoxy-N-methyl-anilino)-6-oxo-hexyl]carbamate (**27d**) (1.625 mg, 2.039 mmol), T3P® (3.605 mL, 6.117 mmol), DIEA (2.137 mL, 12.23 mmol) and 20.39 mL of EtOAc. The suspension was stirred 24 hours at 80°C. Same quantities of T3P® and DIEA were added twice at 24 and 48 h. The medium was then evaporated, the residue was dissolved in EtOAc, washed with water and brine, organic phase was dried over MgSO₄ and evaporated. Purification of the crude by flash chromatography using as eluent a mixture of cyclohexane/EtOAc (7/3) gave 507 mg of the titled compound as a yellow solid, leading to a 32% yield. MS [M+H]⁺ *m/z* = 779. ¹H NMR (300 MHz, CDCl₃): δ (ppm) 1.42-1.56 (m, 2H), 1.61-1.74 (m, 2H), 2.43 (t, *J* = 7.4 Hz, 2H), 2.83 (s, 3H), 3.15-3.22 (m, 2H),

3.80 (s, 3H), 3.81 (s, 3H), 4.07 (s, 2H), 4.21 (t, $J = 6.8$ Hz, 2H), 4.38 (d, $J = 7.0$ Hz, 2H), 5.03 (brs, 1H), 6.04 (dd, $J = 8.7, 2.8$ Hz, 1H), 6.18 (d, $J = 2.8$ Hz, 1H), 6.70-6.81 (m, 3H), 6.88-6.94 (m, 4H), 7.09-7.20 (m, 1H), 7.30(t, $J = 7.4$ Hz, 2H), 7.38 (d, $J = 7.4$ Hz, 2H), 7.60 (d, $J = 7.2$ Hz, 2H), 7.75 (d, $J = 7.2$ Hz, 2H).

4-[2-[(2,6-Difluorophenyl)methylsulfanyl]-5-(3,4-dimethoxy-N-methyl-anilino)-1-(4-fluorophenyl)imidazol-4-yl]butylammonium;formate (27). To a solution of 9H-fluoren-9-ylmethyl N-[4-[2-[(2,6-difluorophenyl)methylsulfanyl]-5-(3,4-dimethoxy-N-methyl-anilino)-1-(4-fluorophenyl)imidazol-4-yl]butyl]carbamate (**27e**) (0.24 g, 0.31 mmol) in EtOAc (1.45 mL) was added piperidine (0.06 mL, 0.62 mmol). The reaction mixture was stirred at room temperature overnight. The reaction mixture was then evaporated under reduced pressure. Purification of the crude by preparative HPLC (ammonium formate buffer pH 3.8) gave 100 mg of the desired product as yellowish oil, leading to a 60% yield. MS $[M+H]^+$ $m/z = 557$. HRMS found 585.2126; $C_{30}H_{31}F_3N_4O_3S$ requires 585.2147. 1H NMR (300 MHz, $CDCl_3$): δ (ppm) 1.60-1.80 (m, 4H), 2.32-2.50 (m, 2H), 2.82 (s, 3H), 2.90-3.00 (m, 2H), 3.80 (s, 3H), 3.81 (s, 3H), 3.94 (s, 2H), 6.03 (dd, $J = 8.7, 2.4$ Hz, 1H), 6.17 (d, $J = 2.4$ Hz, 1H), 5.50-6.50 (m, 3H), 6.70-6.82 (m, 3H), 6.83-6.95 (m, 4H), 7.10-7.21 (m, 1H), 8.46 (brs, 1H). ^{13}C NMR (75 MHz, $CDCl_3$): δ (ppm) 25.8, 25.9, 26.9, 27.6, 39.0, 56.0, 56.6, 70.6, 98.2, 103.8, 111.3 (m), 112.9, 114.0 (t, $J = 19.3$ Hz), 115.9 (d, $J = 22.8$ Hz), 129.2 (d, $J = 9.0$ Hz), 129.3 (t, $J = 9.2$ Hz), 131.1 (d, $J = 3.1$ Hz), 134.7, 136.4, 137.2, 142.2, 142.9, 149.9, 161.1 (dd, $J = 249.7, 7.8$ Hz), 162.3 (d, $J = 249.1$ Hz), 168.6.

Methyl (4S)-4-(tert-butoxycarbonylamino)-5-(3,4-dimethoxy-N-methyl-anilino)-5-oxopentanoate (28a). In a 50 mL flask were added 3,4-dimethoxy-N-methyl-aniline (Intermediate 1a) (500 mg, 2.99 mmol), 6 mL of EtOAc, (2R)-2-(tert-butoxycarbonylamino)-5-methoxy-5-

oxo-pentanoic acid (937.55 mg, 3.59 mmol), T3P® (2.64 mL, 4.49 mmol) and DIEA (1.57 mL, 8.97 mmol). The reaction mixture was then stirred at 50°C for 1 hour. The reaction mixture was diluted in EtOAc, washed with a saturated aqueous solution of NaHCO₃ and with brine, and the organic phase was dried over MgSO₄ and evaporated to dryness to give 1.187 g of the desired product as brown oil, leading to a 97% yield. It was used without further purification in the next step of the synthesis. MS [M+H]⁺ *m/z* = 411.

(1S)-1-[(3,4-Dimethoxyphenyl)-methyl-carbamoyl]-4-methoxy-4-oxo-

butyl]ammonium;2,2,2-trifluoroacetate (28b). Methyl (4S)-4-(*tert*-butoxycarbonylamino)-5-(3,4-dimethoxy-*N*-methyl-anilino)-5-oxo-pentanoate (**28a**) (1.19 g, 2.89 mmol) and 1.5 mL of TFA were dissolved in 5 mL of DCM and the reaction mixture was stirred at room temperature for 1 h. The reaction mixture was evaporated to dryness to give 1.23 g of the titled compound as purple oil. The product will be used in the next step of the synthesis without further purification (yield was considered to be 100%). MS [M+H]⁺ *m/z* = 311.

Methyl (4S)-5-(3,4-dimethoxy-*N*-methyl-anilino)-4-[[*(Z)*-*N*-(4-fluorophenyl)-*C*-sulfanyl-carbonimidoyl]amino]-5-oxo-pentanoate (28c). 4-fluorophenylisothiocyanate (0.44 g, 2.89 mmol) and NEt₃ (0.39 mL, 2.89 mmol) were added in a 500 mL flask in 20 mL of ethanol. (1S)-1-[(3,4-dimethoxyphenyl)-methyl-carbamoyl]-4-methoxy-4-oxo-butyl]ammonium;2,2,2-trifluoroacetate (**28b**) (1.23 g, 2.89 mmol) was dissolved in 20 mL of ethanol, NEt₃ (0.47 mL, 3.47 mmol) were added, and the mixture was added dropwise at room temperature. Then 1 mL of NEt₃ are added to reach pH 10. After 30 min of reaction, the conversion was complete. The reaction mixture was evaporated to dryness. Purification of the crude by flash chromatography using as eluent a mixture of cyclohexane/EtOAc (50/50) gave 940 mg of the titled compound as yellowish oil, leading to a 70% yield. MS [M+H]⁺ *m/z* = 464. ¹H NMR (300 MHz, CDCl₃): δ

(ppm) 1.73-1.89 (m, 1H) ; 1.89-2.03 (m, 2H), 2.10-2.37 (m, 2H), 3.22 (s, 3H), 3.57 (s, 3H), 3.92 (s, 3H), 3.94 (s, 3H), 6.91 (s, 2H), 7.00-7.12 (m, 3H), 7.27 (s, 2H), 7.28 (m, 1H), 8.26 (s, 1H).

Methyl (4S)-4-[[*(Z)*-C-[(2,6-difluorophenyl)methylsulfanyl]-N-(4-fluorophenyl)carbonimidoyl]amino]-5-(3,4-dimethoxy-N-methyl-anilino)-5-oxo-pentanoate

(28d). In a 50 mL flask were added methyl 2-(bromomethyl)-1,3-difluoro-benzene (419.82 mg, 2.03 mmol), K₂CO₃ (308.3 mg, 2.23 mmol) and 10.2 mL of acetonitrile. The suspension was stirred at room temperature for 10 min, and methyl (4S)-5-(3,4-dimethoxy-N-methyl-anilino)-4-[(4-fluorophenyl)carbamoithioylamino]-5-oxo-pentanoate **(28c)** (940 mg, 2.03 mmol) was then added at the reaction mixture and it was stirred at room temperature overnight. The medium was then evaporated, residue was dissolved in EtOAc, washed with water, brine, and dried over MgSO₄. The crude was evaporated to dryness to give 1.05 g of the desired product as dark oil, leading to a 87% yield. It was used without further purification in the next step of the synthesis. MS [M+H]⁺ *m/z* = 590. ¹H NMR (300 MHz, CDCl₃): δ (ppm) 1.93 (brs, 2H), 2.29 (brs, 2H), 3.27 (s, 3H), 3.60 (s, 3H), 3.66 (s, 3H), 3.88 (s, 4H), 4.10 (brs, 2H), 4.70 (brs, 1H), 5.40 (brs, 1H), 6.72 (brs, 2H), 6.83-6.94 (m, 8H).

Methyl 3-[2-[(2,6-difluorophenyl)methylsulfanyl]-5-(3,4-dimethoxy-N-methyl-anilino)-1-(4-fluorophenyl)imidazol-4-yl]propanoate (28). In a 100 mL flask, were added methyl (4S)-4-[[*(Z)*-C-[(2,6-difluorophenyl)methylsulfanyl]-N-(4-fluorophenyl)carbonimidoyl]amino]-5-(3,4-dimethoxy-N-methyl-anilino)-5-oxo-pentanoate **(28d)** (1 g, 1.7 mmol), T3P® (3.01 mL, 5.1 mmol), DIEA (1.88 mL, 10.21 mmol), and 17 mL of EtOAc. The medium was stirred at 80°C for 24 hours. The reaction mixture was diluted in EtOAc and washed with water, brine, and dried over MgSO₄ and evaporated to dryness. The conversion was not complete. The residue was dissolved in 17 mL of EtOAc. T3P® (3.01 mL, 5.1 mmol), DIEA (1.88 mL, 10.21 mmol) were

added at the reaction mixture and it was stirred at 80°C for 24 h. The reaction mixture was diluted in EtOAc, washed with water and brine. Organic phase was dried over MgSO₄ and evaporated. The crude was purified by flash chromatography using as eluent a mixture of cyclohexane/EtOAc (70/30) to give 265 mg of the desired product with the starting material. The crude was again dissolved in EtOAc and T3P® (0.6 mL, 1.018 mmol), DIEA (0.376 mL, 2.035 mmol) were added and the reaction mixture was stirred at 80°C for 24 hours. The reaction mixture was diluted in EtOAc, washed with water and brine. Organic phase was dried over MgSO₄ and evaporated. The crude was then purified by flash chromatography using as eluent a mixture of cyclohexane/EtOAc (70/30) to give 104 mg of the desired product as yellowish oil, leading to a 11% yield. MS [M+H]⁺ *m/z* = 572.2. HRMS found 572.1814; C₂₉H₂₈F₃N₃O₄S requires 572.1831. ¹H NMR (300 MHz, CDCl₃): δ (ppm) 2.67-2.72 (m, 4H), 2.85 (s, 3H), 3.62 (s, 3H), 3.79 (s, 3H), 3.80 (s, 3H), 4.07 (s, 2H), 6.04 (dd, *J* = 8.7, 2.8 Hz, 1H), 6.17 (d, *J* = 2.8 Hz, 1H), 6.72 (d, *J* = 8.7 Hz, 1H), 6.77 (t, *J* = 7.7 Hz, 2H), 6.87-6.92 (m, 4H), 7.01-7.21 (m, 1H).

3-[2-[(2,6-Difluorophenyl)methylsulfanyl]-5-(3,4-dimethoxy-N-methyl-anilino)-1-(4-fluorophenyl)imidazol-4-yl]propanoic acid (29). Methyl 3-[2-[(2,6-difluorophenyl)methylsulfanyl]-5-(3,4-dimethoxy-N-methyl-anilino)-1-(4-

fluorophenyl)imidazol-4-yl]propanoate (28) (104.6 mg, 0.18 mmol) was dissolved in MeOH (1.83 mL) and NaOH 1 N (640 μL, 0.64 mmol) was added. The mixture was stirred overnight at room temperature and evaporated to dryness. The residue was dissolved in DCM and washed with aqueous 1N HCl, water and brine. The organic phase was dried over MgSO₄ and evaporated to dryness to give 95 mg of the titled compound as yellowish oil, leading to a 93% yield. MS [M+H]⁺ *m/z* = 558.3. HRMS found 558.1650; C₂₈H₂₆F₃N₃O₄S requires 558.1674. ¹H NMR (300 MHz, CDCl₃): δ (ppm) 2.73 (s, 4H), 2.84 (s, 3H), 3.79 (s, 3H), 3.80 (s, 3H), 4.09 (s, 2H), 6.03

(dd, $J = 8.7, 2.6$ Hz, 1H), 6.16 (d, $J = 2.6$ Hz, 1H), 6.73 (d, $J = 8.7$ Hz, 1H), 6.78 (t, $J = 7.9$ Hz, 2H), 6.85-6.98 (m, 4H), 7.11-7.23 (m, 1H), 8.75 (brs, 1H). ^{13}C NMR (75 MHz, CDCl_3): δ (ppm) 21.1, 26.7, 33.5, 38.9, 56.1, 56.5, 98.4, 104.1, 111.4 (m), 112.9, 113.4 (t, $J = 19.2$ Hz), 116.2 (d, $J = 23.0$ Hz), 129.1 (d, $J = 8.9$ Hz), 129.6 (t, $J = 10.2$ Hz), 130.4 (d, $J = 3.2$ Hz), 134.6, 135.2, 137.1, 142.5, 150.0, 161.1 (dd, $J = 250.0, 7.6$ Hz), 162.5 (d, $J = 250.0$ Hz), 175.8.

4-[2-[(2,6-Difluorophenyl)methylsulfanyl]-5-(3,4-dimethoxy-N-methyl-anilino)-1-(4-

fluorophenyl)imidazol-4-yl]butyl-trimethyl-ammonium;formate (30). In a 5 mL flask was diluted 4-[2-[(2,6-difluorophenyl)methylsulfanyl]-5-(3,4-dimethoxy-N-methyl-anilino)-1-(4-fluorophenyl)imidazol-4-yl]butylammonium;formate (**27**) (45 mg, 0.07 mmol) in 400 μL of a mixture of $\text{Et}_2\text{O}/\text{THF}$ (1/1). Iodomethane (18.59 μL , 0.3 mmol) and DIEA (13.01 μL , 0.07 mmol) were added at the reaction mixture and it was stirred at room temperature overnight. The reaction mixture was evaporated to dryness. In a 5 mL flask was diluted 4-[2-[(2,6-difluorophenyl)methylsulfanyl]-5-(3,4-dimethoxy-N-methyl-anilino)-1-(4-fluorophenyl)imidazol-4-yl]butylammonium;formate (30 mg, 0.05 mmol) in 250 μL of a mixture of $\text{Et}_2\text{O}/\text{THF}$ (1/1). Iodomethane (12.4 μL , 0.2 mmol) and DIEA (8.67 μL , 0.05 mmol) were added at the reaction mixture and it was stirred at room temperature overnight. The reaction mixture was evaporated to dryness. The crude was diluted in EtOAc and washed with water and brine, dried over MgSO_4 and evaporated to dryness. Purification of the crude by preparative chromatography (ammonium formate buffer pH 3.8) gave 7.3 mg of the desired product as yellowish oil, leading to a 20% yield. MS $[\text{M}+\text{H}]^+$ $m/z = 599$. HRMS found 599.2665; $\text{C}_{32}\text{H}_{38}\text{F}_3\text{N}_4\text{O}_2\text{S}$ requires 599.2668. ^1H NMR (300 MHz, CDCl_3): δ (ppm) 1.69 (brs, 2H), 1.82 (brs, 2H), 2.45 (t, $J = 6.6$ Hz, 2H), 2.87 (s, 3H), 3.31 (brs, 9H), 3.45 (brs, 2H), 3.82 (s, 3H), 3.83 (s, 3H), 4.03 (s, 2H), 6.06 (dd, $J = 8.6, 2.6$ Hz, 1H), 6.18 (d, $J = 2.7$ Hz, 1H), 6.76 (d, $J = 8.6$ Hz,

1H), 6.81 (t, $J = 7.8$ Hz, 2H), 6.90-6.98 (m, 4H), 7.15-7.25 (m, 1H), 8.61 (s, 1H), ^{13}C NMR (75 MHz, CDCl_3): δ (ppm) 22.6, 25.3, 25.6, 26.6, 29.8, 34.1, 39.2, 53.5, 56.2, 56.7, 66.9, 98.5, 104.1, 111.5 (m), 113.0, 114.1 (t, $J = 19.2$ Hz), 116.1 (d, $J = 22.9$ Hz), 129.1 (d, $J = 8.4$ Hz), 129.4 (t, $J = 10.2$ Hz), 131.1 (d, $J = 3.1$ Hz), 134.9, 136.3, 136.9, 142.3, 143.0, 149.9, 161.2 (dd, $J = 249.3, 7.8$ Hz), 162.4 (d, $J = 249.3$ Hz).

AUTHOR INFORMATION

Corresponding Author

*For B.D.: phone, +33 (0)320 964 924; fax, +33 (0) 320 964; 709;

e-mail: benoit.deprez@univ-lille2.fr

*For J.C.: phone, +33 (0)320 964 928;

email: julie.charton@univ-lille2.fr

Author Contributions

These authors contributed equally.

◇ These authors contributed equally.

ACKNOWLEDGMENT

We are grateful to the institutions that support our laboratory: INSERM, Université de Lille, Institut Pasteur de Lille. This project was supported by Conseil Régional Nord-Pas de Calais, ERDF (convention n°11003609), Etat DRRT, European Genomic Institute for Diabetes' (EGID, ANR-10-LABX-46), the European Research Council (ERC Grant Immunobile, contract 694717), European Commission, INSERM, Université Lille 2 (Appel à projets «orientations stratégiques»: convention n°A007) and SATT Nord (M0075/SATTNORD). Manuel Lasalle and

Vanessa Hoguet are recipients of a doctoral fellowship of the French Ministère de la Recherche. NMR acquisitions were done at the Laboratoire d'Application de Résonance Magnétique Nucléaire (LARMN), Lille, France. Bart Staels is a member of the Institut Universitaire de France.

ABBREVIATIONS

EtOAc, ethyl acetate; CH₃CN, acetonitrile; DCE, 1,2-dichloroethane; DCM, dichloromethane; DIEA, diisopropylethylamine; DIO, diet-induced obese; DME, dimethoxyethane; DMF, N,N-dimethylformamide; DMSO, dimethyl sulfoxide; EtOH, ethanol; eq, equivalent; GI, gastrointestinal; GLP-1, Glucagon Like Peptide-1; GP-BAR1, G-protein coupled bile acid receptor 1; HFD, High Fat Diet; MeOH, methanol; PBS, phosphate buffered saline; SAR, structure–activity relationships; TEA, triethylamine; TCDI, 1,1'-Thiocarbonyldiimidazole; TGR5, Takeda G-protein-coupled receptor 5; THF, tetrahydrofuran; TLC, thin layer chromatography. T3P, 1-Propylphosphonic acid cyclic anhydride.

REFERENCES

- (1) Lefebvre, P.; Cariou, B.; Lien, F.; Kuipers, F.; Staels, B. Role of bile acids and bile acid receptors in metabolic regulation. *Physiol. Rev.* **2009**, *89*, 147-191.
- (2) Wang, H.; Chen, J.; Hollister, K.; Sowers, L. C.; Forman, B. M. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. *Mol. Cell* **1999**, *3*, 543-553.

- (3) Maruyama, T.; Miyamoto, Y.; Nakamura, T.; Tamai, Y.; Okada, H.; Sugiyama, E.; Nakamura, T.; Itadani, H.; Tanaka, K. Identification of membrane-type receptor for bile acids (M-BAR). *Biochem. Biophys. Res. Commun.* **2002**, *298*, 714-719.
- (4) Kawamata, Y.; Fujii, R.; Hosoya, M.; Harada, M.; Yoshida, H.; Miwa, M.; Fukusumi, S.; Habata, Y.; Itoh, T.; Shintani, Y.; Hinuma, S.; Fujisawa, Y.; Fujino, M. A G protein-coupled receptor responsive to bile acids. *J. Biol. Chem.* **2003**, *278*, 9435-9440.
- (5) Porez, G.; Prawitt, J.; Gross, B.; Staels, B. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. *J. Lipid. Res.* **2012**, *53*, 1723-1737.
- (6) Campbell, J. E.; Drucker, D. J. Pharmacology, physiology, and mechanisms of incretin hormone action. *Cell Metab.* **2013**, *17*, 819-837.
- (7) Watanabe, M.; Houten, S. M.; Matakai, C.; Christoffolete, M. A.; Kim, B. W.; Sato, H.; Messaddeq, N.; Harney, J. W.; Ezaki, O.; Kodama, T.; Schoonjans, K.; Bianco, A. C.; Auwerx, J. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. *Nature* **2006**, *439*, 484-489.
- (8) Broeders, E. P.; Nascimento, E. B.; Havekes, B.; Brans, B.; Roumans, K. H.; Tailleux, A.; Schaart, G.; Kouach, M.; Charton, J.; Deprez, B.; Bouvy, N. D.; Mottaghy, F.; Staels, B.; van Marken Lichtenbelt, W. D.; Schrauwen, P. The bile acid chenodeoxycholic acid increases human brown adipose tissue activity. *Cell Metab.* **2015**, *22*, 418-426.
- (9) Lavoie, B.; Balemba, O. B.; Godfrey, C.; Watson, C. A.; Vassileva, G.; Corvera, C. U.; Nelson, M. T.; Mawe, G. M. Hydrophobic bile salts inhibit gallbladder smooth muscle function

via stimulation of GPBAR1 receptors and activation of KATP channels. *J. Physiol.* **2010**, *588*, 3295-3305.

(10) Keitel, V.; Cupisti, K.; Ullmer, C.; Knoefel, W. T.; Kubitz, R.; Häussinger, D. The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders. *Hepatology* **2009**, *50*, 861-870.

(11) Alemi, F.; Kwon, E.; Poole, D. P.; Lieu, T.; Lyo, V.; Cattaruzza, F.; Cevikbas, F.; Steinhoff, M.; Nassini, R.; Materazzi, S.; Guerrero-Alba, R.; Valdez-Morales, E.; Cottrell, G. S.; Schoonjans, K.; Geppetti, P.; Vanner, S. J.; Bunnett, N. W.; Corvera, C. U. The TGR5 receptor mediates bile acid-induced itch and analgesia. *J. Clin. Invest.* **2013**, *123*, 1513-1530.

(12) Futatsugi, K.; Bahnck, K. B.; Brenner, M. B.; Buxton, J.; Chin, J. E.; Coffey, S. B.; Dubins, J.; Flynn, D.; Gautreau, D.; Guzman-Perez, A.; Hadcock, J. R.; Hepworth, D.; Herr, M.; Hinchey, T.; Janssen, A. M.; Jennings, S. M.; Jiao, W.; Lavergne, S. Y.; Li, B.; Li, M.; Munchhof, M. J.; Orr, S. T. M.; Piotrowski, D. W.; Roush, N. S.; Sammons, M.; Stevens, B. D.; Storer, G.; Wang, J.; Warmus, J. S.; Wei, L.; Wolford, A. C. Optimization of triazole-based TGR5 agonists towards orally available agents. *Med. Chem. Comm.* **2013**, *4*, 205-210.

(13) Piotrowski, D. W.; Futatsugi, K.; Warmus, J. S.; Orr, S. T.; Freeman-Cook, K. D.; Londregan, A. T.; Wei, L.; Jennings, S. M.; Herr, M.; Coffey, S. B.; Jiao, W.; Storer, G.; Hepworth, D.; Wang, J.; Lavergne, S. Y.; Chin, J. E.; Hadcock, J. R.; Brenner, M. B.; Wolford, A. C.; Janssen, A. M.; Roush, N. S.; Buxton, J.; Hinchey, T.; Kalgutkar, A. S.; Sharma, R.; Flynn, D. A. Identification of tetrahydropyrido[4,3-d]pyrimidine amides as a new class of orally bioavailable TGR5 agonists. *ACS Med. Chem. Lett.* **2013**, *4*, 63-68.

- (14) Fryer, R. M.; Ng, K. J.; Nodop Mazurek, S. G.; Patnaude, L.; Skow, D. J.; Muthukumarana, A.; Gilpin, K. E.; Dinallo, R. M.; Kuzmich, D.; Lord, J.; Sanyal, S.; Yu, H.; Harcken, C.; Cerny, M. A.; Cerny, M. C.; Hickey, E. R.; Modis, L. K. G protein-coupled bile acid receptor 1 stimulation mediates arterial vasodilation through a $K_{Ca}1.1$ (BK_{Ca})-dependent mechanism. *J. Pharmacol. Exp. Ther.* **2014**, *348*, 421-431.
- (15) Charmot, D. Non-systemic drugs: a critical review. *Curr. Pharm. Des.* **2012**, *18*, 1434-1445.
- (16) Duan, H.; Ning, M.; Zou, Q.; Ye, Y.; Feng, Y.; Zhang, L.; Leng, Y.; Shen, J. Discovery of intestinal targeted TGR5 agonists for the treatment of type 2 diabetes. *J. Med. Chem.* **2015**, *58*, 3315-3328.
- (17) Cao, H.; Chen, Z.-X.; Wang, K.; Ning, M.-M.; Zou, Q.-A.; Feng, Y.; Ye, Y.-L.; Leng, Y.; Shen, J.-H. Intestinally-targeted TGR5 agonists equipped with quaternary ammonium have an improved hypoglycemic effect and reduced gallbladder filling effect. *Sci. Rep.* **2016**, *6*, 28676.
- (18) Kramer, W.; Glombik, H. Bile acid reabsorption inhibitors (BARI): novel hypolipidemic drugs. *Curr. Med. Chem.* **2006**, *13*, 997-1016.
- (19) Bollu, V.; Boren, B. C.; Dalgard, J. E.; Flatt, B. T.; HAQ, N.; Hudson, S.; Mohan, R.; Morrissey, M.; Pratt, B.; Wang T.-L. Triazole and imidazole derivatives for use as TGR5 agonists in the treatment of diabetes and obesity. WO2010/093845, **2010**.
- (20) Zamansky, I.; Galvin, G.; Girardet, J.-L. Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate, and uses thereof. WO/2011/085009, **2011**.

- (21) Lasalle, M.; Picon, S.; Rajaa, B.; Hoguet, V.; Van Obbergen, J.; Roussel, P.; Deprez, B.; Charton, J. Access to newly functionalized imidazole derivatives: efficient synthesis of novel 5-amino-2-thioimidazoles using propylphosphonic anhydride (®T3P). *Tetrahedron Lett.* **2015**, *56*, 1011-1014.
- (22) Fournie-Zaluski, M.-C.; Llorens-Cortes, C.; Roques, B. P.; Corvol, P. Novel derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulphonates) and compositions containing same. US 2006/0135602, **2006**.
- (23) Egan, W. J.; Merz, K. M.; Baldwin, J. J. Prediction of drug absorption using multivariate statistics. *J. Med. Chem.* **2000**, *43*, 3867-3877.
- (24) Veber, D. F.; Johnson, S. R.; Cheng, H. Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates. *J. Med. Chem.* **2002**, *45*, 2615-2623.
- (25) Katrin, P.; Patric, S.; Kristina, L.; Per, A. Polar molecular surface properties predict the intestinal absorption of drugs in humans. *Pharm. Res.* **1997**, *14*, 568-571.
- (26) Li, T.; Holmstrom, S. R.; Kir, S.; Umetani, M.; Schmidt, D. R.; Kliewer, S. A.; Mangelsdorf, D. J. The G protein-coupled bile acid receptor, TGR5, stimulates gallbladder filling. *Mol.Endocrinol.* **2011**, *25*, 1066-1071.
- (27) Briere, D.A.; Ruan, X.; Cheng, C.C.; Siesky, A.M.; Fitch, T.E.; Dominguez, C.; Gutierrez Sanfeliciano, S.; Montero, C.; Suen, C.S.; Xu, Y.; Coskun, T.; Michael, M.D. Novel small molecule agonist of TGR5 possesses anti-diabetic effects but causes gallbladder filling in mice. *PLoS ONE* **2015**, *10*, e0136873.

(28) Brighton, C. A.; Rievaj, J.; Kuhre, R. E.; Glass, L. L.; Schoonjans, K.; Holst, J. J.; Gribble, F. M.; Reimann, F. Bile acids trigger GLP-1 release predominantly by accessing basolaterally located G protein-coupled bile acid receptors. *Endocrinology* **2015**, *156*, 3961-3970

(29) Charton, J.; Deprez, B.; Leroux, F., Staels, B.; Muhr-Tailleux A.; Hennuyer, N.; Lestavel, S.; Lasalle M.; Dubanchet, B. Imidazol- or 1,2,4-triazol-derivatives and their use. WO2015/189330 A1, **2015**

(30) Sevin, E.; Dehouck, L.; Fabulas-da Costa, A.; Cecchelli, R.; Dehouck, M. P.; Lundquist, S.; Culot, M. Accelerated Caco-2 cell permeability model for drug discovery. *J. Pharmacol. Toxicol. Methods* **2013**, *68*, 334-339.

Table of Content Graphic

